

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 May 2007 (24.05.2007)

PCT

(10) International Publication Number
WO 2007/059082 A1

(51) International Patent Classification:

A61K 51/00 (2006.01) C12N 5/06 (2006.01)
G01N 33/53 (2006.01) C07K 16/46 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2006/044090

(22) International Filing Date:

13 November 2006 (13.11.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/735,574 10 November 2005 (10.11.2005) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/735,574 (CIP)
Filed on 10 November 2005 (10.11.2005)

(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 322 E. Main Street, Branford, CT 06405 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): TSE, Kam, Fai [CN/US]; 7 Hurd Bridge Road, Clinton, CT 06413 (US).
POLLACK, Vincent, A. [US/US]; 55 Vinegar Hill Road,

Gales Ferry, CT 06335 (US). MACDOUGALL, John [CA/US]; 117 Russell Street, Hamden, CT 06517 (US). SHENOY, Suresh, G. [IN/US]; 15 Millwood Drive, Branford, CT 06405 (US). MANSFIELD, Traci [US/US]; 257 East River Road, Guilford, CT 06437 (US). LICHENSTEIN, Henri [US/US]; 88 Greenbrier Drive, Guilford, CT 06437 (US). JEFFERS, Michael, E. [US/US]; 14 Flax Mill Hollow, Branford, CT 06405 (US). LAROCHELLE, William, J. [US/US]; 15 Devonshire Lane, Madison, CT 06443 (US).


(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC, One Financial Center, Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: METHOD OF TREATING OVARIAN AND RENAL CANCER USING ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN

ELISA assay of anti-TIM-1 mAbs 1.29, 2.56.2, 2.59.2, and 2.45.1 against the TIM-1 antigen



(57) Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— with international search report

**METHOD OF TREATING OVARIAN AND RENAL CANCER USING
ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN
DOMAIN 1 (TIM-1) ANTIGEN**

Background of the Invention

Field of the Invention

[0001] The invention disclosed herein is related to antibodies directed to the antigen T cell, immunoglobulin domain and mucin domain 1 (TIM-1) proteins and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Description of the Related Art

[0002] A new family of genes encoding T cell, immunoglobulin domain and mucin domain (TIM) proteins (three in humans and eight in mice) have been described recently with emerging roles in immunity. Kuchroo *et al.*, *Nat Rev Immunol* 3:454-462 (2003); McIntire *et al.*, *Nat Immunol* 2:1109-1116 (2001). The TIM gene family members reside in chromosomal regions, 5q33.2 in human and 11B1.1 in mouse, and have been linked to allergy and autoimmune diseases. Shevach, *Nat Rev Immunol* 2:389-400 (2002); Wills-Karp *et al.*, *Nat Immunol* 4:1050-1052 (2003).

[0003] One TIM family member, TIM-1, is also known as Hepatitis A virus cellular receptor (HAVcr-1) and was originally discovered as a receptor for Hepatitis A virus (HAV) (Kaplan *et al.*, *EMBO J* 15(16):4282-96 (1996)). This gene was later cloned as kidney injury molecule 1 (KIM-1) (Ichimura *et al.*, *J Biol Chem* 273:4135-4142 (1998); Han *et al.*, *Kidney Int* 62:237-244 (2002)).

[0004] Kaplan *et al.* isolated the cellular receptor for hepatitis A virus from a cDNA library from a primary African Green Monkey Kidney (AGMK) cell line expressing the receptor. See U.S. Patent No. 5,622,861. The disclosed utility of the polypeptides and nucleic acids was to diagnose infection by hepatitis A virus, to separate hepatitis A virus

from impurities in a sample, to treat infection as well as to prevent infection by hepatitis A virus. Furthermore, the polypeptides could be expressed in transformed cells and used to test efficacy of compounds in an anti-hepatitis A virus binding assay.

[0005] The human homolog, hHAVcr-1 (aka TIM-1), was described by Feigelsstock *et al.*, *J Virology* 72(8): 6621-6628 (1998). The same molecules were described in PCT Publication Nos: WO 97/44460 and WO 98/53071 and U.S. Patent No. 6,664,385 as Kidney Injury-related Molecules (KIM) that were found to be upregulated in renal tissue after injury to the kidney. The molecules were described as being useful in a variety of therapeutic interventions, specifically, renal disease, disorder or injury. For example, PCT Publication No. WO 02/098920 describes antibodies to KIM and describes antibodies that inhibit the shedding of KIM-1 polypeptide from KIM-1 expressing cells e.g., renal cells, or renal cancer cells.

[0006] TIM-1 is a type 1 membrane protein that contains a novel six-cysteine immunoglobulin-like domain and a mucin threonine/serine/proline-rich (T/S/P) domain. TIM-1 was originally identified in rat. TIM-1 has been found in mouse, African green monkey, and humans (Feigelsstock *et al.*, *J Virol* 72(8):6621-8 (1998). The African green monkey ortholog is most closely related to human TIM-1 showing 77.6% amino acid identity over 358 aligned amino acids. Rat and mouse orthologs exhibit 50% (155/310) and 45.6% (126/276) amino acid identity respectively, although over shorter segments of aligned sequence than for African green monkey. Monoclonal antibodies to the Ig-like domain of TIM-1 have been shown to be protective against Hepatitis A Virus infection *in vitro*. Silberstein *et al.*, *J Virol* 75(2):717-25 (2001). In addition, Kim-1 was shown to be expressed at low levels in normal kidney but its expression is increased dramatically in postischemic kidney. Ichimura *et al.*, *J Biol Chem* 273(7):4135-42 (1998). HAVCR-1 is also expressed at elevated levels in clear cell carcinomas and cancer cell lines derived from the same.

[0007] TIM-1 shows homology to the P-type "trefoil" domain suggesting that it may have similar biological activity to other P-type trefoil family members. Some trefoil domain containing proteins have been shown to induce cellular scattering and invasion when used to treat kidney, colon and breast tumor cell lines. Prest *et al.*, *FASEB J* 16(6):592-4 (2002). In addition, some trefoil containing proteins confer cellular resistance to anoikis, an anchorage-related apoptosis phenomenon in epithelium. Chen *et al.*, *Biochem Biophys Res Commun* 274(3):576-82 (2000).

[0008] TIM-1 maps to a region of human chromosome 5 known as Tapr in the murine sytenic region that has been implicated in asthma. Tapr, a major T cell regulatory locus, controls the development of airway hyperreactivity. Wills-Karp, *Nature Immunology* 2:1095-1096 (2001); McIntire *et al.*, *Nature Immunology* 2:1109-1116 (2001).

Summary of the Invention

[0009] Embodiments of the invention described herein are based upon the development of human monoclonal antibodies, or binding fragments thereof, that bind TIM-1 and affect TIM-1 function. TIM-1 is expressed at elevated levels in pathologies, such as neoplasms and inflammatory diseases. Inhibition of the biological activity of TIM-1 can thus prevent inflammation and other desired effects, including TIM-1 induced cell proliferation. Embodiments of the invention are based upon the generation and identification of isolated antibodies, or binding fragments thereof, that bind specifically to TIM-1.

[0010] Accordingly, one embodiment of the invention includes isolated antibodies, or fragments of those antibodies, that specifically bind to TIM-1. As known in the art, the antibodies can advantageously be, for example, monoclonal, chimeric and/or fully human antibodies. Embodiments of the invention described herein also provide cells for producing these antibodies.

[0011] Some embodiments of the invention described herein relate to monoclonal antibodies that bind TIM-1 and affect TIM-1 function. Other embodiments relate to fully human anti-TIM-1 antibodies and anti-TIM-1 antibody preparations with desirable properties from a therapeutic perspective, including strong binding affinity for TIM-1, the ability to neutralize TIM-1 *in vitro* and *in vivo*, and the ability to inhibit TIM-1 induced cell proliferation.

[0012] In a preferred embodiment, antibodies described herein bind to TIM-1 with very high affinities (Kd). For example a human, rabbit, mouse, chimeric or humanized antibody that is capable of binding TIM-1 with a Kd less than, but not limited to, 10^{-7} , 10^{-8} , 10^{-9} , 10^{-10} , 10^{-11} , 10^{-12} , 10^{-13} or 10^{-14} M, or any range or value therein. Affinity and/or avidity measurements can be measured by KinExA[®] and/or BIACORE[®], as described herein.

[0013] In one embodiment, the invention provides an isolated antibody that specifically binds to T cell, immunoglobulin domain and mucin domain 1 (TIM-1). In some

embodiments, the isolated antibody has a heavy chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50.

[0014] In another embodiment, the invention provides an isolated antibody that specifically binds to T cell, immunoglobulin domain and mucin domain 1 (TIM-1) and has a light chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

[0015] In yet another embodiment, the invention provides an isolated antibody that specifically binds to TIM-1 and has a heavy chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 and has a light chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

[0016] Another embodiment of the invention is a fully human antibody that specifically binds to TIM-1 and has a heavy chain polypeptide comprising an amino acid sequence comprising the complementarity determining region (CDR) with one of the sequences shown in Table 4. It is noted that CDR determinations can be readily accomplished by those of ordinary skill in the art. See for example, Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, Fifth Edition, NIH Publication 91-3242, Bethesda MD [1991], vols. 1-3.

[0017] Yet another embodiment is an antibody that specifically binds to TIM-1 and has a light chain polypeptide comprising an amino acid sequence comprising a CDR comprising one of the sequences shown in Table 5. In certain embodiments the antibody is a fully human monoclonal antibody.

[0018] A further embodiment is an antibody that binds to TIM-1 and comprises a heavy chain polypeptide comprising an amino acid sequence comprising one of the CDR sequences shown in Table 4 and a light chain polypeptide comprising an amino acid sequence comprising one of the CDR sequences shown in Table 5. In certain embodiments the antibody is a fully human monoclonal antibody.

[0019] Another embodiment of the invention is a fully human antibody that binds to orthologs of TIM-1. A further embodiment herein is an antibody that cross-competes for binding to TIM-1 with the fully human antibodies described herein.

[0020] Other embodiments includes methods of producing high affinity antibodies to TIM-1 by immunizing a mammal with human TIM-1, or a fragment thereof, and one or more orthologous sequences or fragments thereof.

[0021] It will be appreciated that embodiments of the invention are not limited to any particular form of an antibody. For example, the anti-TIM-1 antibody can be a full length antibody (e.g., having an intact human Fc region) or an antibody fragment (e.g., a Fab, Fab', F(ab')₂, Fv, or single chain antibodies). In addition, the antibody can be manufactured from a hybridoma that secretes the antibody, or from a recombinantly produced cell that has been transformed or transfected with a gene or genes encoding the antibody.

[0022] Some embodiments of the invention include isolated nucleic acid molecules encoding any of the anti-TIM-1 antibodies described herein, vectors having an isolated nucleic acid molecule encoding the anti-TIM-1 antibody, and a host cell transformed with such a nucleic acid molecule. In addition, one embodiment of the invention is a method of producing an anti-TIM-1 antibody by culturing host cells under conditions wherein a nucleic acid molecule is expressed to produce the antibody followed by recovering the antibody from the host cell.

[0023] In other embodiments the invention provides compositions, including an antibody, or functional fragment thereof, and a pharmaceutically acceptable carrier.

[0024] In some embodiments, the invention includes pharmaceutical compositions having an effective amount of an anti-TIM-1 antibody in admixture with a pharmaceutically acceptable carrier or diluent. In yet other embodiments, the anti-TIM-1 antibody, or a fragment thereof, is conjugated to a therapeutic agent. The therapeutic agent can be, for example, a toxin, a radioisotope, or a chemotherapeutic agent. Preferably, such antibodies can be used for the treatment of pathologies, including for example, tumors and cancers, such as ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate and bladder cancer, as well as other inflammatory conditions. More preferably, the antibodies can be used to treat renal and ovarian carcinomas.

[0025] In still further embodiments, the antibodies described herein can be used for the preparation of a medicament for the effective treatment of TIM-1 induced cell proliferation in an animal, wherein said monoclonal antibody specifically binds to TIM-1.

[0026] Yet another embodiment is the use of an anti-TIM-1 antibody in the preparation of a medicament for the treatment of diseases such as neoplasms and inflammatory conditions. In one embodiment, the neoplasm includes, without limitation, tumors and cancers, such as ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, colorectal, thyroid, pancreatic, prostate and bladder cancer.

[0027] In yet another aspect, the invention includes a method for effectively treating pathologies associated with the expression of TIM-1. These methods include selecting an animal in need of treatment for a condition associated with the expression of TIM-1, and administering to said animal a therapeutically effective dose of a fully human monoclonal antibody, wherein said antibody specifically binds to TIM-1.

[0028] Preferably a mammal and, more preferably, a human, receives the anti-TIM-1 antibody. In a preferred embodiment, neoplasms are treated, including, without limitation, renal and pancreatic tumors, head and neck cancer, ovarian cancer, gastric (stomach) cancer, melanoma, lymphoma, prostate cancer, liver cancer, lung cancer, renal cancer, bladder cancer, colon cancer, esophageal cancer, and brain cancer.

[0029] Further embodiments of the invention include the use of an antibody of in the preparation of medicament for the effective treatment of neoplastic disease in an animal, wherein said monoclonal antibody specifically binds to TIM-1. Treatable neoplastic diseases include, for example, ovarian cancer, bladder cancer, lung cancer, glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and prostate cancer.

[0030] In some embodiments, the invention includes a method for inhibiting cell proliferation associated with the expression of TIM-1. These methods include selecting an animal in need of treatment for TIM-1 induced cell proliferation and administering to said animal a therapeutically effective dose of a fully human monoclonal antibody, wherein the antibody specifically binds TIM-1. In other embodiments, cells expressing TIM-1 are treated with an effective amount of an anti-TIM-1 antibody or a fragment thereof. The method can be performed *in vivo*.

[0031] The methods can be performed *in vivo* and the patient is preferably a human patient. In a preferred embodiment, the methods concern the treatment of neoplastic diseases, for example, tumors and cancers, such as renal (kidney) cancer, pancreatic cancer, head and neck cancer, ovarian cancer, gastric (stomach) cancer, melanoma, lymphoma,

prostate cancer, liver cancer, breast cancer, lung cancer, bladder cancer, colon cancer, esophageal cancer, and brain cancer.

[0032] In some embodiments, the anti-TIM-1 antibody is administered to a patient, followed by administration of a clearing agent to remove excess circulating antibody from the blood.

[0033] In some embodiments, anti-TIM-1 antibodies can be modified to enhance their capability of fixing complement and participating in complement-dependent cytotoxicity (CDC). In one embodiment, anti-TIM-1 antibodies can be modified, such as by an amino acid substitution, to alter their clearance from the body. Alternatively, some other amino acid substitutions can slow clearance of the antibody from the body.

[0034] In another embodiment, the invention provides an article of manufacture including a container. The container includes a composition containing an anti-TIM-1 antibody, and a package insert or label indicating that the composition can be used to treat neoplastic or inflammatory diseases characterized by the overexpression of TIM-1.

[0035] Yet another embodiment provides methods for assaying the level of TIM-1 in a patient sample, comprising contacting an anti-TIM-1 antibody with a biological sample from a patient, and detecting the level of binding between said antibody and TIM-1 in said sample. In more specific embodiments, the biological sample is blood.

[0036] In one embodiment, the invention includes an assay kit for detecting TIM-1 and TIM-1 orthologs in mammalian tissues or cells to screen for neoplastic diseases or inflammatory conditions. The kit includes an antibody that binds to TIM-1 and a means for indicating the reaction of the antibody with TIM-1, if present. Preferably the antibody is a monoclonal antibody. In one embodiment, the antibody that binds TIM-1 is labeled. In another embodiment the antibody is an unlabeled first antibody and the kit further includes a means for detecting the first antibody. In one embodiment, the means includes a labeled second antibody that is an anti-immunoglobulin. Preferably the antibody is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radiopaque material.

[0037] Another embodiment of the invention includes a method of diagnosing diseases or conditions in which an antibody prepared as described herein is utilized to detect the level of TIM-1 in a patient sample. In one embodiment, the patient sample is blood or blood serum. In further embodiments, methods for the identification of risk factors,

diagnosis of disease, and staging of disease is presented which involves the identification of the overexpression of TIM-1 using anti-TIM-1 antibodies.

[0038] Embodiments of the invention described herein also pertain to variants of a TIM-1 protein that function as either TIM-1 agonists (mimetics) or as TIM-1 antagonists.

[0039] Another embodiment of the invention is the use of monoclonal antibodies directed against the TIM-1 antigen coupled to cytotoxic chemotherapeutic agents or radiotherapeutic agents such as anti-tumor therapeutics.

[0040] One embodiment provides an isolated antibody that blocks simultaneous binding to TIM-1 antigen by an antibody having a heavy chain sequence comprising an the amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50. Another embodiment provides an isolated antibody that binds to TIM-1 antigen and that cross reacts with an antibody having a heavy chain sequence comprising the amino acid sequence from the group consisting of SEQ ID NOS: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50.

[0041] Another embodiment of the invention provides an isolated antibody that binds to an epitope of SEQ ID NO: 87 on the TIM-1 antigen of SEQ ID NO. 54, and that cross reacts with an antibody having a heavy chain sequence comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50. In still another embodiment, the invention provides an isolated antibody that binds to an epitope of SEQ ID NO: 87 on the TIM-1 antigen of SEQ ID NO. 54, wherein said antibody blocks simultaneous binding to TIM-1 antigen by an antibody having a heavy chain sequence comprising the amino acid sequence selected from the group comprising SEQ ID NOS: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50.

Brief Description of the Drawings

[0042] Figure 1 is a bar graph of the results of an ELISA assay of anti-TIM-1 monoclonal antibodies 1.29, 2.56.2, 2.59.2, and 2.45.1 against the TIM-1 antigen.

[0043] Figure 2 is a bar graph of the results of an ELISA assay of anti-TIM-1 monoclonal antibodies 1.29, 2.56.2, 2.59.2, and 2.45.1 against irrelevant protein.

[0044] Figure 3 shows staining of Renal Cell Cancer (3A) and Pancreatic Cancer (3B) with the anti-TIM-1 mAb 2.59.2.

[0045] Figure 4 is a bar graph of clonogenic assay results of anti-TIM-1 monoclonal antibody mediated toxin killing in the ACHN kidney cancer cell line.

[0046] Figure 5 is a bar graph of clonogenic assay results of anti-TIM-1 monoclonal antibody mediated toxin killing in the BT549 breast cancer cell line.

[0047] Figure 6 is a bar graph of the results of a clonogenic assay of CAKI-1 cells treated with Auristatin E (AE) conjugated antibodies.

[0048] Figure 7 is a bar graph of the results of a clonogenic assay of BT549 cells treated with Auristatin E (AE) conjugated antibodies.

[0049] Figure 8 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2, 2.56.2 and 2.45.1 significantly inhibit IL-4 release from Th1 cells compared to the control PK16.3 mAb.

[0050] Figure 9 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2 and 2.45.1 significantly inhibit IL-4 release from Th2 cells compared to control PK16.3 mAb.

[0051] Figure 10 is a bar graph showing that anti-TIM-1 monoclonal antibody 2.59.2 significantly inhibited IL-5 release from Th1 cells compared to control PK16.3 mAb.

[0052] Figure 11 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2 and 1.29 significantly inhibited IL-5 release from Th2 cells compared to control PK16.3 mAb.

[0053] Figure 12 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2, 1.29 and 2.56.2 significantly inhibited IL-10 release from Th1 cells compared to control PK16.3 mAb.

[0054] Figure 13 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2, 1.29 and 2.45.1 significantly inhibited IL-10 release from Th2 cells compared to control PK16.3 mAb.

[0055] Figure 14 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2, 1.29 and 2.56.2 significantly inhibited IL-13 release from Th1 cells compared to control PK16.3 mAb.

[0056] Figure 15 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2 and 1.29 significantly inhibited IL-13 release from Th2 cells compared to control PK16.3 mAb.

[0057] Figure 16 is a bar graph showing that anti-TIM-1 monoclonal antibodies did not inhibit IFN γ release from Th1 cells compared to control PK16.3 mAb.

[0058] Figure 17 is a bar graph showing that anti-TIM-1 monoclonal antibodies 2.59.2 and 2.45.1 significantly inhibited IFN γ release from Th2 cells compared to control PK16.3 mAb.

[0059] Figures 18A-18T are bar graphs showing BrdU incorporation assay results from experiments in which the neutralization of various human anti-TIM-1 monoclonal antibodies was assessed.

[0060] Figures 19A through 19D are line graphs showing the results of antibody conjugate studies performed using the plant toxin Saporin conjugated to TIM-1-specific antibodies and irrelevant antibodies (Figures 19A-19C). Additional negative controls included irrelevant antibodies alone without toxin (Figure 19D).

[0061] Figure 20 is a graph showing tumor growth inhibition and complete regression of IGROV1 ovarian carcinoma xenografts in athymic mice after treatment with 6.25 to 50 mg/kg i.v. every 4 days for 4 treatments. The responses of tumor-bearing animals to reference drugs such as vinblastine (1.7 mg/kg i.v. q4d X4) and paclitaxel (15.0 mg/kg i.v. q2d X4) are also shown. Control groups were treated with either phosphate-buffered saline (PBS) or physiological saline. CR014-vcMMAE was toxic to the test animals at 50 mg/kg/treatment (n= 1/6) and at 100 mg/kg/treatment (n= 6/6).

Detailed Description of the Preferred Embodiment

[0062] Embodiments of the invention described herein are based upon the generation and identification of isolated antibodies that bind specifically to T cell, immunoglobulin domain and mucin domain 1 (TIM-1). As discussed below, TIM-1 is expressed at elevated levels in clear cell carcinomas and cancer cell lines derived from the same. Accordingly, antibodies that bind to TIM-1 are useful for the treatment and inhibition of carcinomas. In addition, antibodies that bind TIM-1 are also useful for reducing cell migration and enhancing apoptosis of kidney cancer cells.

[0063] Accordingly, embodiments of the invention described herein provide isolated antibodies, or fragments of those antibodies, that bind to TIM-1. As known in the art, the antibodies can advantageously be, *e.g.*, monoclonal, chimeric and/or human antibodies. Embodiments of the invention described herein also provide cells for producing these antibodies.

[0064] Another embodiment of the invention provides for using these antibodies for diagnostic or therapeutic purposes. For example, embodiments of the invention provide

methods and antibodies for inhibiting the expression of TIM-1 associated with cell proliferation. Preferably, the antibodies are used to treat neoplasms such as renal and pancreatic tumors, head and neck cancer, ovarian cancer, gastric (stomach) cancer, melanoma, lymphoma, prostate cancer, liver cancer, breast cancer, lung cancer, renal cancer, bladder cancer, colon cancer, esophageal cancer, and brain cancer. In association with such treatment, articles of manufacture comprising these antibodies are provided. Additionally, an assay kit comprising these antibodies is provided to screen for cancers or tumors.

[0065] Additionally, the nucleic acids described herein, and fragments and variants thereof, may be used, by way of nonlimiting example, (a) to direct the biosynthesis of the corresponding encoded proteins, polypeptides, fragments and variants as recombinant or heterologous gene products, (b) as probes for detection and quantification of the nucleic acids disclosed herein, (c) as sequence templates for preparing antisense molecules, and the like. Such uses are described more fully in the following disclosure.

[0066] Furthermore, the TIM-1 proteins and polypeptides described herein, and fragments and variants thereof, may be used, in ways that include (a) serving as an immunogen to stimulate the production of an anti-TIM-1 antibody, (b) a capture antigen in an immunogenic assay for such an antibody, (c) as a target for screening for substances that bind to a TIM-1 polypeptide described herein, and (d) a target for a TIM-1 specific antibody such that treatment with the antibody affects the molecular and/or cellular function mediated by the target. TIM-1 polypeptide expression or activity can promote cell survival and/or metastatic potential. Conversely, a decrease in TIM-1 polypeptide expression or inhibition of its function reduces tumor cell survival and invasiveness in a therapeutically beneficial manner.

[0067] Single chain antibodies (scFv's) and bispecific antibodies specific for TIM-1 are useful particularly because it may more readily penetrate a tumor mass due to its smaller size relative to a whole IgG molecule. Studies comparing the tumor penetration between whole IgG molecules and scFv's have been described in the literature. The scFv can be derivatized with a toxin or radionuclide in order to destroy tumor cells expressing the TIM-1 antigen, in a manner similar to the IgG2 or IgG4 anti-TIM-1 toxin labeled or radionuclide derivatized whole antibodies already discussed, but with the advantage of being able to penetrate the tumor more fully, which may translate into

increased efficacy in eradicating the tumor. A specific example of a biologically active anti-TIM-1 scFv is provided herein.

Sequence Listing

[0068] The heavy chain and light chain variable region nucleotide and amino acid sequences of representative human anti-TIM-1 antibodies are provided in the sequence listing, the contents of which are summarized in Table 1 below.

Table 1

mAb ID No.:	Sequence	SEQ ID NO:
1.29	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	1
	Amino acid sequence of the variable region of the heavy chain	2
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	3
	Amino acid sequence of the variable region of the light chain	4
1.37	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	5
	Amino acid sequence of the variable region of the heavy chain	6
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	7
	Amino acid sequence of the variable region of the light chain	8
2.16	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	9
	Amino acid sequence of the variable region of the heavy chain	10
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	11
	Amino acid sequence of the variable region of the light chain	12

2.17	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	13
	Amino acid sequence of the variable region of the heavy chain	14
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	15
	Amino acid sequence of the variable region of the light chain	16
2.24	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	17
	Amino acid sequence of the variable region of the heavy chain	18
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	19
	Amino acid sequence of the variable region of the light chain	20
2.45	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	21
	Amino acid sequence of the variable region of the heavy chain	22
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	23
	Amino acid sequence of the variable region of the light chain	24
2.54	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	25
	Amino acid sequence of the variable region of the heavy chain	26
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	27
	Amino acid sequence of the variable region of the light chain	28
2.56	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	29
	Amino acid sequence of the variable region of the heavy chain	30
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	31
	Amino acid sequence of the variable region of the light chain	32

2.59	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	33
	Amino acid sequence of the variable region of the heavy chain	34
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	35
	Amino acid sequence of the variable region of the light chain	36
2.61	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	37
	Amino acid sequence of the variable region of the heavy chain	38
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	39
	Amino acid sequence of the variable region of the light chain	40
2.70	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	41
	Amino acid sequence of the variable region of the heavy chain	42
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	43
	Amino acid sequence of the variable region of the light chain	44
2.76	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	45
	Amino acid sequence of the variable region of the heavy chain	46
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	47
	Amino acid sequence of the variable region of the light chain	48
2.70.2	Nucleotide sequence encoding the variable region and a portion of the constant region of the heavy chain	49
	Amino acid sequence of the variable region and a portion of the constant region of the heavy chain	50
	Nucleotide sequence encoding the variable region and a portion of the constant region of the light chain	51
	Amino acid sequence of the variable region and a portion of the constant region of the light chain	52

Definitions

[0069] Unless otherwise defined, scientific and technical terms used in connection with the invention described herein shall have the meanings that are commonly

understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook *et al. Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference. The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[0070] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0071] The term "TIM-1" refers to T cell, immunoglobulin domain and mucin domain 1. In one embodiment, TIM-1 refers to a polypeptide comprising the amino acid sequence of SEQ ID NO: 54.

[0072] The term "polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus. Preferred polypeptides in accordance with the invention comprise human heavy chain immunoglobulin molecules and human kappa light chain immunoglobulin molecules, as well as antibody molecules formed by combinations comprising the heavy chain immunoglobulin molecules with light chain immunoglobulin molecules, such as the kappa light chain immunoglobulin molecules, and vice versa, as well as fragments and analogs thereof.

[0073] The term "polynucleotide" as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA.

[0074] The term "isolated polynucleotide" as used herein shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the isolated polynucleotide (1) is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.

[0075] The term "isolated protein" referred to herein means a protein of cDNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g., free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

[0076] The term "oligonucleotide" referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g. for probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant. Oligonucleotides described herein can be either sense or antisense oligonucleotides.

[0077] Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as upstream sequences; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as downstream sequences.

[0078] The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or

polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring.

[0079] The term “naturally occurring nucleotides” referred to herein includes deoxyribonucleotides and ribonucleotides. The term “modified nucleotides” referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term “oligonucleotide linkages” referred to herein includes oligonucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. *See, e.g., LaPlanche et al., Nucl. Acids Res.* 14:9081 (1986); *Stec et al., J. Am. Chem. Soc.* 106:6077 (1984); *Stein et al., Nucl. Acids Res.* 16:3209 (1988); *Zon et al., Anti-Cancer Drug Design* 6:539 (1991); *Zon et al., Oligonucleotides and Analogues: A Practical Approach*, pp. 87-108 (F. Eckstein, ed., Oxford University Press, Oxford England (1991)); *Stec et al., U.S. Patent No. 5,151,510*; *Uhlmann and Peyman, Chemical Reviews* 90:543 (1990), the disclosures of which are hereby incorporated by reference. An oligonucleotide can include a label for detection, if desired.

[0080] The term “operably linked” as used herein refers to positions of components so described are in a relationship permitting them to function in their intended manner. A control sequence operably linked to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

[0081] The term “control sequence” as used herein refers to polynucleotide sequences which are necessary to effect the expression and processing of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term control sequences is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

[0082] The term “selectively hybridize” referred to herein means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments thereof described herein selectively hybridize to nucleic acid strands under hybridization and wash conditions

that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments described herein and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%.

[0083] Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M.O., in *Atlas of Protein Sequence and Structure*, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program.

[0084] The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (*i.e.*, is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence.

[0085] In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA."

[0086] The following terms are used to describe the sequence relationships between two or more polynucleotide or amino acid sequences: "reference sequence," "comparison window," "sequence identity," "percentage of sequence identity," and "substantial identity." A "reference sequence" is a defined sequence used as a basis for a

sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or 8 amino acids in length, and often at least 48 nucleotides or 16 amino acids in length. Since two polynucleotides or amino acid sequences may each (1) comprise a sequence (*i.e.*, a portion of the complete polynucleotide or amino acid sequence) that is similar between the two molecules, and (2) may further comprise a sequence that is divergent between the two polynucleotides or amino acid sequences, sequence comparisons between two (or more) molecules are typically performed by comparing sequences of the two molecules over a comparison window to identify and compare local regions of sequence similarity. A "comparison window," as used herein, refers to a conceptual segment of at least 18 contiguous nucleotide positions or 6 amino acids wherein a polynucleotide sequence or amino acid sequence may be compared to a reference sequence of at least 18 contiguous nucleotides or 6 amino acid sequences and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions, deletions, substitutions, and the like (*i.e.*, gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman, *Adv. Appl. Math.*, 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.*, 48:443 (1970), by the search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci. (U.S.A.)*, 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, (Genetics Computer Group, 575 Science Dr., Madison, Wis.), Geneworks, or MacVector software packages), or by inspection, and the best alignment (*i.e.*, resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected.

[0087] The term "sequence identity" means that two polynucleotide or amino acid sequences are identical (*i.e.*, on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window. The term percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I) or residue occurs in both sequences to yield the number of matched positions, dividing the

number of matched positions by the total number of positions in the comparison window (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence.

[0088] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. *See Immunology - A Synthesis* (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides described herein. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the righthand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

[0089] As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine,

leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine.

[0090] As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the invention described herein, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99% sequence identity to the antibodies or immunoglobulin molecules described herein. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Assays are described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary

sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie *et al.*, *Science*, 253:164 (1991). Thus, the foregoing examples demonstrate that those of skill in the art can recognize sequence motifs and structural conformations that may be used to define structural and functional domains described herein.

[0091] Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts). A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (*e.g.*, a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in *Proteins, Structures and Molecular Principles* (Creighton, Ed., W. H. Freeman and Company, New York (1984)); *Introduction to Protein Structure* (C. Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton *et al.*, *Nature*, 354:105 (1991), which are each incorporated herein by reference.

[0092] The term "polypeptide fragment" as used herein refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full-length cDNA sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long, preferably at least 14 amino acids long, more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long. The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has at least one of the following properties: (1) specific binding to a TIM-1, under suitable binding

conditions, (2) ability to block appropriate TIM-1 binding, or (3) ability to inhibit the growth and/or survival of TIM-1 expressing cells *in vitro* or *in vivo*. Typically, polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

[0093] Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compounds are termed peptide mimetics or peptidomimetics. Fauchere, *J. Adv. Drug Res.*, 15:29 (1986); Veber and Freidinger, *TINS*, p.392 (1985); and Evans *et al.*, *J. Med. Chem.*, 30:1229 (1987), which are incorporated herein by reference. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a biochemical property or pharmacological activity), such as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂--, and --CH₂SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch, *Ann. Rev. Biochem.*, 61:387 (1992), incorporated herein by reference); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

[0094] "Antibody" or "antibody peptide(s)" refer to an intact antibody, or a binding fragment thereof that competes with the intact antibody for specific binding. Binding fragments are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab', F(ab')₂, Fv, and single-chain antibodies. An antibody other than a bispecific or bifunctional antibody is understood to have each of its binding sites identical. An antibody substantially inhibits adhesion of a receptor to a counterreceptor when an excess of antibody reduces the quantity

of receptor bound to counterreceptor by at least about 20%, 40%, 60% or 80%, and more usually greater than about 85% (as measured in an *in vitro* competitive binding assay).

[0095] Digestion of antibodies with the enzyme, papain, results in two identical antigen-binding fragments, known also as "Fab" fragments, and a "Fc" fragment, having no antigen-binding activity but having the ability to crystallize. Digestion of antibodies with the enzyme, pepsin, results in the a "F(ab')₂" fragment in which the two arms of the antibody molecule remain linked and comprise two-antigen binding sites. The F(ab')₂ fragment has the ability to crosslink antigen.

[0096] "Fv" when used herein refers to the minimum fragment of an antibody that retains both antigen-recognition and antigen-binding sites.

[0097] "Fab" when used herein refers to a fragment of an antibody which comprises the constant domain of the light chain and the CH1 domain of the heavy chain.

[0098] The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is $\leq 1 \mu\text{M}$, preferably $\leq 100 \text{ nM}$ and most preferably $\leq 10 \text{ nM}$.

[0099] The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

[0100] The term "pharmaceutical agent" or "drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. Other chemistry terms herein are used according to conventional usage in the art, as exemplified by *The McGraw-Hill Dictionary of Chemical Terms* (Parker, S., Ed., McGraw-Hill, San Francisco (1985)), incorporated herein by reference).

[0101] The term "antineoplastic agent" is used herein to refer to agents that have the functional property of inhibiting a development or progression of a neoplasm in a human, particularly a malignant (cancerous) lesion, such as a carcinoma, sarcoma, lymphoma, or leukemia. Inhibition of metastasis is frequently a property of antineoplastic agents.

[0102] As used herein, “substantially pure” means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, 90%, 95%, and 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

[0103] “Active” or “activity” in regard to a TIM-1 polypeptide refers to a portion of a TIM-1 polypeptide which has a biological or an immunological activity of a native TIM-1 polypeptide. “Biological” when used herein refers to a biological function that results from the activity of the native TIM-1 polypeptide. A preferred biological activity includes, for example, regulation of cellular growth.

[0104] “Label” or “labeled” as used herein refers to the addition of a detectable moiety to a polypeptide, for example, a radiolabel, fluorescent label, enzymatic label chemiluminescent labeled or a biotinyl group. Radioisotopes or radionuclides may include ^3H , ^{14}C , ^{15}N , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I , fluorescent labels may include rhodamine, lanthanide phosphors or FITC and enzymatic labels may include horseradish peroxidase, β -galactosidase, luciferase, alkaline phosphatase.

[0105] “Mammal” when used herein refers to any animal that is considered a mammal. Preferably, the mammal is human.

[0106] “Liposome” when used herein refers to a small vesicle that may be useful for delivery of drugs that may include the TIM-1 polypeptide described herein or antibodies to such a TIM-1 polypeptide to a mammal.

[0107] The term “patient” includes human and veterinary subjects.

Antibody Structure

[0108] The basic whole antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable domain of about 100 to 110 or more amino acids

primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains are classified as kappa and lambda light chains. Human heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. *See generally, Fundamental Immunology* Ch. 7 (Paul, W., ed., 2d ed. Raven Press, N.Y. (1989)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair form the antibody binding site.

[0109] The variable domains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the heavy and light chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each region is in accordance with the definitions of Kabat, *Sequences of Proteins of Immunological Interest* (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk, *J. Mol. Biol.* 196:901-917 (1987); Chothia *et al.*, *Nature* 342:878-883 (1989).

[0110] A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. *See, e.g.,* Songsivilai & Lachmann, *Clin. Exp. Immunol.* 79: 315-321 (1990), Kostelny *et al.*, *J. Immunol.* 148:1547-1553 (1992). Bispecific antibodies do not exist in the form of fragments having a single binding site (e.g., Fab, Fab', and Fv).

[0111] It will be appreciated that such bifunctional or bispecific antibodies are contemplated and encompassed by the invention. A bispecific single chain antibody with specificity to TIM-1 and to the CD3 antigen on cytotoxic T lymphocytes can be used to direct these T cells to tumor cells expressing TIM-1 and cause apoptosis and eradication of the tumor. Two bispecific scFv constructs for this purpose are described herein. The scFv components specific for TIM-1 can be derived from anti-TIM-1 antibodies described herein. In some embodiments, the anti-TIM-1 antibody components disclosed in Tables 4 and 5 can be used to generate a biologically active scFv directed against TIM-1. In a preferred

embodiment, the scFv components are derived from mAb 2.70. The anti-CD3 scFv component of the therapeutic bispecific scFv was derived from a sequence deposited in Genbank (accession number CAE85148). Alternative antibodies known to target CD3 or other T cell antigens may similarly be effective in treating malignancies when coupled with anti-TIM-1, whether on a single-chain backbone or a full IgG.

Human Antibodies and Humanization of Antibodies

[0112] Embodiments of the invention described herein contemplate and encompass human antibodies. Human antibodies avoid certain of the problems associated with antibodies that possess murine or rat variable and/or constant regions. The presence of such murine or rat derived proteins can lead to the rapid clearance of the antibodies or can lead to the generation of an immune response against the antibody by a mammal other than a rodent.

Human Antibodies

[0113] The ability to clone and reconstruct megabase-sized human loci in YACs and to introduce them into the mouse germline provides a powerful approach to elucidating the functional components of very large or crudely mapped loci as well as generating useful models of human disease. An important practical application of such a strategy is the "humanization" of the mouse humoral immune system. Introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated offers the opportunity to develop human antibodies in the mouse. Fully human antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derivatized Mabs and thus to increase the efficacy and safety of the antibodies administered to humans. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation, autoimmunity, and cancer, which require repeated antibody administrations.

[0114] One approach toward this goal was to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci in anticipation that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. This general strategy was demonstrated in connection with our generation of the first XenoMouse® strains as published in 1994. See Green *et al.*, *Nature Genetics* 7:13-21 (1994). The XenoMouse® strains were engineered with yeast artificial chromosomes

(YACs) containing 245 kb and 190 kb-sized germline configuration fragments of the human heavy chain locus and kappa light chain locus, respectively, which contained core variable and constant region sequences. *Id.* The XENOMOUSE® strains are available from Abgenix, Inc. (Fremont, CA). Greater than approximately 80% of the human antibody repertoire has been introduced through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and kappa light chain loci, respectively, to produce XenoMouse® mice.

[0115] The production of the XENOMOUSE® is further discussed and delineated in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30, 1992, filed 08/031,801, filed March 15, 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995, 08/430, 938, April 27, 1995, 08/464,584, filed June 5, 1995, 08/464,582, filed June 5, 1995, 08/463,191, filed June 5, 1995, 08/462,837, filed June 5, 1995, 08/486,853, filed June 5, 1995, 08/486,857, filed June 5, 1995, 08/486,859, filed June 5, 1995, 08/462,513, filed June 5, 1995, 08/724,752, filed October 2, 1996, and 08/759,620, filed December 3, 1996 and U.S. Patent Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598 and Japanese Patent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2. *See also* Mendez *et al.*, *Nature Genetics* 15:146-156 (1997) and Green and Jakobovits, *J. Exp. Med.* 188:483-495 (1998). *See also* European Patent No. EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, WO 98/24893, published June 11, 1998, WO 00/76310, published December 21, 2000. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirety.

[0116] Alternative approaches have utilized a "minilocus" approach, in which an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani *et al.* and U.S. Patent Nos. 5,545,806, 5,625,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,877,397, 5,874,299, and 6,255,458 each to Lonberg and Kay, U.S. Patent No. 5,591,669 and 6,023,010 to

Krimpenfort and Berns, U.S. Patent Nos. 5,612,205, 5,721,367, and 5,789,215 to Berns *et al.*, and U.S. Patent No. 5,643,763 to Choi and Dunn, and GenPharm International U.S. Patent Application Serial Nos. 07/574,748, filed August 29, 1990, 07/575,962, filed August 31, 1990, 07/810,279, filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,068, filed June 23, 1992, 07/990,860, filed December 16, 1992, 08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 1994, the disclosures of which are hereby incorporated by reference. *See also* European Patent No. 0 546 073 B1, International Patent Application Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884 and U.S. Patent No. 5,981,175, the disclosures of which are hereby incorporated by reference in their entirety. *See further* Taylor *et al.*, 1992, Chen *et al.*, 1993, Tuaillon *et al.*, 1993, Choi *et al.*, 1993, Lonberg *et al.*, (1994), Taylor *et al.*, (1994), and Tuaillon *et al.*, (1995), Fishwild *et al.*, (1996), the disclosures of which are hereby incorporated by reference in their entirety.

[0117] While chimeric antibodies have a human constant region and a murine variable region, it is expected that certain human anti-chimeric antibody (HACA) responses will be observed, particularly in chronic or multi-dose utilizations of the antibody. Thus, it would be desirable to provide fully human antibodies against TIM-1 in order to vitiate concerns and/or effects of human anti-mouse antibody (HAMA) or HACA response.

Humanization and Display Technologies

[0118] Antibodies with reduced immunogenicity can be generated using humanization and library display techniques. It will be appreciated that antibodies can be humanized or primatized using techniques well known in the art. *See e.g.*, Winter and Harris, *Immunol Today* 14:43-46 (1993) and Wright *et al.*, *Crit. Reviews in Immunol.* 12:125-168 (1992). The antibody of interest can be engineered by recombinant DNA techniques to substitute the CH1, CH2, CH3, hinge domains, and/or the framework domain with the corresponding human sequence (*see* WO 92/02190 and U.S. Patent Nos. 5,530,101, 5,585,089, 5,693,761, 5,693,792, 5,714,350, and 5,777,085). Also, the use of Ig cDNA for construction of chimeric immunoglobulin genes is known in the art (Liu *et al.*, *P.N.A.S.* 84:3439 (1987) and *J. Immunol.* 139:3521 (1987)). mRNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA. The cDNA of interest can be

amplified by the polymerase chain reaction using specific primers (U.S. Pat. Nos. 4,683,195 and 4,683,202). Alternatively, an expression library is made and screened to isolate the sequence of interest encoding the variable region of the antibody is then fused to human constant region sequences. The sequences of human constant regions genes can be found in Kabat *et al.*, "Sequences of Proteins of Immunological Interest," N.I.H. publication no. 91-3242 (1991). Human C region genes are readily available from known clones. The choice of isotype will be guided by the desired effector functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity. Preferred isotypes are IgG1, IgG2 and IgG4. Either of the human light chain constant regions, kappa or lambda, can be used. The chimeric, humanized antibody is then expressed by conventional methods. Expression vectors include plasmids, retroviruses, YACs, EBV derived episomes, and the like.

[0119] Antibody fragments, such as Fv, F(ab')₂ and Fab can be prepared by cleavage of the intact protein, e.g., by protease or chemical cleavage. Alternatively, a truncated gene is designed. For example, a chimeric gene encoding a portion of the F(ab')₂ fragment would include DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.

[0120] Consensus sequences of H and L J regions can be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.

[0121] Expression vectors include plasmids, retroviruses, YACs, EBV derived episomes, and the like. A convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody can be joined to any strong promoter, including retroviral LTRs, e.g., SV-40 early promoter, (Okayama *et al.*, *Mol. Cell. Bio.* 3:280 (1983)), Rous sarcoma virus LTR (Gorman *et al.*, *P.N.A.S.* 79:6777 (1982)), and moloney murine leukemia virus LTR (Grosschedl *et al.*, *Cell* 41:885 (1985)). Also, as will be appreciated, native Ig promoters and the like can be used.

[0122] Further, human antibodies or antibodies from other species can be generated through display-type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and other techniques, using techniques well known in the art and the resulting molecules can be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art. Wright and Harris, *supra.*, Hanes and Plutchau, *PNAS USA* 94:4937-4942 (1997) (ribosomal display), Parmley and Smith, *Gene* 73:305-318 (1988) (phage display), Scott, *TIBS* 17:241-245 (1992), Cwirla *et al.*, *PNAS USA* 87:6378-6382 (1990), Russel *et al.*, *Nucl. Acids Res.* 21:1081-1085 (1993), Hoganboom *et al.*, *Immunol. Reviews* 130:43-68 (1992), Chiswell and McCafferty, *TIBTECH* 10:80-84 (1992), and U.S. Patent No. 5,733,743. If display technologies are utilized to produce antibodies that are not human, such antibodies can be humanized as described above.

[0123] Using these techniques, antibodies can be generated to TIM-1 expressing cells, TIM-1 itself, forms of TIM-1, epitopes or peptides thereof, and expression libraries thereto (*see e.g.* U.S. Patent No. 5,703,057) which can thereafter be screened as described above for the activities described above.

Antibody Therapeutics

[0124] In certain respects, it can be desirable in connection with the generation of antibodies as therapeutic candidates against TIM-1 that the antibodies be capable of fixing complement and participating in complement-dependent cytotoxicity (CDC). Such antibodies include, without limitation, the following: murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, rather, the antibody as generated can possess any isotype and the antibody can be isotype switched thereafter using conventional techniques that are well known in the art. Such techniques include the use of direct recombinant techniques (*see, e.g.*, U.S. Patent No. 4,816,397), cell-cell fusion techniques (*see, e.g.*, U.S. Patent Nos. 5,916,771 and 6,207,418), among others.

[0125] In the cell-cell fusion technique, a myeloma or other cell line is prepared that possesses a heavy chain with any desired isotype and another myeloma or other cell line is prepared that possesses the light chain. Such cells can, thereafter, be fused and a cell line expressing an intact antibody can be isolated.

[0126] By way of example, the TIM-1 antibody discussed herein is a human anti-TIM-1 IgG2 antibody. If such antibody possessed desired binding to the TIM-1 molecule, it could be readily isotype switched to generate a human IgM, human IgG1, or human IgG3 isotype, while still possessing the same variable region (which defines the antibody's specificity and some of its affinity). Such molecule would then be capable of fixing complement and participating in CDC.

Design and Generation of Other Therapeutics

[0127] Due to their association with renal and pancreatic tumors, head and neck cancer, ovarian cancer, gastric (stomach) cancer, melanoma, lymphoma, prostate cancer, liver cancer, breast cancer, lung cancer, renal cancer, bladder cancer, colon cancer, esophageal cancer, and brain cancer, antineoplastic agents comprising anti-TIM-1 antibodies are contemplated and encompassed by the invention.

[0128] Moreover, based on the activity of the antibodies that are produced and characterized herein with respect to TIM-1, the design of other therapeutic modalities beyond antibody moieties is facilitated. Such modalities include, without limitation, advanced antibody therapeutics, such as bispecific antibodies, immunotoxins, and radiolabeled therapeutics, generation of peptide therapeutics, gene therapies, particularly intrabodies, antisense therapeutics, and small molecules.

[0129] In connection with the generation of advanced antibody therapeutics, where complement fixation is a desirable attribute, it can be possible to sidestep the dependence on complement for cell killing through the use of bispecifics, immunotoxins, or radiolabels, for example.

[0130] For example, in connection with bispecific antibodies, bispecific antibodies can be generated that comprise (i) two antibodies one with a specificity to TIM-1 and another to a second molecule that are conjugated together, (ii) a single antibody that has one chain specific to TIM-1 and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to TIM-1 and the other molecule. Such bispecific antibodies can be generated using techniques that are well known for example, in connection with (i) and (ii) *see, e.g., Fanger et al., Immunol Methods* 4:72-81 (1994) and Wright and Harris, *supra* and in connection with (iii) *see, e.g., Traunecker et al., Int. J. Cancer (Suppl.)* 7:51-52 (1992). In each case, the second specificity can be made to the

heavy chain activation receptors, including, without limitation, CD16 or CD64 (*see, e.g., Deo et al., 18:127 (1997)*) or CD89 (*see, e.g., Valerius et al., Blood 90:4485-4492 (1997)*). Bispecific antibodies prepared in accordance with the foregoing would be likely to kill cells expressing TIM-1, and particularly those cells in which the TIM-1 antibodies described herein are effective.

[0131] With respect to immunotoxins, antibodies can be modified to act as immunotoxins utilizing techniques that are well known in the art. *See, e.g., Vitetta, Immunol Today 14:252 (1993)*. *See also* U.S. Patent No. 5,194,594. In connection with the preparation of radiolabeled antibodies, such modified antibodies can also be readily prepared utilizing techniques that are well known in the art. *See, e.g., Junghans et al., in Cancer Chemotherapy and Biotherapy 655-686 (2d ed., Chafner and Longo, eds., Lippincott Raven (1996))*. *See also* U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules would be likely to kill cells expressing TIM-1, and particularly those cells in which the antibodies described herein are effective.

[0132] In connection with the generation of therapeutic peptides, through the utilization of structural information related to TIM-1 and antibodies thereto, such as the antibodies described herein (as discussed below in connection with small molecules) or screening of peptide libraries, therapeutic peptides can be generated that are directed against TIM-1. Design and screening of peptide therapeutics is discussed in connection with Houghten *et al., Biotechniques 13:412-421 (1992)*, Houghten, *PNAS USA 82:5131-5135 (1985)*, Pinalla *et al., Biotechniques 13:901-905 (1992)*, Blake and Litzi-Davis, *BioConjugate Chem. 3:510-513 (1992)*. Immunotoxins and radiolabeled molecules can also be prepared, and in a similar manner, in connection with peptidic moieties as discussed above in connection with antibodies.

[0133] Assuming that the TIM-1 molecule (or a form, such as a splice variant or alternate form) is functionally active in a disease process, it will also be possible to design gene and antisense therapeutics thereto through conventional techniques. Such modalities can be utilized for modulating the function of TIM-1. In connection therewith the antibodies, as described herein, facilitate design and use of functional assays related thereto. A design and strategy for antisense therapeutics is discussed in detail in International Patent Application No. WO 94/29444. Design and strategies for gene therapy are well known. However, in particular, the use of gene therapeutic techniques involving intrabodies could

prove to be particularly advantageous. See, e.g., Chen *et al.*, *Human Gene Therapy* 5:595-601 (1994) and Marasco, *Gene Therapy* 4:11-15 (1997). General design of and considerations related to gene therapeutics, is also discussed in International Patent Application No. WO 97/38137.

[0134] Small molecule therapeutics can also be envisioned. Drugs can be designed to modulate the activity of TIM-1, as described herein. Knowledge gleaned from the structure of the TIM-1 molecule and its interactions with other molecules, as described herein, such as the antibodies described herein, and others can be utilized to rationally design additional therapeutic modalities. In this regard, rational drug design techniques such as X-ray crystallography, computer-aided (or assisted) molecular modeling (CAMM), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can be utilized to focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with the molecule or specific forms thereof which can be used to modify or modulate the activity of TIM-1. Such structures can be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey *et al.*, *Genetically Engineered Human Therapeutic Drugs* (Stockton Press, NY (1988)). Further, combinatorial libraries can be designed and synthesized and used in screening programs, such as high throughput screening efforts.

TIM-1 Agonists And Antagonists

[0135] Embodiments of the invention described herein also pertain to variants of a TIM-1 protein that function as either TIM-1 agonists (mimetics) or as TIM-1 antagonists. Variants of a TIM-1 protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the TIM-1 protein. An agonist of the TIM-1 protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the TIM-1 protein. An antagonist of the TIM-1 protein can inhibit one or more of the activities of the naturally occurring form of the TIM-1 protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the TIM-1 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the TIM-1 protein.

[0136] Variants of the TIM-1 protein that function as either TIM-1 agonists (mimetics) or as TIM-1 antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the TIM-1 protein for protein agonist or antagonist activity. In one embodiment, a variegated library of TIM-1 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of TIM-1 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential TIM-1 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of TIM-1 sequences therein. There are a variety of methods which can be used to produce libraries of potential TIM-1 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential TIM-1 variant sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (*see, e.g.*, Narang, *Tetrahedron* 39:3 (1983); Itakura *et al.*, *Annu. Rev. Biochem.* 53:323 (1984); Itakura *et al.*, *Science* 198:1056 (1984); Ike *et al.*, *Nucl. Acid Res.* 11:477 (1983).

Radioimmuno & Immunochemotherapeutic Antibodies

[0137] Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. Therefore, there is a need to improve the selectivity. One strategy is to couple therapeutics to antibodies that recognize tumor-associated antigens. This increases the exposure of the malignant cells to the ligand-targeted therapeutics but reduces the exposure of normal cells to the same agent. *See* Allen, *Nat. Rev. Cancer* 2(10):750-63 (2002).

[0138] The TIM-1 antigen is one of these tumor-associated antigens, as shown by its specific expression on cellular membranes of tumor cells by FACS and IHC. Therefore one embodiment of the invention is to use monoclonal antibodies directed against the TIM-1 antigen coupled to cytotoxic chemotherapeutic agents or radiotherapeutic agents as anti-tumor therapeutics.

[0139] Radiolabels are known in the art and have been used for diagnostic or therapeutic radioimmuno conjugates. Examples of radiolabels includes, but are not limited to, the following: radioisotopes or radionuclides (e.g., ^3H , ^{14}C , ^{15}N , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I , ^{177}Lu , Rhenium-186, Rhenium-188, Samarium-153, Copper-64, Scandium-47). For example, radionuclides which have been used in radioimmunoconjugate guided clinical diagnosis include, but are not limited to: ^{131}I , ^{125}I , ^{123}I , ^{99}Tc , ^{67}Ga , as well as ^{111}In . Antibodies have also been labeled with a variety of radionuclides for potential use in targeted immunotherapy (*see* Peirersz *et al.*, 1987). Monoclonal antibody conjugates have also been used for the diagnosis and treatment of cancer (e.g., *Immunol. Cell Biol.* 65:111-125). These radionuclides include, for example, ^{188}Re and ^{186}Re as well as ^{90}Y , and to a lesser extent ^{199}Au and ^{67}Cu . ^{131}I have also been used for therapeutic purposes. U.S. Patent No. 5,460,785 provides a listing of such radioisotopes. Radiotherapeutic chelators and chelator conjugates are known in the art. *See* U.S. Patent Nos. 4,831,175, 5,099,069, 5,246,692, 5,286,850, and 5,124,471.

[0140] Immunoradiopharmaceuticals utilizing anti-TIM-1 antibodies can be prepared utilizing techniques that are well known in the art. *See, e.g.*, Junghans *et al.*, in *Cancer Chemotherapy and Biotherapy* 655-686 (2d ed., Chafner and Longo, eds., Lippincott Raven (1996)), U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, RE 35,500, 5,648,471, and 5,697,902.

[0141] Cytotoxic immunoconjugates are known in the art and have been used as therapeutic agents. Such immunoconjugates may for example, use maytansinoids (U.S. Patent No. 6,441,163), tubulin polymerization inhibitor, auristatin (Mohammad *et al.*, *Int. J. Oncol.* 15(2):367-72 (1999); Doronina *et al.*, *Nature Biotechnology* 21(7):778-784 (2003)), dolastatin derivatives (Ogawa *et al.*, *Toxicol Lett.* 121(2):97-106 (2001); 21(3):778-784), Mylotarg® (Wyeth Laboratories, Philadelphia, PA); maytansinoids (DM1), taxane or mertansine (ImmunoGen Inc.). Immunotoxins utilizing anti-TIM-1 antibodies may be prepared by techniques that are well known in the art. *See, e.g.*, Vitetta, *Immunol Today* 14:252 (1993); U.S. Patent No. 5,194,594.

[0142] Bispecific antibodies may be generated using techniques that are well known in the art for example, *see, e.g.*, Fanger *et al.*, *Immunol Methods* 4:72-81 (1994); Wright and Harris, *supra*; Traunecker *et al.*, *Int. J. Cancer (Suppl.)* 7:51-52 (1992). In each case, the first specificity is to TIM-1, the second specificity may be made to the heavy chain activation receptors, including, without limitation, CD16 or CD64 (*see, e.g.*, Deo *et al.*,

18:127 (1997)) or CD89 (*see, e.g., Valerius et al., Blood* 90:4485-4492 (1997)). Bispecific antibodies prepared in accordance with the foregoing would kill cells expressing TIM-1.

[0143] Depending on the intended use of the antibody, i.e., as a diagnostic or therapeutic reagent, radiolabels are known in the art and have been used for similar purposes. For example, radionuclides which have been used in clinical diagnosis include, but are not limited to: ^{131}I , ^{125}I , ^{123}I , ^{99}Tc , ^{67}Ga , as well as ^{111}In . Antibodies have also been labeled with a variety of radionuclides for potential use in targeted immunotherapy. *See Peirersz et al., (1987)*. Monoclonal antibody conjugates have also been used for the diagnosis and treatment of cancer. *See, e.g., Immunol. Cell Biol.* 65:111-125. These radionuclides include, for example, ^{188}Re and ^{186}Re as well as ^{90}Y , and to a lesser extent ^{199}Au and ^{67}Cu . I-(131) have also been used for therapeutic purposes. U.S. Pat. No. 5,460,785 provides a listing of such radioisotopes.

[0144] Patents relating to radiotherapeutic chelators and chelator conjugates are known in the art. For example, U.S. Pat. No. 4,831,175 of Gansow is directed to polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates containing the same, and methods for their preparation. U.S. Pat. Nos. 5,099,069, 5,246,692, 5,286,850, and 5,124,471 of Gansow also relate to polysubstituted DTPA chelates.

[0145] Cytotoxic chemotherapies are known in the art and have been used for similar purposes. For example, U.S. Pat. No. 6,441,163 describes the process for the production of cytotoxic conjugates of maytansinoids and antibodies. The anti-tumor activity of a tubulin polymerization inhibitor, auristatin PE, is also known in the art. Mohammad *et al., Int. J. Oncol.* 15(2):367-72 (Aug 1999).

Preparation of Antibodies

[0146] Briefly, XenoMouse® lines of mice were immunized with TIM-1 protein, lymphatic cells (such as B-cells) were recovered from the mice that express antibodies and were fused with a myeloid-type cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines were screened and selected to identify hybridoma cell lines that produce antibodies specific to TIM-1. Alternatively, instead of being fused to myeloma cells to generate hybridomas, the recovered B cells, isolated from immunized XenoMouse® lines of mice, with reactivity against TIM-1 (determined by e.g. ELISA with TIM-1-His protein), were then isolated using a TIM-1-specific hemolytic plaque assay.

Babcock *et al.*, *Proc. Natl. Acad. Sci. USA*, 93:7843-7848 (1996). In this assay, target cells such as sheep red blood cells (SRBCs) were coated with the TIM-1 antigen. In the presence of a B cell culture secreting the anti-TIM-1 antibody and complement, the formation of a plaque indicates specific TIM-1-mediated lysis of the target cells. Single antigen-specific plasma cells in the center of the plaques were isolated and the genetic information that encodes the specificity of the antibody isolated from single plasma cells.

[0147] Using reverse-transcriptase PCR, the DNA encoding the variable region of the antibody secreted was cloned and inserted into a suitable expression vector, preferably a vector cassette such as a pcDNA, more preferably the pcDNA vector containing the constant domains of immunoglobulin heavy and light chain. The generated vector was then be transfected into host cells, preferably CHO cells, and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

[0148] In general, antibodies produced by the above-mentioned cell lines possessed fully human IgG2 heavy chains with human kappa light chains. The antibodies possessed high affinities, typically possessing Kd's of from about 10^{-6} through about 10^{-11} M, when measured by either solid phase and solution phase. These mAbs can be stratified into groups or "bins" based on antigen binding competition studies, as discussed below.

[0149] As will be appreciated, antibodies, as described herein, can be expressed in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies can be used for transformation of a suitable mammalian host cell. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference). The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

[0150] Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels and produce antibodies with constitutive TIM-1 binding properties.

Therapeutic Administration and Formulations

[0151] The compounds of the invention are formulated according to standard practice, such as prepared in a carrier vehicle. The term "pharmacologically acceptable carrier" means one or more organic or inorganic ingredients, natural or synthetic, with which the mutant proto-oncogene or mutant oncoprotein is combined to facilitate its application. A suitable carrier includes sterile saline although other aqueous and non-aqueous isotonic sterile solutions and sterile suspensions known to be pharmaceutically acceptable are known to those of ordinary skill in the art. In this regard, the term "carrier" encompasses liposomes and the antibody (See Chen *et al.*, *Anal. Biochem.* 227: 168-175 (1995) as well as any plasmid and viral expression vectors.

[0152] Any of the novel polypeptides of this invention may be used in the form of a pharmaceutically acceptable salt. Suitable acids and bases which are capable of forming salts with the polypeptides of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases.

[0153] A compound of the invention is administered to a subject in a therapeutically-effective amount, which means an amount of the compound which produces a medically desirable result or exerts an influence on the particular condition being treated. An effective amount of a compound of the invention is capable of ameliorating or delaying progression of the diseased, degenerative or damaged condition. The effective amount can be determined on an individual basis and will be based, in part, on consideration of the physical attributes of the subject, symptoms to be treated and results sought. An effective amount can be determined by one of ordinary skill in the art employing such factors and using no more than routine experimentation.

[0154] The compounds of the invention may be administered in any manner which is medically acceptable. This may include injections, by parenteral routes such as

intravenous, intravascular, intraarterial, subcutaneous, intramuscular, intratumor, intraperitoneal, intraventricular, intraepidural, or others as well as oral, nasal, ophthalmic, rectal, or topical. Sustained release administration is also specifically included in the invention, by such means as depot injections or erodible implants. Localized delivery is particularly contemplated, by such means as delivery via a catheter to one or more arteries, such as the renal artery or a vessel supplying a localized tumor.

[0155] Biologically active anti-TIM-1 antibodies as described herein can be used in a sterile pharmaceutical preparation or formulation to reduce the level of serum TIM-1 thereby effectively treating pathological conditions where, for example, serum TIM-1 is abnormally elevated. Anti-TIM-1 antibodies preferably possess adequate affinity to potently suppress TIM-1 to within the target therapeutic range, and preferably have an adequate duration of action to allow for infrequent dosing. A prolonged duration of action will allow for less frequent and more convenient dosing schedules by alternate parenteral routes such as subcutaneous or intramuscular injection.

[0156] When used for *in vivo* administration, the antibody formulation must be sterile. This is readily accomplished, for example, by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. The antibody ordinarily will be stored in lyophilized form or in solution. Therapeutic antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having an adapter that allows retrieval of the formulation, such as a stopper pierceable by a hypodermic injection needle.

[0157] The route of antibody administration is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, intrathecal, inhalation or intralesional routes, or by sustained release systems as noted below. The antibody is preferably administered continuously by infusion or by bolus injection.

[0158] An effective amount of antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it is preferred that the therapist titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. Typically, the clinician will administer antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays or by the assays described herein.

[0159] Antibodies, as described herein, can be prepared in a mixture with a pharmaceutically acceptable carrier. This therapeutic composition can be administered intravenously or through the nose or lung, preferably as a liquid or powder aerosol (lyophilized). The composition can also be administered parenterally or subcutaneously as desired. When administered systemically, the therapeutic composition should be sterile, pyrogen-free and in a parenterally acceptable solution having due regard for pH, isotonicity, and stability. These conditions are known to those skilled in the art. Briefly, dosage formulations of the compounds described herein are prepared for storage or administration by mixing the compound having the desired degree of purity with physiologically acceptable carriers, excipients, or stabilizers. Such materials are non-toxic to the recipients at the dosages and concentrations employed, and include buffers such as TRIS HCl, phosphate, citrate, acetate and other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium and/or nonionic surfactants such as TWEEN, PLURONICS or polyethyleneglycol.

[0160] Sterile compositions for injection can be formulated according to conventional pharmaceutical practice as described in *Remington: The Science and Practice of Pharmacy* (20th ed, Lippincott Williams & Wilkins Publishers (2003)). For example, dissolution or suspension of the active compound in a vehicle such as water or naturally occurring vegetable oil like sesame, peanut, or cottonseed oil or a synthetic fatty vehicle like ethyl oleate or the like can be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.

[0161] Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer *et al.*, *J. Biomed Mater. Res.*, (1981) 15:167-277 and Langer, *Chem. Tech.*, (1982) 12:98-105, or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*,

Biopolymers, (1983) 22:547-556), non-degradable ethylene-vinyl acetate (Langer *et al.*, *supra*), degradable lactic acid-glycolic acid copolymers such as the LUPRON Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D(-)-3-hydroxybutyric acid (EP 133,988).

[0162] While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated proteins remain in the body for a long time, they can denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for protein stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through disulfide interchange, stabilization can be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

[0163] Sustained-released compositions also include preparations of crystals of the antibody suspended in suitable formulations capable of maintaining crystals in suspension. These preparations when injected subcutaneously or intraperitoneally can produce a sustained release effect. Other compositions also include liposomally entrapped antibodies. Liposomes containing such antibodies are prepared by methods known per se: U.S. Pat. No. DE 3,218,121; Epstein *et al.*, *Proc. Natl. Acad. Sci. USA*, (1985) 82:3688-3692; Hwang *et al.*, *Proc. Natl. Acad. Sci. USA*, (1980) 77:4030-4034; EP 52,322; EP 36,676; EP 88,046; EP 143,949; 142,641; Japanese patent application 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324.

[0164] The dosage of the antibody formulation for a given patient will be determined by the attending physician taking into consideration various factors known to modify the action of drugs including severity and type of disease, body weight, sex, diet, time and route of administration, other medications and other relevant clinical factors. Therapeutically effective dosages can be determined by either *in vitro* or *in vivo* methods.

[0165] An effective amount of the antibodies, described herein, to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it is preferred for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 0.001mg/kg to up to

100mg/kg or more, depending on the factors mentioned above. Typically, the clinician will administer the therapeutic antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays or as described herein.

[0166] It will be appreciated that administration of therapeutic entities in accordance with the compositions and methods herein will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures can be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. *See also* Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance." *Regul. Toxicol. Pharmacol.* 32(2):210-8 (2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals." *Int. J. Pharm.* 203(1-2):1-60 (2000), Charman WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts." *J Pharm Sci* .89(8):967-78 (2000), Powell *et al.* "Compendium of excipients for parenteral formulations" *PDA J Pharm Sci Technol.* 52:238-311 (1998) and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

[0167] It is expected that the antibodies described herein will have therapeutic effect in treatment of symptoms and conditions resulting from TIM-1 expression. In specific embodiments, the antibodies and methods herein relate to the treatment of symptoms resulting from TIM-1 expression including symptoms of cancer. Further embodiments, involve using the antibodies and methods described herein to treat cancers, such as cancer of the lung, colon, stomach, kidney, prostate, or ovary.

Diagnostic Use

[0168] TIM-1 has been found to be expressed at low levels in normal kidney but its expression is increased dramatically in postischemic kidney. Ichimura *et al.*, *J. Biol.*

Chem. 273(7):4135-42 (1998). As immunohistochemical staining with anti-TIM-1 antibody shows positive staining of renal, kidney, prostate and ovarian carcinomas (see below), TIM-1 overexpression relative to normal tissues can serve as a diagnostic marker of such diseases.

[0169] Antibodies, including antibody fragments, can be used to qualitatively or quantitatively detect the expression of TIM-1 proteins. As noted above, the antibody preferably is equipped with a detectable, *e.g.*, fluorescent label, and binding can be monitored by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. These techniques are particularly suitable if the amplified gene encodes a cell surface protein, *e.g.*, a growth factor. Such binding assays are performed as known in the art.

[0170] *In situ* detection of antibody binding to the TIM-1 protein can be performed, for example, by immunofluorescence or immunoelectron microscopy. For this purpose, a tissue specimen is removed from the patient, and a labeled antibody is applied to it, preferably by overlaying the antibody on a biological sample. This procedure also allows for determining the distribution of the marker gene product in the tissue examined. It will be apparent for those skilled in the art that a wide variety of histological methods are readily available for *in situ* detection.

Epitope Mapping

[0171] The specific part of the protein immunogen recognized by an antibody may be determined by assaying the antibody reactivity to parts of the protein, for example an N terminal and C terminal half. The resulting reactive fragment can then be further dissected, assaying consecutively smaller parts of the immunogen with the antibody until the minimal reactive peptide is defined. Anti-TIM-1 mAb 2.70.2 was assayed for reactivity against overlapping peptides designed from the antigen sequence and was found to specifically recognize the amino acid sequence PLPRQNHE (SEQ ID NO:96) corresponding to amino acids 189-202 of the TIM-1 immunogen (SEQ ID NO:54). Furthermore using an alanine scanning technique, it has been determined that the second proline and the asparagine residues appear to be important for mAb 2.70.2 binding.

[0172] Alternatively, the epitope that is bound by the anti-TIM-1 antibodies of the invention may be determined by subjecting the TIM-1 immunogen to SDS-PAGE either in the absence or presence of a reduction agent and analyzed by immunoblotting. Epitope

mapping may also be performed using SELDI. SELDI ProteinChip® (LumiCyte) arrays used to define sites of protein-protein interaction. TIM-1 protein antigen or fragments thereof may be specifically captured by antibodies covalently immobilized onto the PROTEINCHIP array surface. The bound antigens may be detected by a laser-induced desorption process and analyzed directly to determine their mass.

[0173] The epitope recognized by anti-TIM-1 antibodies described herein may be determined by exposing the PROTEINCHIP Array to a combinatorial library of random peptide 12-mer displayed on Filamentous phage (New England Biolabs). Antibody-bound phage are eluted and then amplified and taken through additional binding and amplification cycles to enrich the pool in favor of binding sequences. After three or four rounds, individual binding clones are further tested for binding by phage ELISA assays performed on antibody-coated wells and characterized by specific DNA sequencing of positive clones.

Examples

[0174] The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as limiting upon the invention described herein.

Example 1

Preparation of monoclonal antibodies that bind TIM-1

[0175] The soluble extracellular domain of TIM-1 was used as the immunogen to stimulate an immune response in XenoMouse® animals. A DNA (CG57008-02), which encodes the amino acid sequence for the TIM-1 extracellular domain (minus the predicted N-terminal signal peptide) was subcloned to the baculovirus expression vector, pMelV5His (CuraGen Corp., New Haven, CT), expressed using the pBlueBac baculovirus expression system (Invitrogen Corp., Carlsbad, CA), and confirmed by Western blot analyses. The nucleotide sequence below encodes the polypeptide used to generate antibodies.

```
TCTGTAAAGGTTGGTGGAGAGGCAGGTCCATCTGTCACACTACCCTGCCACTAC
AGTGGAGCTGTCACATCAATGTGCTGGAATAGAGGCTCATGTTCTCTATTTCACA
TGCCAAAATGGCATTGTCTGGACCAATGGAACCCACGTCACCTATCGGAAGGA
CACACGCTATAAGCTATTGGGGGACCTTCAAGAAGGGATGTCTCTTTGACCAT
AGAAAATACAGCTGTGTCTGACAGTGGCGTATATTGTTGCCGTGTTGAGCACCG
TGGGTGGTTCAATGACATGAAAATCACCGTATCATTGGAGATTGTGCCACCCAA
GGTCACGACTACTCCAATTGTCACAACTGTTCCAACCGTCACGACTGTTTCAAC
GAGCACCAGTGTCCAACGACAACGACTGTTCCAACGACAACGTTCCAACAAC
AATGAGCATTCCAACGACAACGACTGTTCCGACGACAATGACTGTTTCAACGAC
```

AACGAGCGTTCCAACGACAACGAGCATTCCAACAACAACAAGTGTTCCAGTGA
 CAACAACGGTCTCTACCTTTGTTCTCCAATGCCTTTGCCCAGGCAGAACCATG
 AACCAGTAGCCACTTCACCATCTTCACCTCAGCCAGCAGAAACCCACCCTACGA
 CACTGCAGGGAGCAATAAAGGAGAGAACCCACCAGCTCACCATTGTACTCTTAC
 ACAACAGATGGGAATGACACCGTGACAGAGTCTTCAGATGGCCTTTGGAATAA
 CAATCAAACCTCAACTGTTCTAGAACATAGTCTACTG (SEQ ID NO:53)

[0176] The amino acid sequence encoded thereby is as follows:

SVKVGGEAGPSVTLPCHYSGAVTSMCWNRGSCSLFTCQNGIVWTNGTHVTYRKDT
 RYKLLGDLRRDVSLENTAVSDSGVYCCRVEHRGWFNDMKITVSLEIVPPKVT
 TPIVTTVPTVTTVRTSTTVPTTTTVPTTTVPTTMSIPTTTTVPTTMTVSTTTSVPTTTSI
 PTTTSVPVTTTVSTFVPPMPLPRQNHEPVATSPSSPQPAETHPTTLQGAIRREPTSSPL
 YSYTTDGNDDTVTESSDGLWNNNQTLFLEHSL (SEQ ID NO:54)

[0177] To facilitate purification of recombinant TIM-1, the expression construct can incorporate coding sequences for the V5 binding domain V5 and a HIS tag. Fully human IgG2 and IgG4 monoclonal antibodies (mAb), directed against TIM-1 were generated from human antibody-producing XenoMouse® strains engineered to be deficient in mouse antibody production and to contain the majority of the human antibody gene repertoire on megabase-sized fragments from the human heavy and kappa light chain loci as previously described in Yang *et al.*, *Cancer Res.* (1999). Two XenoMouse® strains, an hIgG2 (xmg-2) strain and an IgG4 (3C-1) strain, were immunized with the TIM-1 antigen (SEQ ID NO: 54). Both strains responded well to immunization (Tables 2 and 3).

Table 2

Serum titer of XENOMOUSE® hIgG₂ strain immunized with TIM-1 antigen.

Group 1: 5 mice (hIgG₂ strain); mode of immunization = footpad

Mouse ID	Reactivity to TIM-1 Titers via hIgG	
	Bleed After 4 inj.	Bleed After 6 inj.
M716-1	600,000	600,000
M716-2	600,000	500,000
M716-3	200,000	400,000
M716-4	300,000	200,000
M716-5	400,000	400,000
Negative Control	75	110
Positive Control	-	600,000

Table 3**Serum titer of XENOMOUSE® IgG₄ strain immunized with TIM-1 antigen****Group 2: 5 mice (IgG₄ strain); mode of immunization = footpad**

Mouse ID	Reactivity to TIM-1 Titers via hIgG	
	Bleed After 4 inj.	Bleed After 6 inj.
M326-2	15,000	73,000
M326-3	7,500	60,000
M329-1	27,000	30,000
M329-3	6,500	50,000
M337-1	2,500	16,000
Negative Control	<100	90
Positive Control	-	600,000

[0178] Hybridoma cell lines were generated from the immunized mice. Selected hybridomas designated 1.29, 1.37, 2.16, 2.17, 2.24, 2.45, 2.54, 2.56, 2.59, 2.61, 2.70, and 2.76 (and subclones thereof) were further characterized. The antibodies produced by cell lines 1.29 and 1.37 possess fully human IgG2 heavy chains with human kappa light chains while those antibodies produced by cell lines 2.16, 2.17, 2.24, 2.45, 2.54, 2.56, 2.59, 2.61, 2.70, and 2.76 possess fully human IgG4 heavy chains with human kappa light chains.

[0179] The amino acid sequences of the heavy chain variable domain regions of twelve anti-TIM-1 antibodies with their respective germline sequences are shown in Table 4 below. The corresponding light chain variable domain regions amino acid sequence is shown in Table 5 below. "X" indicates any amino acid, preferably the germline sequence in the corresponding amino acid position. The CDRs (CDR1, CDR2, and CDR3) and FRs (FR1, FR2, and FR3) in the immunoglobulins are shown under the respective column headings.

Table 4. Heavy Chain Analysis

mAb	SEQ ID NO.	D	FR1	CDR1	FR2	CDR2	FR3	CDR3	J
	55	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	XXDY	WGQGTILVTVSSA
2.54	26	VH3-33/-/-/JH4b	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFTNYGLH	WVRQAPGKG LDWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCTR	DLDY	WGQGTILVTVSSA
	56	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAX	XXDYSSXXXYGMDV	WGQGTILVTVSSA
2.76	46	VH3-33/D3-22/JH6b	XXXXXQSGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	DFYDSSRYHYGMDV	WGQGTILVTVSSA
	57	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	XXXXSSSWYXXFDY	WGQGTILVTVSSA
2.59	34	VH4-31/D6-13/JH4b	XXXXXQSGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	ESPHSSNNWISGFDC	WGQGTILVTVSSA
	58	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	DYDSSXXXXXFDY	WGQGTILVTVSSA
2.70	42		QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	DYDSSRRHHWGFY	WGQGTILVTVSSA
2.24	18		QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	DYDSSRRHHWGFY	WGQGTILVTVSSA
2.61	38	VH3-33/D3-22/JH4b	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	DYDSSRRHHWGFY	WGQGTILVTVSSA
2.56	30		QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLRAEDTAVYYCAR	DYDSSRRHHWGFY	WGQGTILVTVSSA
	59	Germline	EVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	RIKSKTDGGTTDYAAPVKG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	XDXXXDY	WGQGTILVTVSSA
2.16	10	VH3-15/D3-16/JH4b	XXXXXQSGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	RIKSKTDGGTTDYAAPVKG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	VNDVDY	WGQGTILVTVSSA
	60	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	XXXWXXXFDY	WGQGTILVTVSSA
1.29	2	VH4-61/D1-7/JH4b	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	DYDWSFHDY	WGQGTILVTVSSA
	61	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	XXXSGDY	WGQGTILVTVSSA
2.45	22	VH3-15/D6-19/JH4b	XXXXXQSGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	VNDSDY	WGQGTILVTVSSA
	62	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	VDNSGDY	WGQGTILVTVSSA
1.37	6	VH3-7/-/-/JH4b	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	XDY	WGQGTILVTVSSA
	63	Germline	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	WDY	WGQGTILVTVSSA
2.17	14	VH3-48/-/-/JH4b	QVQLVESGGGVQVQ GRSLRLSCAAS	GFTFSSYGMH	WVRQAPGKG LEWVA	VIWYDGSNKYYADSVKGG	RFTISRDNKNTLYLQMN SLKTEDTAVYYCTX	XXDY	WGQGTILVTVSSA

Table 5. Light Chain Analysis

mAb	SEQ ID NO.	J	FR1	CDR1	FR2	CDR2	FR3	CDR3	J
	64	Germline	EIVLTQSPGTLISLS PGERATLSC	RASQSVSSSYLA	WYQKPGQAPR LLIY	GASSRAT	GIPDRFSGSGGTDFTLISRL EPEDFAVYYC	QOYGSXXLT	FGGGTKVEIKR
2.54	28	A27/JK4	ETQLTQSPGTLISLS PGERVTLSC	RASQSVNNYLA	WYQKPGQAPR LLIY	GASSRAT	GIPDRFSGSGGTDFTLISRL EPEDCAECYC	QOYGSLLPLT	FGGGTKVEIKR
	65	Germline	DIVMTQSPSLSPVT PGEPAISIC	RSSQSLHNSNGYN YLD	WYLRPGQSPQ LLIY	LGSNRAS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQALQTXXT	FGGGTKVEIKR
2.16	12		XXLTQSPSLSPVT PGEPAISIC	RSSQSLHNSNGYN YLD	WYLRPGQSPQ LLIY	LGSNRAS	GVDRFSGSGGTDFTLKISR EAEDIGLYYC	MQALQTPLT	FGGGTKVDIKR
2.45	24	A3/JK4	XXXXTQSPSLSPVT PGEPAISIC	RSSQSLHNSNGYN YLD	WYLRPGQSPQ LLIY	LGSNRAS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQALQTPLT	FGGGTKVEIKR
	66	Germline	DIQMTQSPSSLSAS VGDRVTITC	RASQGIKNDLG	WYQKPGKAPK RLIY	AASSLQS	GVPSRFSGSGGTDFTLISL QPEDFATYYC	LQHSYPLT	FGGGTKVEIKR
1.29	4	A30/JK4	DIQMTQSPSSLSAS IGDRVTITC	RASQGIKNDLG	WYQKPGKAPK RLIY	AASSLQS	GVPSRFSGSGGTDFTLISL QPEDFATYYC	LQHSYPLT	FGGGTKVEIKR
	67	Germline	DIVMTQSPSLSPVT LQGPASISIC	RSSQSLVHSDGNT YLS	WYQKPGQPPR LLIY	KISNRFS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQATQPPXIT	FGQGTKLEIKR
2.17	16	A23/JK5	HIQLTQSPSLSPVT LQGPASISIC	RSSQSLVHSDGNT YLN	WYQKPGQPPR LLIY	KISTRFS	GVDRFSGSGGTDFTLKISR ETDDVGIIYC	MQTTQIPQIT	FGQGTKLEIKR
	68	Germline	DIQMTQSPSSLSAS VGDRVTITC	RASQSISSYLN	WYQKPGKAPK LLIY	AASSLQS	GVPSRFSGSGGTDFTLISL QPEDFATYYC	QOYSTPPT	FGQGTKVEIKR
2.24	20	O12/JK1	DIQMTQSPSSLSAS VGDRVTITC	RASQSISSYLN	WYQKPGKAPK LLIY	AASSLQS	GVPSRFSGSGGTDFTLISL QPEDFATYYC	QOYSTPPT	FGQGTKVEIKR
	69	Germline	DIVMTQSPSLSPVT LQGPASISIC	RSSQSLVHSDGNT YLS	WYQKPGQPPR LLIY	KISNRFS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQATQFPQT	FGQGTKVEIKR
1.37	8	A23/JK1	DIVMTQSPSLSPVT LQGPASISIC	RSSQSLVHSDGNT YLN	WYQKPGQPPR LLIY	MISNRFS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQATESPQT	FGQGTKVEIKR
	70	Germline	DIVMTQSPSLSPVT PGEPAISIC	RSSQSLVHSDGNT TYLD	WYLRPGQSPQ LLIY	TLISYRAS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQRIEFPIT	FGQGTKLEIKR
2.70	44		DIVMTQSPSLSPVT PGEPAISIC	RSSQSLVHSDGNT TYLD	WYLRPGQSPQ LLIY	TLISYRAS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQRIEFPIT	FGQGTKLEIKR
2.56	32	O1/JK5	DIVMTQSPSLSPVT PGEPAISIC	RSSQSLVHSDGNT TYLD	WYLRPGQSPQ LLIY	TLISYRAS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQRIEFPIT	FGQGTKLEIKR
2.76	48		XXXXTQSPSLSPVT PGEPAISIC	RSSQSLVHSDGNT TYLD	WYLRPGQSPQ LLIY	TVSYRAS	GVDRFSGSGGTDFTLKISR EAEDVGYYC	MQRIEFPIT	FGQGTKLEIKR
	71	Germline	RIVLTQSPDFQSVT PKEKVTITC	RASQSIGSSLIH	WYQKPDQSPK LLIK	YASQSF	GVPSRFSGSGGTDFTLINSL EAEDAATYYC	HQSSSLPFT	FGPGTKVDIKR
2.59	36	A26/JK3	XXXXTQSPDFQSVT PKEKVTITC	RASQSIGSSLIH	WYQKPDQSPK LLIK	YASQSF	GVPSRFSGSGGTDFTLINSL EAEDAATYYC	HQSSSLPFT	FGPGTKVDIKR
	72	Germline	DIQMTQSPSSLSAS VGDRVTITC	RASQGIKNDLG	WYQKPGKAPK RLIY	AASSLQS	GVPSRFSGSGGTDFTLISL QPEDFATYYC	LQHSYPPX	FGQGTKLEIKR
2.61	40	A30/JK2	DIQMTQSPSSRCAS VGDRVTITC	RASQGIKNDLA	WYQKPGKAPK RLIY	AASSLQS	GVPSRFSGSGGTDFTLISL QPEDFAAAYC	LQHSYPPS	FGQGTKLEIKR

[0180] Human antibody heavy chain VH3-33 was frequently selected in productive rearrangement for producing antibody successfully binding to TIM-1. Any variants of a human antibody VH3-33 germline in a productive rearrangement making antibody to TIM-1 is within the scope of the invention. Other heavy chain V regions selected in TIM-1 binding antibodies included: VH4-31, VH3-15, VH4-61, VH3-7 and VH3-48. The light chain V regions selected included: A27, A3, A30, A23, O12, O1, and A26. It is understood that the $\lambda\kappa$ XenoMouse® may be used to generate anti-TIM-1 antibodies utilizing lambda V regions.

[0181] The heavy chain variable domain germ line usage of the twelve anti-TIM-1 antibodies is shown in Table 6. The light chain variable domain germ line usage is shown in Table 7 (below).

Table 6. Germ Line Usage of the Heavy Chain Variable Domain Regions

mAb	V Heavy	V Sequence	#N's	N	D1	D1 Sequence	#N's	N	D2	D2 Sequence	#N's	N	JH	J Sequence	Constant Region	CDR1	CDR2	CDR3
2.16	VH3-15 (1-285)	TGTACC	5	TCA GT	D3-16 (291-296)	CGATAA	-N.A.-	-N.A.-	-N.A.-	-N.A.-	7	TGACGTG	JH4b (304-343)	GACTAC	G4 (344-529)	64-93	136-192	289-309
2.70	VH3-33 (1-290)	GAGAGA	0		D3-22 (291-306)	TTACTATGAT AATAGT (SEQ ID NO: 73)	-N.A.-	-N.A.-	-N.A.-	-N.A.-	15	AGACATCA CTGGGG (SEQ ID NO: 74)	JH4b (322-364)	TTTGAC	G4 (365-502)	70-99	142-192	289-330
2.59	VH4-31 (2-284)	GAGAGA	8	ATC CCC TC	D6-13 (293-309)	ATAGCAGCAA CTGGTAC (SEQ ID NO: 75)	-N.A.-	-N.A.-	-N.A.-	-N.A.-	5	TCGGG	JH4b (315-358)	CTTTGA	G4 (359-545)	61-96	139-186	283-324
2.24	VH3-33 (1-296)	GAGAGA	0		D3-22 (297-312)	TTACTATGAT AATAGT (SEQ ID NO: 76)	-N.A.-	-N.A.-	-N.A.-	-N.A.-	15	AGACATCA CTGGGG (SEQ ID NO: 77)	JH4b (328-370)	TTTGAC	G4 (371-568)	76-105	148-198	295-336
1.29	VH4-61 (1-293)	GAGAGA	5	TTA TG	D1-7 (299-304)	ACTGGA	-N.A.-	-N.A.-	-N.A.-	-N.A.-	6	GCTTCC	JH4b (311-355)	ACTTTG	G2 (356-491)	70-105	148-195	292-321
2.61	VH3-33 (1-296)	GAGAGA	0		D3-22 (297-312)	TTACTATGAT AATAGT (SEQ ID NO: 78)	-N.A.-	-N.A.-	-N.A.-	-N.A.-	15	AGACATCA CTGGGG (SEQ ID NO: 79)	JH4b (328-370)	TTTGAC	G4 (371-534)	76-105	148-198	295-336
2.76	VH3-33 (1-281)	TGCGAG	6	GGA TTT	D3-22 (288-300)	CTATGATAGT AGT (SEQ ID NO: 80)	-N.A.-	-N.A.-	-N.A.-	-N.A.-	7	CGTTACC	JH6b (308-358)	ACTAGG	G4 (359-544)	64-93	136-186	283-324
2.54	VH3-33 (1-296)	GCGAGA	-	-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	2	TC	JH4b (299-340)	TTGACT	G4 (341-537)	76-105	148-198	295-306
1.37	VH3-7 (7- 300)	GCGAGA	-	-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	3	TGG	JH4b (304-343)	GACTAC	G2 (344-469)	82-111	154-204	301-309
2.17	VH3-48 (2-291)	TGTGCG	-	-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	-N.A.-	5	CGGGA	JH4b (297-340)	CTTTGA	G4 (341-538)	76-105	148-198	295-306
2.45	VH3-15 (2-286)	CCACAG	7	TCG ATA A	D6-19 (294-299)	CAGTGG	-N.A.-	-N.A.-	-N.A.-	-N.A.-	0		JH4b (300-340)	TGACTA	G4 (341-526)	61-90	133-189	286-306
2.56	VH3-33 (1-290)	GAGAGA	0		D3-22 (291-301)	TTACTATGAT A (SEQ ID NO: 81)	-N.A.-	-N.A.-	-N.A.-	-N.A.-	20	CGAGTCGG CATCAGTG GGGG (SEQ ID NO: 82)	JH4b (322-364)	TTTGAC	G4 (365-527)	70-99	142-192	289-330

Table 7. Germ Line Usage of the Light Chain Variable Domain Regions

mab	VL	V Sequence	#N's	N	JL	J Sequence	Constant Region	CDRL	CDR2	CDR3
2.70	O1 (46-348)	TTTCCT	0		JK5 (349-385)	ATCAC	IGKC (386-522)	115-165	211-231	328-354
2.59	A26 (1-272)	TTTACC	0		JK3 (273-310)	ATTCAC	IGKC (311-450)	58-90	136-156	253-279
2.24	O12 (1-287)	CCCTCC	0		JK1 (288-322)	GACGTT	IGKC (323-472)	70-102	148-168	265-291
1.29	A30 (46-331)	ACCCTC	0		JK4 (332-367)	TCACCTT	IGKC (368-504)	115-147	193-213	310-336
2.56	O1 (46-348)	TTTCCT	0		JK5 (349-385)	ATCAC	IGKC (386-521)	115-165	211-231	328-354
2.61	A30 (1-287)	CCCTCC	3	CAG	JK2 (291-322)	TTTGG	IGKC (323-470)	70-102	148-168	265-291
2.76	O1 (1-290)	GTTC	0		JK5 (291-328)	GATCAC	IGKC (329-419)	58-108	154-174	271-297
1.37	A23 (43-344)	TCCTCA	0		JK1 (345-379)	GACGTT	IGKC (380-454)	112-159	205-225	322-348
2.17	A23 (1-302)	TCCTCA	1	A	JK5 (304-340)	ATCAC	IGKC (341-490)	70-117	163-183	280-309
2.54	A27 (1-286)	GCTCAC	4	TCCC	JK4 (291-328)	GCTCAC	IGKC (329-480)	70-105	151-171	268-297
2.16	A3 (2-290)	AACTCC	2	GC	JK4 (293-328)	TCACCTT	IGKC (329-447)	61-108	154-174	271-297
2.45	A3 (1-287)	AACTCC	2	GC	JK4 (290-325)	TCACCTT	IGKC (326-465)	58-105	151-171	268-294

[0182] The sequences encoding monoclonal antibodies 1.29, 1.37, 2.16, 2.17, 2.24, 2.45, 2.54 2.56, 2.59, 2.61, 2.70, and 2.76, respectively, including the heavy chain nucleotide sequence (A), heavy chain amino acid sequence (B) and the light chain nucleotide sequence (C) with the encoded amino acid sequence (D) are provided in the sequence listing as summarized in Table 1 above. A particular monoclonal antibody, 2.70, was further subcloned and is designated 2.70.2, see Table 1.

Example 2

Antibody reactivity with membrane bound TIM-1 protein by FACS.

[0183] Fluorescent Activated Cell Sorter (FACS) analysis was performed to demonstrate the specificity of the anti-TIM-1 antibodies for cell membrane-bound TIM-1 antigen and to identify preferred antibodies for use as a therapeutic or diagnostic agent. The analysis was performed on two renal cancer cell lines, ACHN (ATCC#:CRL-1611) and CAKI-2 (ATCC#:HTB-47). A breast cancer cell line that does not express the TIM-1 antigen, BT549, was used as a control. Table 8 shows that both antibodies 2.59.2 and 2.70.2 specifically bound to TIM-1 antigen expressed on ACHN and CAKI-2 cells, but not antigen negative BT549 cells. Based on the Geo Mean Ratios normalized to the irrelevant antibody isotype control (pK16), ACHN cells had a higher cell surface expression of TIM-1 protein than CAKI-2 cells.

Table 8

Antibody	BIN	Geo Mean Ratio (relative to negative control)		
		ACHN	CAKI-2	BT549
2.59.2	1	15.2	7.7	1.4
2.70.2	6	19.4	8.8	1.8
1.29	1	17.9		1.2
2.16.1	2	7.9		1.5
2.56.2	5	12.2		1.5
2.45.1	8	4.3		1.1

Example 3

Specificity of the anti-TIM-1 monoclonal antibodies

[0184] The anti-TIM-1 antibodies bound specifically to TIM-1 protein but not an irrelevant protein in an ELISA assay. TIM-1 antigen (with a V5-HIS tag) specific binding results for four of the anti-TIM-1 monoclonal antibodies (1.29, 2.56.2, 2.59.2, and 2.45.1) as well as an isotype matched control mAb PK16.3 are shown in Figure 1. The X axis depicts the antibodies used in the order listed above and the Y axis is the optical density. The respective binding of these antibodies to the irrelevant protein (also with a V5-HIS tag) is shown in Figure 2.

ELISA Protocol.

[0185] A 96-well high protein binding ELISA plate (Corning Costar cat. no. 3590) was coated with 50 μ L of the TIM-1 antigen at a concentration of 5 μ g/mL diluted in coating buffer (0.1M Carbonate, pH9.5), and incubated overnight at 4 oC. The wells were then washed five times with 200-300 μ L of 0.5% Tween-20 in PBS. Next, plates were blocked with 200 μ L of assay diluent (Pharmingen, San Diego, CA, cat. no. 26411E) for at least 1 hour at room temperature. Anti-TIM-1 monoclonal antibodies were then diluted in assay diluent with the final concentrations of 7, 15, 31.3, 62.5, 125, 250, 500 and 1000 ng/mL. An anti-V5-HRP antibody was used at 1:1000 to detect the V5 containing peptide as the positive control for the ELISA. Plates were then washed again as described above. Next 50 μ L of each antibody dilution was added to the proper wells, then incubated for at least 2 hours at room temp. Plates were washed again as described above, then 50 μ L of secondary antibody (goat anti-human-HRP) was added at 1:1000 and allowed to incubate for 1 hour at room temp. Plates were washed again as described above then developed with 100 μ L of TMB substrate solution/well (1:1 ratio of solution A+B) (Pharmingen, San Diego, CA, cat. no. 2642KK). Finally, the reaction was stopped with 50 μ L sulfuric acid and the plates read at 450nm with a correction of 550nm.

Example 4

Antibody Sequences

[0186] In order to analyze structures of antibodies, as described herein, genes encoding the heavy and light chain fragments out of the particular hybridoma were cloned. Gene cloning and sequencing was accomplished as follows. Poly(A)+ mRNA was isolated

from approximately 2×10^5 hybridoma cells derived from immunized XenoMouse® mice using a Fast-Track kit (Invitrogen). The generation of random primed cDNA was followed by PCR. Human VH or human Vκ family specific variable domain primers (Marks *et al.*, 1991) or a universal human VH primer, MG-30 (CAGGTGCAGCTGGAGCAGTCIGG) (SEQ ID NO:83) were used in conjunction with primers specific for the human:

Cy2 constant region (MG-40d; 5'-GCT GAG GGA GTA GAG TCC TGA GGA-3' (SEQ ID NO:84));

Cy1 constant region (HG1; 5' CAC ACC GCG GTC ACA TGG C (SEQ ID NO:85)); or

Cy3 constant region (HG3; 5' CTA CTC TAG GGC ACC TGT CC (SEQ ID NO:86))

or the human Cκ constant domain (hκP2; as previously described in Green *et al.*, 1994). Sequences of human MAbs-derived heavy and kappa chain transcripts from hybridomas were obtained by direct sequencing of PCR products generated from poly(A⁺) RNA using the primers described above. PCR products were also cloned into pCRII using a TA cloning kit (Invitrogen) and both strands were sequenced using Prism dye-terminator sequencing kits and an ABI 377 sequencing machine. All sequences were analyzed by alignments to the "V BASE sequence directory" (Tomlinson *et al.*, MRC Centre for Protein Engineering, Cambridge, UK) using MacVector and Geneworks software programs.

[0187] In each of Tables 4-7 above, CDR domains were determined in accordance with the Kabat numbering system. See Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)).

Example 5

Epitope binning and BiaCore® affinity determination

Epitope binning

[0188] Certain antibodies, described herein were "binned" in accordance with the protocol described in U.S. Patent Application Publication No. 20030157730, published on August 21, 2003, entitled "Antibody Categorization Based on Binding Characteristics."

[0189] MxhIgG conjugated beads were prepared for coupling to primary antibody. The volume of supernatant needed was calculated using the following formula: $(n+10) \times 50\mu\text{L}$ (where n = total number of samples on plate). Where the concentration was

known, 0.5µg/mL was used. Bead stock was gently vortexed, then diluted in supernatant to a concentration of 2500 of each bead per well or 0.5X10⁵ /mL and incubated on a shaker in the dark at room temperature overnight, or 2 hours if at a known concentration of 0.5µg/mL. Following aspiration, 50µL of each bead was added to each well of a filter plate, then washed once by adding 100µL/well wash buffer and aspirating. Antigen and controls were added to the filter plate 50µL/well then covered and allowed to incubate in the dark for 1 hour on shaker. Following a wash step, a secondary unknown antibody was added at 50µL/well using the same dilution (or concentration if known) as used for the primary antibody. The plates were then incubated in the dark for 2 hours at room temperature on shaker followed by a wash step. Next, 50µL/well biotinylated mxhIgG diluted 1:500 was added and allowed to incubate in the dark for 1 hour on shaker at room temperature. Following a wash step, 50µL/well Streptavidin-PE was added at 1:1000 and allowed to incubate in the dark for 15 minutes on shaker at room temperature. Following a wash step, each well was resuspended in 80µL blocking buffer and read using a Luminex system.

[0190] Table 9 shows that the monoclonal antibodies generated belong to eight distinct bins. Antibodies bound to at least three distinct epitopes on the TIM-1 antigen.

Determination of anti-TIM-1 mAb affinity using BiaCore® analysis

[0191] BiaCore® analysis was used to determine binding affinity of anti-TIM-1 antibody to TIM-1 antigen. The analysis was performed at 25°C using a BiaCore® 2000 biosensor equipped with a research-grade CM5 sensor chip. A high-density goat α human antibody surface over a CM5 BiaCore® chip was prepared using routine amine coupling. Antibody supernatants were diluted to ~ 5 µg/mL in HBS-P running buffer containing 100 µg/mL BSA and 10 mg/mL carboxymethyl dextran. The antibodies were then captured individually on a separate surface using a 2 minute contact time, and a 5 minute wash for stabilization of antibody baseline.

[0192] TIM-1 antigen was injected at 292 nM over each surface for 75 seconds, followed by a 3-minute dissociation. Double-referenced binding data were obtained by subtracting the signal from a control flow cell and subtracting the baseline drift of a buffer inject just prior to the TIM-1 injection. TIM-1 binding data for each mAb were normalized for the amount of mAb captured on each surface. The normalized, drift-corrected responses were also measured. The kinetic analysis results of anti-TIM-1 mAb binding at 25°C are listed in Table 9 below.

Table 9
Competition Bins and K_Ds for TIM-1-specific mAbs

Bin	Antibody	Affinity nM by BIAcore
1	2.59	0.38
	1.29	3.64
2	2.16	0.79
3	2.17	2.42
4	1.37	2.78
	2.76	0.57
	2.61	1.0
5	2.24	2.42
	2.56	1.1
6	2.70	2.71
7	2.54	3.35
8	2.45	1.15

Example 6

Epitope Mapping

[0193] Anti-TIM-1 mAb 2.70.2 was assayed for reactivity against overlapping peptides designed from the TIM-1 antigen sequence. Assay plates were coated with the TIM-1 fragment peptides, using irrelevant peptide or no peptide as controls. Anti-TIM-1 mAb 2.70.2 was added to the plates, incubated, washed and then bound antibody was detected using anti-human Ig HRP conjugate. Human antibody not specific to TIM-1, an isotype control antibody or no antibody served as controls. Results showed that mAb 2.70.2 specifically reacted with a peptide having the amino acid sequence PMPLPRQNHEPVAT (SEQ ID NO:87), corresponding to amino acids 189-202 of the TIM-1 immunogen (SEQ ID NO:54).

[0194] Specificity of mAb 2.70.2 was further defined by assaying against the following peptides:

- A) PMPLPRQNHEPVAT (SEQ ID NO:87)
- B) PMPLPRQNHEPV (SEQ ID NO:88)
- C) PMPLPRQNHE (SEQ ID NO:89)
- D) PMPLPRQN (SEQ ID NO:90)
- E) PMPLPR (SEQ ID NO:91)

F) PLPRQNHEPVAT (SEQ ID NO:92)

G) PRQNHEPVAT (SEQ ID NO:93)

H) QNHEPVAT (SEQ ID NO:94)

I) HEPVAT (SEQ ID NO:95)

[0195] Results showed mAb 2.70.2 specifically bound to peptides A, B, C, and F, narrowing the antibody epitope to PLPRNHE (SEQ ID NO:96)

[0196] As shown in Table 10, synthetic peptides were made in which each amino acid residue of the epitope was replaced with an alanine and were assayed for reactivity with mAb 2.70.2. In this experiment, the third proline and the asparagines residues were determined to be critical for mAb 2.70.2 binding. Furthermore, assays of peptides with additional N or C terminal residues removed showed mAb 2.70.2 binding was retained by the minimal epitope LPRQNH (SEQ ID NO:97)

Table 10

										SEQ ID NO:	mAb 2.70.2 Reactivity
P	M	P	L	P	R	Q	N	H	E	89	+
P	M	P	A	P	R	Q	N	H	E	98	+
P	M	P	L	A	R	Q	N	H	E	99	-
P	M	P	L	P	A	Q	N	H	E	100	+
P	M	P	L	P	R	A	N	H	E	101	+
P	M	P	L	P	R	Q	A	H	E	102	-
P	M	P	L	P	R	Q	N	A	E	103	+
		P	L	P	R	Q	N	H	E	104	+
			L	P	R	Q	N	H	E	105	+
		P	L	P	R	Q	N	H	E	106	+
			L	P	R	Q	N	H	E	107	+

Example 7

Immunohistochemical (IHC) analysis of TIM-1 expression in normal and tumor tissues

[0197] Immunohistochemical (IHC) analysis of TIM-1 expression in normal and tumor tissue specimens was performed with techniques known in the art. Biotinylated fully

human anti-TIM-1 antibodies 2.59.2, 2.16.1 and 2.45.1 were analyzed. Streptavidin-HRP was used for detection.

[0198] Briefly, tissues were deparaffinized using conventional techniques, and then processed using a heat-induced epitope retrieval process to reveal antigenic epitopes within the tissue sample. Sections were incubated with 10% normal goat serum for 10 minutes. Normal goat serum solution was drained and wiped to remove excess solution. Sections were incubated with the biotinylated anti-TIM-1 mAb at 5 µg/mL for 30 minutes at 25°C, and washed thoroughly with PBS. After incubation with streptavidin-HRP conjugate for 10 minutes, a solution of diaminobenzidine (DAB) was applied onto the sections to visualize the immunoreactivity. For the isotype control, sections were incubated with a biotinylated isotype matched negative control mAb at 5 µg/mL for 30 minutes at 25°C instead of biotinylated anti-TIM-1 mAb. The results of the IHC studies are summarized in Tables 11 and 12.

[0199] The specimens were graded on a scale of 0-3, with a score of 1+ indicating that the staining is above that observed in control tissues stained with an isotype control irrelevant antibody. The corresponding histological specimens from one renal tumor and the pancreatic tumor are shown in Figure 3 (A and B). In addition to these the renal and pancreatic tumors, specimens from head and neck cancer, ovarian cancer, gastric cancer, melanoma, lymphoma, prostate cancer, liver cancer, breast cancer, lung cancer, bladder cancer, colon cancer, esophageal cancer, and brain cancer, as well the corresponding normal tissues were stained with anti-TIM-1 mAb 2.59.2. Overall, renal cancer tissue samples and pancreatic cancer tissue samples highly positive when stained with anti-TIM-1 mAb 2.59.2. No staining in normal tissues was seen. These results indicate that TIM-1 is a marker of cancer in these tissues and that anti-TIM-1 mAb can be used to differentiate cancers from normal tissues and to target TIM-1 expressing cells *in vivo*.

Table 11

Immunohistology Renal tumors expression of TIM-1 protein
detected by anti-TIM-1 mAb 2.59.2

Specimen	Cell Type	Histology	Score
1	Malignant cells	Not known	0
1	Other	Not cell associated	2
2	Malignant cells	Clear Cell	2
3	Malignant cells	Clear Cell	0

4	Malignant cells	Clear Cell	3
5	Malignant cells	Clear Cell	2 (occasional)
6	Malignant cells	Not known	2
7	Malignant cells	Clear Cell	2
8	Malignant cells	Clear Cell	0
9	Malignant cells	Clear Cell	2 (occasional)
10	Malignant cells	Clear Cell	1-2
11	Malignant cells	Not known	3 (many)
12	Malignant cells	Clear Cell	1-2
12	Other	Not cell associated	2
13	Malignant cells	Clear Cell	2 (occasional)
14	Malignant cells	Clear Cell	1-2
15	Malignant cells	Clear Cell	3-4
16	Malignant cells	Not known	1-2
17	Malignant cells	Not known	4 (occasional)
18	Malignant cells	Not known	1-2
19	Malignant cells	Clear Cell	0
20	Malignant cells	Clear Cell	3-4
21	Malignant cells	Clear Cell	2 (occasional)
22	Malignant cells	Clear Cell	3
23	Malignant cells	Clear Cell	2
24	Malignant cells	Not known	3-4 occasional
25	Malignant cells	Not known	2-3
26	Malignant cells	Not known	3
27	Malignant cells	Clear Cell	2
27	Other	Not cell associated	2
28	Malignant cells	Not known	2
29	Malignant cells	Clear Cell	2-3
30	Malignant cells	Clear Cell	2
31	Malignant cells	Clear Cell	2-3
32	Malignant cells	Clear Cell	0
33	Malignant cells	Clear Cell	0
34	Malignant cells	Clear Cell	2
34	Other	Not cell associated	2
35	Malignant cells	Clear Cell	2-3
36	Malignant cells	Clear Cell	3
37	Malignant cells	Not known	3
38	Malignant cells	Clear Cell	3
39	Malignant cells	Not known	2
40	Malignant cells	Clear Cell	2-3

Table 12

Normal Human Tissue Immunohistology with anti-TIM-1 mAb 2.59.2

Tissue	Score	
	Specimen 1	Specimen 2
Adrenal Cortex	0	0

Adrenal Medulla	0	1
Bladder: Smooth muscle	0	0
Bladder: Transitional Epithelium	3	0
Brain cortex: Glia	0	0
Brain cortex: Neurons	0	0
Breast: Epithelium	0	0
Breast: Stroma	0	0
Colon: Epithelium	0	0
Colon: Ganglia	0	NA
Colon: Inflammatory compartment	3-4 (occasional)	3 (occasional)
Colon: Smooth muscle	1 (occasional)	0
Heart: Cardiac myocytes	0	0
Kidney cortex: Glomeruli	2-3	2
Kidney cortex: Tubular epithelium	2	2-3
Kidney medulla: Tubular epithelium	2	0
Kidney medulla: other	NA	2-3
Liver: Bile duct epithelium	0	0
Liver: Hepatocytes	1-2	1
Liver: Kupffer cells	0	0
Lung : Airway epithelium	0	0
Lung: Alveolar macrophages	2 (occasional)-3	2-3 (occasional)
Lung: other	3	NA
Lung: Pneumocytes	2-3 (occasional)	2-3 (occasional)
Ovary: Follicle	2 (occasional)	1-2
Ovary: Stroma	1	1 (occasional)
Pancreas: Acinar epithelium	0	1 (occasional)
Pancreas: Ductal epithelium	0	0
Pancreas: Islets of Langerhans	0	0
Placenta: Stroma	0	0
Placenta: Trophoblasts	0	0
Prostate: Fibromuscular stroma	0	0
Prostate: Glandular epithelium	0	0
Skeletal muscle: Myocytes	0	0
Skin: Dermis	0	0
Skin: Epidermis	0	0
Small intestine: Epithelium	0	0
Small intestine: Ganglion	0	0
Small intestine: Inflammatory compartment	0	0
Small intestine: Smooth muscle cells	0	0
Spleen: Red pulp	0	2 (rare)
Spleen: white pulp	0	0
Stomach: Epithelium	0	0
Stomach: Smooth Muscle Cells	0	0
Testis: Leydig cells	2	1-2
Testis: Seminiferous epithelium	1	2

Thymus: Epithelium	0	0
Thymus: Lymphocytes	2 (rare)	2 (occasional)
Thyroid: Follicular epithelium	0	0
Tonsil: Epithelium	0	0
Tonsil: Lymphocytes	3 (occasional)	2 (occasional)
Uterus: Endometrium	0	0
Uterus: Myometrium	0	0

Example 8

Antibody mediated toxin killing

[0200] A clonogenic assay as described in the art was used to determine whether primary antibodies can induce cancer cell death when used in combination with a saporin toxin conjugated secondary antibody reagent. Kohls and Lappi, *Biotechniques*, 28(1):162-5 (2000).

Assay Protocol

[0201] ACHN and BT549 cells were plated onto flat bottom tissue culture plates at a density of 3000 cells per well. On day 2 or when cells reached ~25% confluency, 100 ng/well secondary mAb-toxin (goat anti-human IgG-saporin; Advanced Targeting Systems; HUM-ZAP; cat. no. IT-22) was added. A positive control anti-EGFR antibody, mAb 2.7.2, mAb 2.59.2, or an isotype control mAb was then added to each well at the desired concentration (typically 1 to 500 ng/mL). On day 5, the cells were trypsinized, transferred to a 150 mm tissue culture dish, and incubated at 37 °C. Plates were examined daily. On days 10-12, all plates were Giemsa stained and colonies on the plates were counted. Plating efficiency was determined by comparing the number of cells prior to transfer to 150 mm plates to the number of colonies that eventually formed.

[0202] The percent viability in antigen positive ACHN and antigen negative BT549 cell lines are presented in Figure 4 and Figure 5 respectively. In this study, the cytotoxic chemotherapy reagent 5 Fluorouracil (5-FU) was used as the positive control and induced almost complete killing, whereas the saporin conjugated-goat anti-human secondary antibody alone had no effect. A monoclonal antibody (NeoMarkers MS-269-PABX) generated against the EGF receptor expressed by both cell lines was used to demonstrate primary antibody and secondary antibody- saporin conjugate specific killing. The results indicate that both cell lines were susceptible to EGFR mAb mediated toxin

killing at 100 ng/mL. At the same dose, both the anti-TIM-1 mAb 2.59.2 and the anti-TIM-1 mAb 2.70.2 induced over 90% ACHN cell death as compared to 0% BT549 cell death.

Antibody toxin conjugate mediated killing: Clonogenic Assay

[0203] CAKI-1 and BT549 cells were plated onto flat bottom tissue culture plates at a density of 3000 cells per well. On day 2 or when cells reach ~25% confluency, various concentrations (typically 1 to 1000 ng/ml) of unconjugated and Auristatin E (AE)-conjugated mAb, which included anti-EGFR, anti-TIM-1 mAb 2.7.2, anti-TIM-1 mAb 2.59.2 or isotype control mAb, were added to cells. Each of these antibodies was conjugated to AE. The monoclonal antibody (NeoMarkers MS-269-PABX) generated against the EGF receptor, which is expressed by both cell lines, was used as a positive control to demonstrate specific killing mediated by AE-conjugated antibody. On day 5, the cells were trypsinized, transferred to a 150 mm tissue culture dish, and incubated at 37 °C. Plates were examined daily. On days 10-12, all plates were Giemsa stained and colonies on the plates were counted. Plating efficiency was determined by counting the cells prior to transfer to 150 mm plates and compared to the number of colonies that eventually formed.

[0204] The percent viability in antigen positive CAKI-1 and antigen negative BT549 cell lines are presented in Figures 6 and 7, respectively.

[0205] The results indicate that unconjugated and AE-conjugated isotype control mAb had no effect on growth of both CAKI-1 and BT549 cells. However, both cell lines were susceptible to AE-EGFR mAb mediated toxin killing in a dose-dependent fashion. At the maximum dose, both anti-TIM-1 mAbs (2.59.2 and 2.70.2) induced over 90 % CAKI-1 cell death when compared to their unconjugated counterparts. The response was dose dependent. At the same dose range, both anti-TIM-1 mAbs 2.59.2 and 2.70.2 did not affect the survival of BT549 cells.

Example 9

Human Tumor Xenograft Growth Delay Assay

[0206] A tumor growth inhibition model was used according to standard testing methods. Geran *et al.*, *Cancer Chemother. Rep.* 3:1-104 (1972). Athymic nude mice (nu/nu) were implanted with either tumor cells or tumor fragments from an existing host, in particular, renal (CaKi-1) or ovarian (OVCAR) carcinoma tumor fragments were used. These animals were then treated with an anti-TIM-1 antibody immunotoxin conjugate, for

example, mAb 2.70.2 AE conjugate at doses ranging from 1 to 20 mg/kg body weight, twice weekly for a period of 2 weeks. Tumor volume for treated animals was assessed and compared to untreated control tumors, thus determining the tumor growth delay.

[0207] After reaching a volume of 100 mm³ animals are randomized and individually identified in groups of 5 individuals per cage. Protein or antibody of interest was administered via conventional routes (intraperitoneal, subcutaneous, intravenous, or intramuscular) for a period of 2 weeks. Twice weekly, the animals are evaluated for tumor size using calipers. Daily individual animal weights are recorded throughout the dosing period and twice weekly thereafter. Tumor volume is determined using the formula: Tumor volume (in mm³) = (length x width x height) x 0.536. The volume determinations for the treated groups are compared to the untreated tumor bearing control group. The difference in time for the treated tumors to reach specific volumes is calculated for 500, 1000, 1500 and 2000 mm³. Body weights are evaluated for changes when compared to untreated tumor bearing control animals. Data are reported as tumor growth in volume plotted against time. Body weights for each experimental group are also plotted in graph form.

[0208] Results show that the treatment is well tolerated by the mice. Specifically, complete regressions were noted in both the IGROV1 ovarian (6.25 mg/kg i.v. q4dX4) and the Caki-1 (3.3 mg/kg i.v. q4dX4) renal cell carcinoma models. No overt toxicity was observed in mice at doses up to 25 mg/kg (cumulative dose of 100 mg/kg). These data indicate that treatment with anti-TIM-1 mAb AE conjugate inhibits tumor growth of established CaKi-1 and OVCAR tumors, thus making these antibodies useful in the treatment of ovarian and renal carcinomas.

Example 10

Treatment of Renal Carcinoma with anti-TIM-1 antibodies

[0209] A patient in need of treatment for a renal carcinoma is given an intravenous injection of anti-TIM-1 antibodies coupled to a cytotoxic chemotherapeutic agent or radiotherapeutic agent. The progress of the patient is monitored and additional administrations of anti-TIM-1 antibodies are given as needed to inhibit growth of the renal carcinoma. Following such treatment, the level of carcinoma in the patient is decreased.

Example 11

FACS analysis of expression of TIM-1 protein on CD4+ T cells

[0210] Mononuclear cells were isolated from human blood diluted 1:1 in PBS, by spinning over Ficoll for 20 minutes. The mononuclear cells were washed twice at 1000 rpm with PBS -Mg and Ca and re-suspended in Miltenyi buffer (Miltenyi Biotec Inc., Auburn, CA); PBS, 0.5% BSA, 5 mM EDTA at approximately 108 cells/mL. 20 μ L of CD4 Miltenyi beads were added per 107 cells and incubated for 15 minutes on ice. Cells were washed with a 10-fold excess volume of Miltenyi buffer. A positive selection column (type VS+) (Miltenyi Biotec Inc., Auburn, CA) was washed with 3 mL of Miltenyi buffer. The pelleted cells were re-suspended at 108 cells per mL of Miltenyi buffer and applied to the washed VS column. The column was then washed three times with 3 mL of Miltenyi buffer. Following this, the VS column was removed from the magnetic field and CD4+ cells were eluted from the column with 5 mL of Miltenyi buffer. Isolated CD4+ lymphocytes were pelleted and re-suspended in DMEM 5% FCS plus additives (non-essential amino acids, sodium pyruvate, mercaptoethanol, glutamine, penicillin, and streptomycin) at 106 cells/mL. 1x106 freshly isolated resting CD4+ T cells were transferred into flow cytometry tubes and washed with 2 mL/tube FACS staining buffer (FSB) containing PBS, 1% BSA and 0.05% NaN₃. Cells were spun down and supernatant removed. Cells were blocked with 20% goat serum in FSB for 30 minutes on ice. Cells were washed as above and incubated with 10 μ g/mL of primary human anti-TIM-1 mAb or control PK16.3 mAb in FSB (200 μ L) for 45 minutes on ice followed by washing. Secondary goat anti-human PE conjugated antibody was added at 1:50 dilution for 45 minutes on ice in the dark, washed, resuspended in 500 μ L of PBS containing 1% formaldehyde and kept at 4°C until flow cytometry analysis was performed.

[0211] FACS analysis was performed to determine the expression of TIM-1 protein as detected with five anti-TIM-1 monoclonal antibodies (2.59.2, 1.29, 2.70.2, 2.56.2, 2.45.1) on human and mouse resting CD4+ T cells, as well as human activated and human polarized CD4+ T cells. These analyses demonstrate that freshly isolated resting human CD4+ T cells do not express TIM-1, while a major fraction of polarized human Th2 and Th1 cells do express TIM-1.

[0212] FACS Analysis of the Expression of the TIM-1 protein on human CD4+ Th2 cells using five anti-TIM-1 monoclonal antibodies is shown in Table 13. The

experiment is described in the left-hand column and the labeled antibody is specified along the top row. Data is reported as the geometric mean of the fluorescence intensity.

Table 13

FACS Analysis of the Expression of the TIM-1 protein on human CD4+ Th2 cells

Experiment	Geometric mean of fluorescence intensity					
	Control PK16.3	Anti-TIM-1 mAb				
		1.29	2.45.1	2.56.2	2.59.2	2.70.2
Resting Human CD4+ T cells	4.6	4.7	5.1	6	4.9	N/A
Polarized Human CD4+ Th2 Cells	8.4	22.3	42.4	564.1	22	27.8

[0213] Table 14 demonstrates that over the course of 5 days, continual stimulation of T cells results in an increase in TIM-1 expression, as measured by anti-TIM-1 mAb 2.70.2, as compared to the control PK16.3 antibody. Furthermore, addition of matrix metalloproteinase inhibitor (MMPI) did not measurably increase TIM-1 expression, demonstrating that the receptor is not shed from T cells under these experimental conditions. Thus, expression of the TIM-1 protein and specific antibody binding is specific to activated Th1 and Th2 cells, which in turn, are characteristic of inflammatory response, specifically asthma.

Table 14

Percent of activated T cells that express TIM-1

		<i>Day 0</i>	<i>Day 1</i>	<i>Day 2</i>	<i>Day 4</i>	<i>Day 5</i>
Control PK16.3	- MMPI	1	3	3	1	1
	+ MMPI	1	2	6	2	2
TIM-1 2.70.2	- MMPI	1	8	10	5	13
	+ MMPI	1	10	14	10	19

Example 12

Cytokine assays

[0214] IL-4, IL-5, IL-10, IL-13, and IFN γ production levels by activated Th1 and Th2 cell were measured in culture supernatants treated with anti-TIM-1 antibodies using standard ELISA protocols. Cytokine production by Th1 or Th2 cells treated with anti-TIM-1 antibodies was compared to Th1 or Th2 cells treated with the control PK16.3 antibody. In addition, the following samples were run in parallel as internal controls: i) anti-CD3 treated Th1 or Th2 cells, where no cytokine production is expected because of the absence of co-stimulation, ii) anti-CD3/anti-CD28 stimulated Th1 or Th2 cells, expected to show detectable cytokine production, and iii) untreated Th1 or Th2 cells. CD4 $^{+}$ T cells were isolated as described in the Example above. Isolated CD4 $^{+}$ lymphocytes were then spun down and re-suspended in DMEM 5% FCS plus additives (non-essential amino acids, sodium pyruvate, mercaptoethanol, glutamine, penicillin, and streptomycin) at 10^6 cells/mL. Falcon 6-well non-tissue culture treated plates were pre-coated overnight with anti-CD3 (2 μ g/mL) and anti-CD28 (10 μ g/mL) (600 μ L total in Dulbecco's PBS) overnight at 4°C. The plates were washed with PBS and CD4 $^{+}$ lymphocytes were suspended at 500,000 cells/mL in Th2 medium: DMEM+ 10% FCS plus supplements and IL-2 5ng/mL, IL-4 5 ng/mL, anti-IFN gamma 5 μ g/mL and cells were stimulated 4-6 days at 37 °C and 5% CO $_2$ in the presence of 5 μ g/mL of mAb recognizing the TIM-1 protein or isotype matched negative control mAb PK16.3.

[0215] In another set of experiments, CD4 $^{+}$ lymphocytes were suspended at 500,000 cells/mL in Th1 medium: DMEM+ 10% FCS plus supplements and IL-2 5 ng/mL, IL12 5 ng/mL, anti-IL-4 5 μ g/mL and stimulated 4-6 days 37°C temp and 5% CO $_2$ in the presence of 5 μ g/mL TIM-1 or isotype matched control mAb PK16.3. Cells were washed two times in DMEM and resuspended in DMEM, 10% FCS plus supplements and 2 ng/mL IL-2 (500,000 cells/mL) in the presence of 5 μ g/mL TIM-1 mAb or control PK16.3 mAb and cultured (rested) for 4-6 days at 37°C and 5% CO $_2$. The process of activation and resting was repeated at least once more as described above with the addition of anti-CD95L (anti-FAS ligand) to prevent FAS-mediated apoptosis of cells. Falcon 96-well non-tissue culture treated plates pre-coated overnight with anti-CD3 mAb at 500 ng/mL and costimulatory molecule B7H2 (B7 homolog 2) 5 μ g/mL were washed and 100 μ L of TIM-1 mAb treated Th1 or Th2 (200,000 cells) added per well. After 3 days of culture, the

supernatants were removed and IL-4, IL-5, IL-10, IL-13, and IFN γ levels were determined by ELISA (Pharmingen, San Diego, CA or R&D Systems, Minneapolis, MN).

[0216] As demonstrated below, anti-TIM-1 mAb significantly inhibited release of the tested cytokines by Th1 and Th2 cells (see Figures 8-17). Results where inhibition of cytokine production is significant ($p=0.02-0.008$), are marked on the bar graphs with an asterisk. Tables 15 and 16 summarize the bar graphs in Figures 8-17.

Table 15

Cytokine Inhibition in CD4⁺ Th1 cells using anti-TIM-1 antibodies in two independent human donors

Experiments that demonstrate significant inhibition of cytokine production are marked with an asterisk: P= 0.01 to 0.05 *; P=0.005 to 0.009 **; P=0.001 to 0.004 ***

Donor 12+17		Percentage of Control Antibody				
TH1	Cytokines	IL-5	IL-4	IL-10	IL-13	INF γ
	Anti-TIM-1 mAbs					
	2.56.2	100.17	28.49 *	63.76 *	86.45	93.69
	2.45.1	90.23	39.78 *	83.98	96.25	100.6
	1.29	94.63	81.05	60.77 **	73.95 ***	93.51
	2.59.2	66.62 *	31.40 *	68.99 *	54.5 ***	128.12

Table 16**Cytokine Inhibition in CD4+ Th2 cells using anti-TIM-1 antibodies in two independent human donors**

Experiments that demonstrate significant inhibition of cytokine production are marked with an asterisk: P= 0.01 to 0.05 *; P=0.005 to 0.009 **; P=0.001 to 0.004 ***

Donor 12+17		Percentage of Control Antibody				
TH2	Cytokines	IL-5	IL-4	IL-10	IL-13	INF γ
	Anti-TIM-1 mAbs					
	2.56.2	112.07	103.46	93.97	86.45	88.30
	2.45.1	148.7	25.66 ***	55.97 *	86.81	25.66 *
	1.29	80.26	112.54	44.45 *	48.91 **	112.54
	2.59.2	23.62 *	19.17 **	43.86 *	43.71 ***	19.18 *

[0217] A summary of Th2 cytokine inhibition data obtained from multiple experiments with different donors is provided in Table 17. Each experiment used purified CD4+ cells isolated from whole blood samples from two independent donors. Cytokine production is reported as the percent of cytokine production detected using the control PK16.3 mAb. The anti-TIM-1 mAb used in each experiment is specified along the bottom row. Results that report significant cytokine inhibition are underlined in Table 17 below. The use of "ND" indicates that the experiment was not performed. These results do reflect donor dependent variability but show that mAbs 2.59.2 and 1.29 reproducibly block one or more of the Th2 cytokines.

Table 17Summary of Cytokine Inhibition using anti-TIM-1 mAbs 2.59.2 and 1.29 in 5 independent human donor groups

Results of experiments that report inhibition greater than 50% of that seen using the control PK16.3 antibody are underlined.

Donor ID Cytokine	12+17	12+14	13+14	14	12
IL-4	<u>19</u>	626	130	ND	ND
IL-5	<u>24</u>	<u>5</u>	122	67	<u>2</u>
IL-10	<u>44</u>	83	<u>19</u>	<u>45</u>	109
IL-13	<u>44</u>	ND	<u>17</u>	100	91
	Anti-TIM-1 mAb 2.59.2	Anti-TIM-1 mAb 1.29			

Example 13Construction, expression and purification of anti-TIM-1 scFv.

[0218] The VL and VH domains of mAb 2.70 were used to make a scFv construct. The sequence of the anti-TIM-1 scFv was synthesized by methods known in the art.

[0219] The nucleotide sequence of anti-TIM-1 scFv is as follows:

ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAG
 CCGGCCATGGCCGATATTGTGATGACCCAGACTCCACTCTCCCTGCCCGTCACC
 CCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCGGAGCCTCTTGATAGT
 GATGATGGAAACACCTATTTGGACTGGTACCTGCAGAAGCCAGGGCAGTCTCC
 ACAGCTCCTGATCTACACGCTTTCCTATCGGGCCTCTGGAGTCCCAGACAGGTT
 CAGTGGCAGTGGGTCAGGCACTGATTTCACTGAAAATCAGCAGGGTGGAGG
 CTGAGGATGTTGGAGTTTATTACTGCATGCAACGTGTAGAGTTTCCTATCACCTT
 CGGCCAAGGGACACGACTGGAGATTAACTTTCCGCGGACGATGCGAAAAAGG
 ATGCTGCGAAGAAAGATGACGCTAAGAAAGACGATGCTAAAAAGGACCTCCAG
 GTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAG
 ACTCTCCTGTGCAGCGTCTGGATTCATCTTCAGTCGCTATGGCATGCACTGGGTC
 CGCCAGGCTCCAGGCAAGGGGCTGAAATGGGTGGCAGTTATATGGTATGATGG
 AAGTAATAAACTCTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGA
 CAATCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA
 CGGCTGTGTATTACTGTGCGAGAGATTACTATGATAATAGTAGACATCACTGGG

GGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCGATT
ATAAGGACGATGATGACAAATAG (SEQ ID NO:108)

[0220] The amino acid sequence of mature anti-TIM-1 scFv is as follows:

DIVMTQTPLSLPVTGPGEPAISCRSSRSLLDSDDGNTYLDWYLQKPGQSPQLLIYTLS
YRASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRFEPITFGQGTRLEIKLS
ADDAKKDAAKKDDAKKDDAKKDLQVLVESGGGVVQPGRSLRLSCAASGFIFSR
YGMHWVRQAPGKGLKWWAVIWDGSGNKLADSVKGRFTISRDNKNTLYLQMN
SLRAEDTAVYYCARDYYDNSRHHWGFYWGQGLVTVSSASDYKDDDDK (SEQ
ID NO:109)

[0221] The synthesized DNA can be inserted into the pET-20b(+) expression vector, for periplasmic expression in *E. coli*. Cells are grown and the periplasmic proteins prepared using standard protocols. Purification of the anti-TIM-1 scFv is achieved using an anti-FLAG M2 affinity column as per the manufacturer's directions. The predicted molecular weight of the mature protein is 30222.4 daltons. This purified scFv is used in the assays described below to test for biological activity. The scFv construct is comprised of a signal peptide (SP), VL (VL1) derived from mAb 2.70, a linker (L4) based on the 25 amino acid linker 205C, the VH (VH1) derived from mAb 2.70, and a Tag (in this case the FLAG tag). It will be obvious to those skilled in the art that other SP, linker and tag sequences could be utilized to get the same activity as the anti-TIM-1 scFv antibody described herein.

Example 14

Construction, expression and purification of anti-TIM-1 and anti-CD3 bispecific scFv1

[0222] The basic formula for the construction of this therapeutic protein is as follows:

SP1 – VL1 – L1 – VH1 – L2 – VH2 – L3 – VL2 – Tag

[0223] The signal peptide SP1 is the same as IgG kappa signal peptide VKIII A27 from Medical Research Council (MRC) Centre for Protein Engineering, University of Cambridge, UK.

[0224] Other signal peptides can also be used and will be obvious to those skilled in the art. This protein is designed to be expressed from mammalian cells. The predicted molecular weight of the mature cleaved protein is 54833.3 dalton. L1 corresponds to the (Gly4Ser)₃ linker, while linker 2 (L2) corresponds to the short linker sequence: GGGGS. L3 is an 18 amino acid linker. VH2 corresponds to the anti-CD3 variable heavy chain domain from Genbank (accession number CAE85148) while VL1 corresponds to the

anti-CD3 variable light chain domain from Genbank (accession number CAE85148). The tag being used for this construct is a His tag to facilitate purification and detection of this novel protein. Standard protocols are used to express and purify this His tagged protein, which is tested for activity and tumor cell killing in the protocols described below.

[0225] The amino acid and nucleic acid numbering for the components comprising the anti-TIM-1 and anti-CD3 bispecific scFv1 is as follows:

SP: -20 to -1 aa; -60 to -1 nt

VL1: 1-113 aa; 1-339nt

L1: 114-128 aa; 340-384nt

VH1: 129-251 aa; 385-753nt

L2: 252-256 aa; 754-768nt

VH2: 257-375 aa; 769-1125nt

L3: 376-393 aa; 1126-1179nt

VL2: 394-499 aa; 1180-1497nt

Tag: 500-505 aa; 1498-1515nt

[0226] The nucleotide sequence of anti-TIM-1 and anti-CD3 bispecific scFv1 is as follows:

ATGGAAACCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATAACC
ACCGGAGATATTGTGATGACCCAGACTCCACTCTCCCTGCCCCGTACCCCTGGA
GAGCCGGCCTCCATCTCCTGCAGGTCTAGTCGGAGCCTCTTGATAGTGATGAT
GGAAACACCTATTTGGACTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTC
CTGATCTACACGCTTTCCTATCGGGCCTCTGGAGTCCCAGACAGGTTCACTGGC
AGTGGGTCAAGCACTGATTTCACTGAAAATCAGCAGGGTGGAGGCTGAGGA
TGTTGGAGTTTATTACTGCATGCAACGTGTAGAGTTTCCTATCACCTTCGGCCAA
GGGACACGACTGGAGATTAAAGGTGGTGGTGGTCTGGCGGGCGGGCTCCGG
TGGTGGTGGTTCCTCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGC
CTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCTTCAGTCGCT
ATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGAAATGGGTGGCA
GTTATATGGTATGATGGAAGTAATAAACTCTATGCAGACTCCGTGAAGGGCCGA
TTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGC
CTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATTACTATGATAAT
AGTAGACATCACTGGGGGTTTACTACTGGGGCCAGGGAACCTGGTCACCGTC
TCCTCAGGAGGTGGTGGATCCGATATCAAACCTGCAGCAGTCAGGGGCTGAACT
GGCAAGACCTGGGGCCTCAGTGAAGATGTCCTGCAAGACTTCTGGCTACACCTT
TACTAGGTACACGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGGAAT
GGATTGGATACATTAATCCTAGCCGTGGTTATACTAATTACAATCAGAAGTTCA
AGGACAAGGCCACATTGACTACAGACAAATCCTCCAGCACAGCCTACATGCAA
CTGAGCAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGATATTAT
GATGATCATTACTGCCTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCC
TCAGTCGAAGGTGGAAGTGGAGGTTCTGGTGGAAAGTGGAGGTTCAAGGTGGAGT

CGACGACATTCAGCTGACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGA
 GAAGGTCACCATGACCTGCAGAGCCAGTTCAAGTGTAAGTTACATGAACTGGT
 ACCAGCAGAAGTCAGGCACCTCCCCAAAAGATGGATTTATGACACATCCAAA
 GTGGCTTCTGGAGTCCCTTATCGCTTCAGTGGCAGTGGGTCTGGGACCTCATA
 TCTCTACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAA
 CAGTGGAGTAGTAACCCGCTCACGTTCCGGTGCTGGGACCAAGCTGGAGCTGAA
 ATAG (SEQ ID NO:110)

[0227] The protein sequence of mature anti-TIM-1 and anti-CD3 bispecific scFv1 is as follows:

DIVMTQTPLSLPVTPEPASISCRSSRSLLDSDDGNTYLDWYLQKPGQSPQLLIYTLS
 YRASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRFEPITFGQGRLEIKGG
 GSGGGGSGGGGSQVQLVESGGGVVQGRSLRLSCAASGFIFSRYGMHWVRQAPG
 KGLKWWAVIWDGNSKLYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYC
 ARDYDNSRHHWGFQDYWGQGTLVTVSSGGGSDIKLQQSGAELARPGASVKMSC
 KTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTDDKSSS
 TAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTLTVSSVEGGSGGSGSGS
 GSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYD
 TSKVASGVPIRFGSGSGTSYSLTISSEAEADAATYYCQQWSSNPLTFGAGTKLEL
 K (SEQ ID NO:111)

Example 15

Construction, expression and purification of anti-TIM-1 and anti-CD3 bispecific scFv2:

[0228] The basic formula for the construction of this novel therapeutic protein is as follows:

SP1 – VL1 – L4 – VH1 – L2 – VH2 – L4 – VL2 – Tag

[0229] The signal peptide SP1 is IgG kappa signal peptide VKIII A27 from Medical Research Council (MRC) Centre for Protein Engineering, University of Cambridge, UK. For more information see mrc-cpe.cam.ac.uk/ALIGNMENTS.php?menu=901. Other signal peptides and linkers could also be used to get additional biologically active bispecific single chain antibodies. The protein being described in this example is also designed to be expressed from mammalian cells and is similar to the anti-TIM-1 and anti-CD3 bispecific scFv1, except that it utilizes a different linker as indicated in the basic formula above (L4, as described earlier), and that a Flag tag is used instead of the His tag as in the first example.

[0230] The predicted molecular weight of the mature cleaved protein is 58070.0 dalton. The tag being used for this construct is a FLAG tag to facilitate purification and detection of this novel protein. Standard protocols are used to express this secreted protein

and purify it, which is tested for activity and tumor cell killing in the protocols described below.

[0231] The amino acid and nucleic acid numbering for the components comprising the anti-TIM-1 and anti-CD3 bispecific scFv2 is as follows:

SP: -20 to -1 aa; -60 to -1nt

VL1: 1-113 aa; 1-339nt

L1: 114-138 aa; 340-414nt

VH1: 139-261 aa; 415-783nt

L2: 262-266 aa; 784-798nt

VH2: 267-385 aa; 799-1155nt

L3: 386-410 aa; 1156-1230nt

VL2: 411-516 aa; 1231-1548nt

Tag: 517-524 aa; 1549-1572nt

[0232] The nucleotide sequence of anti-TIM-1 and anti-CD3 bispecific scFv2 is as follows:

ATGGAACCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACC
ACCGGAGATATTGTGATGACCCAGACTCCACTCTCCCTGCCCCGTACCCCTGGA
GAGCCGGCCTCCATCTCCTGCAGGTCTAGTCGGAGCCTCTTGGATAGTGATGAT
GGAAACACCTATTTGGACTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTC
CTGATCTACACGCTTTCCTATCGGGCCTCTGGAGTCCCAGACAGGTTCAGTGGC
AGTGGGTCAGGCACTGATTTCACTGAAAATCAGCAGGGTGGAGGCTGAGGA
TGTTGGAGTTTATTACTGCATGCAACGTGTAGAGTTTCTATCACCTTCGGCCAA
GGGACACGACTGGAGATTAACTTTCCGCGGACGATGCGAAAAAGGATGCTGC
GAAGAAAGATGACGCTAAGAAAGACGATGCTAAAAAGGACCTGCAGGTGCAG
CTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCC
TGTGCAGCGTCTGGATTTCATCTTCAGTCGCTATGGCATGCACTGGGTCCGCCAG
GCTCCAGGCAAGGGGCTGAAATGGGTGGCAGTTATATGGTATGATGGAAGTAA
TAACTCTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTC
CAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTG
TGTATTACTGTGCGAGAGATTACTATGATAATAGTAGACATCACTGGGGGTTTG
ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGAGGTGGTGGATCCG
ATATCAAACCTGCAGCAGTCAGGGGCTGAACTGGCAAGACCTGGGGCCTCAGTG
AAGATGTCTCTGCAAGACTTCTGGCTACACCTTTACTAGGTACACGATGCACTGG
GTAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGATACATTAATCCTAG
CCGTGGTTATACTAATTACAATCAGAAGTTCAAGGACAAGGCCACATTGACTAC
AGACAAATCCTCCAGCACAGCCTACATGCAACTGAGCAGCCTGACATCTGAGG
ACTCTGCAGTCTATTACTGTGCAAGATATTATGATGATCATTACTGCCTTGACTA
CTGGGGCCAAGGCACCACTCTCACAGTCTCCTCACTTTCCGCGGACGATGCGAA
AAAGGATGCTGCGAAGAAAGATGACGCTAAGAAAGACGATGCTAAAAAGGAC
CTGGACATTCAGCTGACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAG
AAGGTCACCATGACCTGCAGAGCCAGTTCAAGTGTAAGTTACATGAACTGGTAC

CAGCAGAAAGTCAGGCACCTCCCCCAAAGATGGATTTATGACACATCCAAAGT
 GGCTTCTGGAGTCCCTTATCGCTTCAGTGGCAGTGGGTCTGGGACCTCATACTCT
 CTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAACAG
 TGGAGTAGTAACCCGCTCACGTTCCGTGCTGGGACCAAGCTGGAGCTGAAAGA
 TTATAAGGACGATGATGACAAATAG (SEQ ID NO:112)

[0233] The protein sequence of mature anti-TIM-1 and anti-CD3 bispecific scFv2 is as follows:

[0234] DIVMTQTPLSLPVTGPGEASISCRSSRSLDSDDGNTYLDWYLQKP
 GQSPQLLIYTLASYRASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQRFEPIT
 FGQGTREIKLSADDAKKDAKKDDAKKDLQVQLVESGGGVVQPGRSRLR
 LSCAASGFISRYGMHWVRQAPGKGLKVVAVIWDGSKNLYADSVKGRFTISRDN
 SKNTLYLQMNSLRSEDYAVYYCARDYYDNSRHHWGFYWGQGTTLTVSSGGGG
 SDIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGGLEWIGYINPS
 RGYTNYNQKFKDKATLTDDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDY
 WGQGTTLTVSSLSADDAKKDAKKDDAKKDLIQLTQSPAIMSASPGEKV
 TMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVVPYRFSGSGSGTSYSLTIS
 SMEAEDAATYYCQQWSSNPLTFGAGTKLELKDYKDDDDK (SEQ ID NO:113)

Example 16

Anti-TIM-1 scFv species biological activity

ELISA Analysis:

[0235] To determine if the anti-TIM-1 and anti-CD3 bispecific scFv1 and scFv2 antibodies bind to specific antigen, ELISA analysis is performed. 1 µg/ml of specific antigen (TIM-1 antigen (CG57008-02)) is bound to ELISA plates overnight in carbonate/bicarbonate buffer (pH approximately 9.2-9.4). Plates are blocked with assay diluent buffer purchased from Pharmingen San Diego, CA), and various concentrations of the anti-TIM-1 scFv bispecific antibodies are added for 1 hour at room temp. Plates are washed in 0.01% Tween 20 in PBS, followed by addition of HRP-conjugated mAb to either the 6-His tag (Invitrogen, Carlsbad, CA) or the FLAG peptide tag or (Sigma, St. Louis, MO) in assay diluent for 60 minutes at room temperature. Color is developed with TMB substrate (Pharmingen), and the reaction stopped with H₂SO₄. Plates are read at A450 nm, and the O.D. value taken as a measure of protein binding.

FACS analysis

[0236] Binding of the anti-TIM-1 and anti-CD3 bispecific scFv1 and scFv2 antibodies, as well as the anti-TIM-1 scFv antibody to cells expressing the antigens

recognized by the anti-TIM-1 human mAbs is examined by FACS analysis. Cells (such as ACHN) are washed in PBS and resuspended in FACS buffer consisting of ice cold PBS with addition of 1% BSA or 1% FBS. The resuspended cells are then incubated on ice with various concentrations of the bispecific antibody for 30 minutes. Cells are washed to remove non-bound antibody. Bound antibody is detected by binding of a secondary labeled mAb (phycoerythrin or FITC labeled) that specifically recognizes the 6-his tag or the FLAG-tag that is engineered on the bispecific antibody sequence. Cells are washed and analyzed for binding of the anti-tag mAb by FACS analysis. Binding of bispecific mAb plus anti-tag mAb is compared to binding of the anti-tag mAb alone.

Cytotoxicity analysis

[0237] To determine if the bispecific antibody has functional activity as defined by the ability of the bispecific to target T cells to TIM-1 expressing normal or tumor cells, the bispecific antibody is tested in a Cytotoxicity assay. T cells are obtained from the low density cells derived from centrifugation of blood over density separation medium (specific density 1.077). T cells can be used in a heterogeneous mix from the peripheral blood mononuclear cell fraction (which also contains B cells, NK cells and monocytes) or further purified from the low-density cells using MACS separation and negative or positive selection. Killing in assays with T cells derived from the blood directly will have less cytolytic activity than cells that have been stimulated *in vitro* with PHA, cytokines, activating monoclonal antibodies or other stimulators of polyclonal T cell activation. Therefore, these activators will be used to further boost the activity of T cells in the functional assays. Many variations of cytotoxicity assays are available. Cytotoxicity assays measure the release of natural products of the cells metabolism upon lysis, such as LDH. Other assays are based around labeling cells with various agents such as radioactive chromium (⁵¹Cr), DELFIA BATDA, CSFE or similar labeling agents and detecting release or change in live cells bound by the agent.

[0238] DELFIA cytotoxicity assays (PerkinElmer Life and Analytical Sciences, Inc. Boston, MA) offer a non-radioactive method to be used in cell mediated cytotoxicity studies. The method is based on loading cells with an acetoxymethyl ester of a fluorescence enhancing ligand. After the ligand has penetrated the cell membrane the ester bonds are hydrolyzed within the cell to form a hydrophilic ligand, which no longer passes through the membrane. After cytolysis the released ligand is introduced to a europium solution to form a

fluorescent chelate. The measured signal correlates directly with the amount of lysed cells. Target cells are resuspended to a concentration of 2×10^6 /ml. 10 μ l of DELFIA BATDA was mixed in a tube with 2 ml of target cells according to the manufacturers instructions. Various concentrations of T cells are added to a fixed concentration of labeled target cells (5000 cells per well) in 96 well U-bottom plates, and incubated for at least 2 hours at 37°C. The plates are spun at approximately 200g, followed by the aspiration of 20 μ l of supernatant, which was then added to a europium solution (200 μ l) in a separate plate. The plate is incubated for 15 minutes at room temperature, followed by analysis on a SAFIRE (Tecan, Maennedorf, Switzerland) according to the manufacturer's instructions. Signal in the test wells are compared to signal in 100% lysis well (10% lysis buffer in place of T cells) and cell with medium alone (spontaneous release), and % specific lysis is calculated from the formula

$$\% \text{specific lysis} = (\text{test} - \text{spontaneous release}) / 100\% \text{ lysis} \times 100.$$

BIAcore kinetic analysis of scFv constructs

[0239] Kinetic measurements to determine the affinity for the scFv constructs (monomer as well as bispecific, containing at least 1 scFv moiety binding to TIM-1) are measured using the methods described earlier for the whole antibodies of this invention. scFv-containing antibody protein affinities to TIM-1 are expected to be within a factor of 10, i.e. between 0.271 – 27.1 nM, of the affinity given for mAb 2.70.

Example 17

Ability of anti-TIM-1 mAb to inhibit the proliferation of human ovary carcinoma cells

[0240] Several fully human monoclonal antibody clones were isolated from the immunizations described above and their ability to inhibit the proliferative potential of OVCAR-5 (human ovary carcinoma) cells was analyzed using the 5-bromo-2-deoxyuridine (BrdU) incorporation assay (described in International Patent Application No. WO 01/25433).

[0241] In the BrdU assay, OVCAR-5 cancer cells (Manassas, VA) were cultured in Dulbeccos Modification of Eagles Medium (DMEM) supplemented with 10% fetal bovine serum or 10% calf serum respectively. The ovarian cancer cell line was grown

to confluence at 37°C in 10% CO₂/air. Cells were then starved in DMEM for 24 hours. Enriched conditioned medium was added (10 µL/100 µL of culture) for 18 hours. BrdU (10 µM) was then added and incubated with the cells for 5 hours. BrdU incorporation was assayed by colorimetric immunoassay according to the manufacturer's specifications (Boehringer Mannheim, Indianapolis, IN).

[0242] The capability of various human anti-TIM-1 monoclonal antibodies to neutralize was assessed. The results provided in Figures 18A-18T are presented in a bar graph format to assist in comparing the levels of BrdU incorporation in OVCAR5 cells upon exposure to various human anti-TIM-1 monoclonal antibodies described herein. As positive and negative controls, OVCAR5 cells were cultured in the presence of either complete media (complete) or restricted serum-containing media (starved). In addition, the monoclonal antibody PK16.3 was included as a negative treatment control representing a human IgG antibody of irrelevant specificity. Human anti-TIM-1 monoclonal antibodies described herein were used at varying doses (10-1000 ng/mL) as compared to a control run utilizing varying concentrations.

Example 18

Antibody conjugate studies

[0243] Additional antibody conjugate studies were performed using the plant toxin saporin conjugated to anti-TIM-1-specific mABs (1.29 and 2.56.2) and various irrelevant antibodies, including, PK16.3 (Figures 19A-19C). Additional negative controls included anti-TIM-1-specific mAB 2.56.2 and irrelevant antibody PK16.3 without toxin (Figure 19D). Four cancer cell lines, three kidney cancer cell lines (ACHN, CAKI, and 786O) and one breast cancer cell line (BT549), were treated for 72 hours with saporin-antibody conjugates or antibodies alone, after which time BrdU was added to monitor proliferation over a 24 hour period. The results are described in Figures 19A-20C for the kidney cancer cell lines and Figure 19D for the breast cancer cell line. All three kidney cancer cell lines were sensitive to treatment with saporin-TIM-1-specific antibody conjugates as evidenced by a measurable decrease in BrdU incorporation. Treatment of the same cell lines with conjugated irrelevant antibodies had little or no effect demonstrating antigen dependent antiproliferative effects. The same studies performed with the BT549

cell line showed that the TIM-1-specific antibody 2.56.2 showed no antiproliferative effect either alone or when conjugated to saporin. The negative controls for these studies appeared to work well with no cytotoxic effects

Example 19

Sequences

[0244] Below are sequences related to monoclonal antibodies against TIM-1. With regard to the amino acid sequences, **bold** indicates framework regions, underlining indicates CDR regions, and *italics* indicates constant regions.

Anti-TIM-1 mAb 1.29

[0245] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'TGGGTCCTGTCCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGC
CTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCGTCAGCAGTG
GTGGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGG
ATTGGGTTTATCTATTACACTGGGAGCACCAACTACAACCCCTCCCTCAAGAGT
CGAGTCTCCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGC
TCTGTGACCGCTGCGGACGCGGCCGTGTATTACTGTGCGAGAGATTATGACTGG
AGCTTCCACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCC
TCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCC
GAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGT
GACGGTGTCTGGAACCTCAGGCGCTCT3' (SEQ ID NO:1)

[0246] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:1:

WVLSQVQLQESGPGGLVKPSETLSLTCTVSGGSVSSGGYYWSWIRQPPGKGLEWI
GFIYYTGSTNYNPSLKS*SRVSISVDTSKNQFSLKLSSVTAADAAVYYCARDYDWSE*
HF*FDYWGGQGLVTVSSA***STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG**
A (SEQ ID NO:114)

[0247] Nucleotide sequence of light chain variable region and a portion of constant region:

5'CAGCTCCTGGGGCTCCTGCTGCTCTGGTTCCCAGGTGCCAGGTGTGACATCCA
GATGACCCAGTCTCCATCCTCCCTGTCTGCATCTATAGGAGACAGAGTCACCAT
CACTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGA
AACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGAAAGTG
GGGTCCCATCAAGGTTCAAGCGCAGTGGATCTGGGACAGAATTCAGTCTCAGCA
TCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAGCATAATA

GTTACCCTCTCACTTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGAACTGTG
GCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA
ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTA
CAGTGGAAGGTGGATAACGCC3' (SEQ ID NO:3)

[0248] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:3:

QLLGLLLWFPGARCDIQMTQSPSSLSASIGDRVTTTCRASQIRNDLGWYQQKPG
KAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISLQPEDFATYYCLOHNSYPLT
FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA
(SEQ ID NO:115)

Anti-TIM-1 mAb 1.37

[0249] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CAGTGTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGG
GGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTACCTTTACTAACTATTGGAT
GAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAC
AGCAAGATGGAAGTGAGAAATACTATGTGGACTCTGTGAGGGGCCGATTACACC
ATCTCCAGAGACAACGCCAAGAAGTCACTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACTCGGCTGTGTATTACTGTGCGAGATGGGACTACTGGGGCCAGG
GAACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCC
TGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTG
GTCAAGGACTACTTCCCCGAACCGGTGAGCGGTGTCGTGGAAC3' (SEQ ID
NO:5)

[0250] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:5:

QCEVQLVESGGGLVQPGGSLRLSCAASGFTFTNYWMSWVRQAPGKGLEWVAN
IQODGSEKYYVDSVRGRFTISRDNKNSLYLQMNSLRAEDSAVYYCARWDYWG
QGTILVTSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVSGVVE (SEQ ID
NO:116)

[0251] Nucleotide sequence of light chain variable region and a portion of constant region:

5'CTTCTGGGGCTGCTAATGCTCTGGGTCCCTGGATCCAGTGGGGATATTGTGAT
GACCCAGACTCCACTCTCCTCAACTGTCATCCTTGGACAGCCGGCCTCCATCTCC
TGCAGGTCTAGTCAAAGCCTCGTACACAGTGATGGAAACACCTACTTGAATTGG
CTTCAGCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTATATGATTTCTAAC
CGGTTCTCTGGGGTCCCAGACAGATTCAAGTGGCAGTGGGGCAGGGACAGATTC
ACACTGAAAATCAGCAGGGTGGAAAGCTGAGGATGTCGGGGTTTATTACTGCAT
GCAAGCTACAGAATCTCCTCAGACGTTCCGCCAAGGGACCAAGGTGGAAATCA

AACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTT
GAAATCTGGAAGGGCCTCTGTTG3' (SEQ ID NO:7)

[0252] Amino acid sequence of light chain variable region and a portion of
constant region encoded by SEQ ID NO:7:

LLGLLMLWVPGSSGDIVMTQTPLSSTVILGQPASISCRSSQSLVHSDGNTYLNWLQ
QRPQGPPRLLIYMISNRFSGVDPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQA
TESPQTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGRASV (SEQ ID NO:117)

Anti-TIM-1 mAb 2.16

[0253] Nucleotide sequence of heavy chain variable region and a portion of
constant :

5'GAGCAGTCGGGGGGAGGCGTGGTAAAGCCTGGGGGGTCTCTTAGACTCTCCT
GTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGACCTGGGTCCGCCAGG
CTCCAGGGAAGGGGCTGGAGTGGGTGGCCGTATTAAAAGGAGAACTGATGGT
GGGACAACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGA
TGATTCAAAAAACACGCTGTATCTGCAAATGAACAACCTGAAAAACGAGGACA
CAGCCGTGTATTACTGTACCTCAGTCGATAATGACGTGGACTACTGGGGCCAGG
GAACCCTGGTCACCGTCTCCTCAGCTTCCACCAAGGGCCCATCCGTCTTCCCCCT
GGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACCTCAGGCGCCCTGAC
CAGCGGCGTGCACACCTTCCCGGCTGTCTACAGTCCTCAGGACTCT3' (SEQ ID
NO:9)

[0254] Amino acid sequence of heavy chain variable region and a portion of
constant region encoded by SEQ ID NO:9:

XXXSEQSGGGVVKPGGSLRLSCAASGFTFSNAWMTWVRQAPGKGLEWVGRIK
RRTDGGTIDYAAPVKGRFTISRDDSKNTLYLQMNNLKNEDTAVYYCTSDNDV
DYWGQGTTLTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGL (SEQ ID NO:118)

[0255] Nucleotide sequence of light chain variable region and a portion of
constant region:

5'CTGACTCAGTCTCCACTCTCCCTGCCCCGTCACCCCTGGAGAGCCGGCCTCCAT
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACCTATTGGA
TTGGTACCTGCAGAAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTC
TAATCGGGCCTCCGGGGTCCCTGACAGGTTCAAGTGGCAGTGGATCAGGCACAG
ATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATATTGGTCTTTATTACT
GCATGCAAGCTCTACAACTCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAC
ATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG
CAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCA
GAGAGGCCAAAGTACAG3' (SEQ ID NO:11)

[0256] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:11:

XXXLTQSP^{LS}LPVTPGEPASISCRSSQSL^{LS}HSNGYNYLDWYLQKPGQSPQLLIYL
GSNRASGVPDRFSGSGSGTDFTLKISRVEAEDIGLYYCMQALOTPLTFGGGTKV
DIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ (SEQ ID NO:119)

Anti-TIM-1 mAb 2.17

[0257] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CAGGTGCAGCTGGAGCAGTCGGGGGGGAGGCTTGGTACAGCCTGGGGGGGTCCC
 TGAGACTCTCCTGTGCAGCCTCTGGATTACCTTCAGTACCTATAGCATGAACT
 GGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGAAGT
 AGTACTAGTACCATATACTATGCAGAGTCCCTGAAGGGCCGATTCACCATCTCC
 AGCGACAATGCCAAGAATTCATATATCTGCAAATGAACAGCCTGAGAGACGA
 GGACACGGCTGTGTATTACTGTGCGCGGGACTTTGACTACTGGGGCCAGGGAAC
 CCTGGTCACCGTCTCCTCAGCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCG
 CCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAG
 GACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGCGCCCTGACCAGC
 GCGTGCACACCTTCCCGGTGTCTACAGTCCTCAGGACTCTACTCCCTCAGC
 A3' (SEQ ID NO:13)

[0258] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:13:

QVQLEQSGGGLVQPGGSLRLSCAASGFTFSTYSMNWVRQAPGKGLEWVSYIRS
STSTIYYAESLKGRFTISSDNAKNSLYLQMNSLRDEDTAVYYCARDFDYWGQGT
LVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
AVLQSSGLYSLS (SEQ ID NO:120)

[0259] Nucleotide sequence of light chain variable region and a portion of constant region:

5'GAAATCCAGCTGACTCAGTCTCCACTCTCCTCACCTGTACCCCTGGACAGCC
 GGCCTCCATCTCCTGCAGGTCTAGTCAAAGCCTCGTACACAGTGATGGAGACAC
 CTACTTGAATTGGCTTCAGCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTA
 TAAGATTTCTACCCGGTTCTCTGGGGTCCCTGACAGATTCAGTGGCAGTGGGGC
 AGGGACAGATTTCACTGAAAATCAGCAGGGTGGAGACTGACGATGTCTGGGA
 TTTATTACTGCATGCAAATACACAAATTCCTCAAATCACCTTCGGCCAAGGGA
 CACGACTGGAGATTAAACGAACGTGTGGCTGCACCATCTGTCTTCATCTTCCCGC
 CATCTGATGAGCAGTTGAAATCTGGAACCTGCTGTGTGTGCCTGCTGAATA
 ACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAA
 TCGGGTA3' (SEQ ID NO:15)

[0260] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:15:

EIQLTQSPLSSPVTLGQPASISCRSSQSLVHSDGDTYLNWLQQRPGQPPRLLIYKI
STRFSGVPDRFSGSGAGTDFTLKISRVEDDVGIIYCMOTTQIPQITFGQGTRLEI
KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG (SEQ ID NO:121)

Anti-TIM-1 mAb 2.24

[0261] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CAGGTGCAGCTGGAGCAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCC
 TGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTCGCTATGGCATGCACT
 GGGTCCGCCAGGCTCCAGGCAAGGGGCTGAAATGGGTGGCAGTTATATGGTAT
 GATGGAAGTAATAAACTCTATGCAGACTCCGTGAAGGGCCGATTACCATCTCC
 AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA
 GGACACGGCTGTGTATTACTGTGCGAGAGATTACTATGATAATAGTAGACATCA
 CTGGGGGTTTGA TACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTTC
 CACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGA
 GAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGAC
 GGTGTCGTGGAACCTCAGGCGCCCTGACCAGCGGCGTGACACCTTCCCGGCTGT
 CCTACAGTCCTCAGGACTCTACTCCCTCAGCA (SEQ ID NO:17)

[0262] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:17:

QVQLEQSGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLKWVAVTW
YDGSNKLYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDYYDNSR
HHWGFQYWGQGT LVT VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVS
WNSGALTSGVHTFPAVLQSSGLYSLS (SEQ ID NO:122)

[0263] Nucleotide sequence of light chain variable region and a portion of constant region:

5'GACATCCAGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
 AGTCACCATCACTTGCCGGGCAAGTCAGAGTATTTATAGTTATTTAAATTGGTA
 TCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTT
 GCAAAGTGGGGTCCCATCCAGGTTCA GTGGCAGTGGATCTGGGACAGATTTAC
 TCTACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACA
 GAGTTACAGTACCCCTCCGACGTTCCGCCAAGGGACCAAGGTGGAAATCAAAC
 GAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGA
 AATCTGGAACCTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGG
 CCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTA3' (SEQ ID NO:19)

[0264] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:19:

DIQL/MT/LQSPSSLSASVGDRVTTTCRASQSIYSYLNWYQQKPGKAPKLLIYAAS
SLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSYSTPPTFGQGTKVEIKR
TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG (SEQ ID NO:123)

Anti-TIM-1 mAb 2.45

[0265] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CAGTCGGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACTCTCCTGTG
 CAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGACCTGGGTCCGCCAGGCTC
 CAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGGAAACTGATGGTGGG
 ACAACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGA
 TTCAGAAAACACGCTGTATCTGCAAATGAACAGCCTGGAAACCGAGGACACAG
 CCGTGTATTACTGTACCACAGTCGATAACAGTGGTGACTACTGGGGCCAGGGAA
 CCCTGGTACCGTCTCCTCAGCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGC
 GCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAA
 GGACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGCGCCCTGACCAG
 CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTCT3' (SEQ ID NO:21)

[0266] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:21:

XXXXXQSGGGLVKPGGSLRLSCAASGFTFSNAWMTWVRQAPGKGLEWVGRIK
RKTIDGGTTDYAAPVKGRFTISRDDSENTLYLQMNSLETEDTAVYYCTTVDNSG
DYWQGQGLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLS (SEQ ID NO:124)

[0267] Nucleotide sequence of light chain variable region and a portion of constant region:

5'ACTCAGTCTCCACTCTCCCTGCCCCGTACCCCTGGAGAGCCGGCCTCCATCTC
 CTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTG
 GTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAA
 TCGGGCCTCCGGGGTCCCTGACAGGTTCAAGTGGCAGTGGATCAGGCACAGATTT
 TACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCAT
 GCAAGCTCTACAACTCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCA
 AACGAAGTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTT
 GAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGA
 GGCCAAAGTACAGTGAAGGTGGATAACGCCCTCA3' (SEQ ID NO:23)

[0268] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:23:

XXXXTQSPLSLPVTPGEPASISCRSSQSLHSNGYNYLDWYLQKPGQSPQLLIYL
GSNRASGVDPDRFSGSGGTDFTLKISRVEAEDVGVYYCMQALOTPLTFGGG
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL (SEQ ID NO:125)

Anti-TIM-1 mAb 2.54

[0269] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CAGGTGCAGCTGGAGCAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCC
 TGAGACTCTCCTGTGCAGCGTCTGGATTACCTTCACTAACTATGGCTTGCAGT
 GGTCCGCCAGGCTCCAGGCAAGGGGCTGGATTGGGTGGCAGTTATATGGTATG
 ATGGAAGTCATAAATTCATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCA
 GAGACAATTCCAAGAACACGCTCTTTCTGCAAATGAACAGCCTGAGAGCCGAG
 GACACGGCTGTGTATTACTGTACGCGAGATCTTGACTACTGGGGCCAGGGAACC
 CTGGTCACCGTCTCCTCAGCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGC
 CCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAG
 GACTACTTCCCCGAACCGGTGACGGTGTCTGGAAGTCAAGCGCCCTGACCAGC
 GCGGTGCACACCTTCCCGGCTGTCTACAGTCCTCAGGACTCTACTCCCTCAGC3'
 (SEQ ID NO:25)

[0270] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:25:

QVQLEQSGGGVVQPGRSLRLSCAASGFTFTNYGLHWVRQAPGKGLDWVAVIW
YDGSHKFYADSVKGRFTISRDN SKNTLFLQMNSLRAEDTAVYYCTRDL DYWGQ
GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHT
FPAYLQSSGLYSLS (SEQ ID NO:126)

[0271] Nucleotide sequence of light chain variable region and a portion of constant region:

5'GAAACGCAGCTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAA
 GAGTCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAACAACACTTAGCCT
 GGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCA
 GCAGGGCCACTGGCATCCCAGACAGGTTCAAGTGGCAGTGGGTCTGGGACAGAC
 TTCCTCTCACCATCAGCAGACTGGAGCCTGAAGATTGTGCAGAGTGTTACTGT
 CAGCAATATGGTAGCTCACTCCCGCTCACTTTCGGCGGAGGGACCAAGGTGGA
 GATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
 GCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC
 AGAGAGGCCAAAGTACAGTGGGAAGGTGGGATAACGCCCTCCAATCGGGTA3'
 (SEQ ID NO:27)

[0272] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:27:

ETQLTQSPGTLSLSPGERVTLSCRASQSVSNNYLAWYQQKPGQAPRLLIYGASS
RATGIPDRFSGSGSGTDFTLTISRLEPEDCAECYCOQYGSSLPLTFGGGTKVEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWEGGITPSNRV (SEQ ID
 NO:127)

Anti-TIM-1 mAb 2.56

[0273] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'GTCCAGTGTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTG
 GGAGGTCCTGAGACTCTCCTGTGCAGCGTCTGGATTACCTTCAGTAGCTATG
 GCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTT
 ATATGGTATGATGGAAGTCATAAATACTATGCAGACTCCGTGAAGGGCCGATTC
 ACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTG
 AGAGCCGAGGACACGGCTGTGTATTACTCTGCGAGAGATTACTATGATACGAGT
 CGGCATCACTGGGGGTTTGACTGCTGGGGCCAGGGAACCCTGGTCAACGCTCTCC
 TCTGCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGC
 ACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
 CCGGTGACGGTGTCTGTGGAACCTCAGGCGCCCTGACCAGCGGCGTGCACACCTTC
 CCGGC3' (SEQ ID NO:29)

[0274] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO: 29:

VQCQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVA
VIWYDGSSHKY/LYA/TDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYSARDY
YDTSRHHWGFDCWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFP (SEQ ID NO:128)

[0275] Nucleotide sequence of light chain variable region and a portion of constant region:

5'CAGCTCCTGGGGCTGCTAATGCTCTGGGTCCCTGGATCCAGTGAGGAAATTGT
 GATGACCCAGACTCCACTCTCCCTGCCCCTCACCCCTGGAGAGCCGGCCTCCAT
 CTCCTGCAGGTCTAGTCAGAGCCTCTTGATAGTGAAGATGGAAACACCTATTT
 GGACTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATACGCT
 TCCCCATCGGGCCTCTGGAGTCCCAGACAGGTTCAAGTGGCAGTGGGTCAGGCAC
 TGATTTCACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGAGTTTATTG
 CTGCATGCAACGTGTAGAGTTTCCTATCACCTTCGGCCAAGGGACACGACTGGA
 GATTAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
 GCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC
 AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGC3' (SEQ ID NO:31)

[0276] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:31:

QLLGLLMLWVPGSSEEIVMTQTPLSLPVTGPGEPAISICRSSQSLLDSEDGNTYLDW
YLQKPGQSPQLLIYTLSHRASGVPDFRFSGSGSGTDFTLKISRVEAEDVGVYCCM
QRVEFPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW
 KYDN (SEQ ID NO:129)

Anti-TIM-1 mAb 2.59

[0277] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CAGTCGGGCCCAAGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGCAC
 TGTCTCTGGTGGCTCCATCAGTAGTGATGGTTACTACTGGAGCTGGATCCGCCA
 GCACCCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATTACAGTGGGAGCA
 CCTTCTACAACCCGTCCCTCAAGAGTCGAGTTGCCATATCAGTGGACACGTCTA
 AGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACTGCCGCGGACACGGCCGTGT
 ATTACTGTGCGAGAGAATCCCCTCATAGCAGCAACTGGTACTCGGGCTTTGACT
 GCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTTCCACCAAGGGCCCAT
 CCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCC
 TGGGCTGCCTGGTCAAGGACTACTTTCCCCGAACCGGTGACGGTGTCTGTGGAAC
 TCAGGCGCCCTGACCAGCGCGTGCACACCTTCCCGGCTGTCTACAGTCCTCA
 GGACTCTCT3' (SEQ ID NO:33)

[0278] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:33:

XXXXXQSGPRLVKPSQTLSTCTVSGGSISSDGYWWSWIRQHPGKGLEWIGYTY
YSGSTFYNP SLKSRVAISVDTSKNQFSLKLSSVTAADTAVYYCARESPHSSNWYS
GFDCWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPRGTGQVVEL
 RRPDQRRRAHLP GCPTVLR TL (SEQ ID NO:130)

[0279] Nucleotide sequence of light chain variable region and a portion of constant region:

5'ACTCAGTCTCCAGACTTTCAGTCTGTGACTCCAAAGGAGAAAGTCACCATCAC
 CTGCCGGGCCAGTCAGAGCATTGGTAGTAGGTTACACTGGTACCAGCAGAAAC
 CAGATCAGTCTCCAAAGCTCCTCATCAAGTATGCTTCCCAGTCCTTCTCAGGGG
 TCCCCTCGAGGTTCAAGTGGCAGTGGATCTGGGACAGATTTACCCCTCACCATCA
 ATAGCCTGGAAGCTGAAGATGCTGCAACGATTACTGTCATCAGAGTAGTAATT
 TACCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGAACTGTGGCTG
 CACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGC
 CTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCCAAAGTACAGTG
 GAAGGTGGATAACGCCCTC3' (SEQ ID NO:35)

[0280] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:35:

XXXXTQSPDFQSVTPKEKVTITCRASOSIGSRLHWYQQKPDQSPKLLIKYASQSF
SGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCHQSSNLPFTFGPGTKVDIKRTVA
APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL (SEQ ID NO:131)

Anti-TIM-1 mAb 2.61

[0281] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CAGGTGCAGCTGGTGGAGGCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCC
 TGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGAAGCTATGGCATGCACT
 GGGTCCGCCAGGCTCCAGGCAAGGGGCTGAAATGGGTGGCAGTTATATGGTAT
 GATGGAAGTAATAAATACTATACAGACTCCGTGAAGGGCCGATTACCATCTCC
 AGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA
 GGACACGGCTGTGTATTACTGTGTGAGAGATTACTATGATAATAGTAGACATCA
 CTGGGGGTTTGACTACTGGGGCCAGGGAACCCCTGGTCACCGTCTCCTCAGCTTC
 CACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGA
 GAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGAC
 GGTGTCGTGGAACCTCAGGCGCCCTGACCAGGCGGCGTGCACACCTTCCCGGC3'
 (SEQ ID NO:37)

[0282] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:37:

QVQLVE/QAGGGVVQPGRSLRLSCAASGFTFRSYGMHWVRQAPGKGLKWVAV
IWYDGSNKY/LYTDVSKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCVRDYYD
NSRHHWGFYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTRRRRAHLP (SEQ ID NO:132)

[0283] Nucleotide sequence of light chain variable region and a portion of constant region:

5'GACATCCAGATGACCCAGTCTCCATCCTCCCGGTGTGCATCCGTAGGAGACAG
 AGTCACCATCACTTGCCGGGCAAGTCAGGGCATCAGAAATGATTTAGCTTGGTA
 TCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTT
 GCAAAGTGGGGTCCCATCAAGGTTCAAGCGCAGTAGATCTGGGACAGAATTCA
 CTCTACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAGCTTATTACTGTCTCCA
 GCATAATAGTTACCTCCAGTTTTGGCCAGGGGACCAAGCTGGAGATCAAACG
 AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA
 ATCTGGAAGTGTAGCGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGC
 CAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGG3' (SEQ ID NO:39)

[0284] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:39:

DIQMTQSPSSRCASVGDRVITTCRASQIRNDLAWYQQKPGKAPKRLIYAASSL
QSGVPSRFSGRSGTEFTLTISLQPEDFAAYYCLOHNSYPPSFGQGTKLEIKRTV
AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS (SEQ ID NO:133)

Anti-TIM-1 mAb 2.70

[0285] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CATGTGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGA
 GGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTTCATCTTCAGTCGCTATGGCAT
 GCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGAAATGGGTGGCAGTTATAT
 GGTATGATGGAAGTAATAAACTCTATGCAGACTCCGTGAAGGGCCGATTACAC
 ATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAG
 AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATTACTATGATAATAGTAG
 ACATCACTGGGGGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC
 AGCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCAC
 CTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACC
 GGTGACGGTGTCTGTGGAACCTCAGGCGCCCTGA3' (SEQ ID NO:41)

[0286] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:41:

HVQVQLVESGGGVVQPGRSLRLSCAASGFIFSRYGMHWVRQAPGKGLKWWAY
IWYDGSNKLYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDYYDN
SRHHWGFDFWGQGTTLTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGAL (SEQ ID NO:134)

[0287] Nucleotide sequence of light chain variable region and a portion of constant region:

5'TCAGTCTCCTGGGGCTGCTAATGCTCTGGGTCCCTGGATCAGTGAGGATATTGT
 GATGACCCAGACTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT
 CTCCTGCAGGTCTAGTCGGAGCCTCTTGGATAGTGATGATGGAAACACCTATTT
 GGACTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTACACGCT
 TTCCTATCGGGCCTCTGGAGTCCCAGACAGGTTTCAGTGGCAGTGGGTTCAGGCAC
 TGATTTACACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGAGTTTATTA
 CTGCATGCAACGTGTAGAGTTTCTATCACCTTCGGCCAAGGGACACGACTGGA
 GATTAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGA
 GCAGTTGAAATCTGGAACCTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC
 AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCT3' (SEQ ID NO:43)

[0288] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:43:

SAPGAANALGPWISEDIVMTQTPLSLPVTGPGEPAISICRSSRSLLDSDDGNTYLDWY
LQKPGQSPQLLIYTL~~SYRAS~~GV~~PDR~~FSGSGSGTDFTLKISRVEAEDVGVYYCMQ
RVEFPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
 VDNA (SEQ ID NO:135)

Anti-TIM-1 mAb 2.70.2

[0289] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'CGGCCGCCTATTTACCCAGAGACAGGGAGAGGCTCTTCTGTGTGTAGTGGTTG
 TGCAGAGCCTCATGCATCACGGAGCATGAGAAGACATTCCCCTCCTGCCACCTG
 CTCTTGTCACGGTTAGCCTGCTGTAGAGGAAGAAGGAGCCGTCGGAGTCCAGC
 ACGGGAGGCGTGGTCTTGTAGTTGTTCTCCGGCTGCCATTGCTCTCCCACTCCA
 CGGCGATGTCGCTGGGGTAGAAGCCTTTGACCAGGCAGGTCAGGCTGACCTGG
 TTCTTGGTCATCTCCTCCTGGGATGGGGGCAGGGTGTACACCTGTGGCTCTCGG
 GGCTGCCCTTTGGCTTTGGAGATGGTTTTCTCGATGGAGGACGGGAGGCCCTTTG
 TTGGAGACCTTGCACTTGTACTCCTTGCCGTTACGCCAGTCCTGGTGCAGGACG
 GTGAGGACGCTGACCACACGGTACGTGCTGTTGAACTGCTCCTCCCGCGGCTTT
 GTCTTGGCATTATGCACCTCCACGCCATCCACGTACCAGTTGAACTGGACCTCG
 GGGTCTTCCTGGCTCACGTCCACCACCACGCACGTGACCTCAGGGGTCCGGGAG
 ATCATGAGAGTGTCTTGGGTTTTGGGGGGAACAGGAAGACTGATGGTCCCCC
 AGGAACTCAGGTGCTGGGCATGATGGGCATGGGGGACCATATTTGGACTCAAC
 TCTCTTGTCACCTTGGTGTGCTGGGCTTGTGATCTACGTTGCAGGTGTAGGTC
 TTCGTGCCCAAGCTGCTGGAGGGCACGGTCACCACGCTGCTGAGGGAGTAGAG
 TCCTGAGGACTGTAGGACAGCCGGAAGGTGTGCACGCCGCTGGTCAGGGCGC
 CTGAGTTCCACGACACCGTCACCGGTTCCGGGAAGTAGTCCTTGACCAGGCAGC
 CCAGGGCGGCTGTGCTCTCGGAGGTGCTCCTGGAGCAGGGCGCCAGGGGGAAG
 ACGGATGGGCCCTTGGTGGAAAGCTGAGGAGACGGTGACCAGGGTTCCTGGCC
 CCAGTAGTCAAACCCCAAGTGATGTCTACTATTATCATAGTAATCTCTCGCACA
 GTAATACACAGCCGTGTCCTCGGCTCTCAGGCTGTTTTCATTTGCAGATACAGCGT
 GTTCTTGGAATTGTCTCTGGAGATGGTGAATCGGCCCTTCACGGAGTCTGCATA
 GAGTTTATTACTTCCATCATACCATATAACTGCCACCCATTTACAGCCCCTTGCCCT
 GGAGCCTGGCGGACCCAGTGCATGCCATAGCGACTGAAGATGAATCCAGACGC
 TGCACAGGAGAGTCTCAGGGACCTCCAGGCTGGACCACGCCTCCCCCAGACTC
 CACCAGCTGCACCTGACACTGGACACCTTTTAAAATAGCCACAAGAAAAAGCC
 AGCTCAGCCCAAACCTCCATGGTGGTCGACT3' (SEQ ID NO:136)

[0290] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:136:

MEFGLSWLFLVAILKGVQCQVQLVESGGGVVQPGRSLRLSCAASGFIESRYGMHW
VRQAPGKGLKWVA~~VIWYDGS~~NKLYADSVKGRFTISRDN~~SKNT~~LYLQMNSLRA
EDTAVYYCARDYYD~~NSRHH~~WGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSE
 STAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYT

*CNV**DH**KPS**NTK**VDK**R**VES**KY**GPP**CP**SC**PA**EFL**GG**PS**VFL**FPP**KPK**DTL**MIS**RT**PE**VT**C*
*VVV**DVS**QED**PEV**QFN**WY**VDG**VEV**HNA**KT**KP**REE**QFN**STY**R**VV**SV**LT**VL**HQ**DW**LN**G**KEY*
*KCK**V**SNK**GLP**SSI**EKT**ISK**AKG**Q**PRE**Q**VY**TL**PP**SQ**EEM**T**KNQ**V**SL**TCL**VK**G**F**Y**P**S**D**I**A**V**E*
*WES**NG**Q**PEN**NYK**TT**PP**V**L**D**S**D**G**S**F**FL**Y**S**R**L**T**V**D**K**S**R**W**Q**E**G**N**V**F**S**C**S**V**M**H**E**A**L**N**H**Y**T**Q*
*KSL**SL**SL**LGK* (SEQ ID NO:137)

[0291] Nucleotide sequence of light chain variable region and a portion of constant region:

5'AGTCGACCACCATGGAAACCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGG
 CTCCCAGATAACCACCGAGATATTGTGATGACCCAGACTCCACTCTCCCTGCCC
 GTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCGGAGCCTCTTG
 GATAGTGATGATGGAAACACCTATTTGGACTGGTACCTGCAGAAGCCAGGGCA
 GTCTCCACAGCTCCTGATCTACACGCTTTCCTATCGGGCCTCTGGAGTCCCAGAC
 AGGTTCAAGTGGCAGTGGGTGAGGCACTGATTTCACTGAAAATCAGCAGGGT
 GGAGGCTGAGGATGTTGGAGTTTATTACTGCATGCAACGTGTAGAGTTTCTAT
 CACCTTCGGCCAAGGGACACGACTGGAGATTAAACGAACTGTGGCTGCACCAT
 CTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGT
 TGTGTGCTGCTGAATAACTTCTATCCCAGAGAGGGCCAAAGTACAGTGGAAGGT
 GGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACA
 GCAAGGACAGCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGAC
 TACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTC
 GCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAGGCGGCCG3' (SEQ ID
 NO:138)

[0292] Amino acid sequence of light chain variable region and portion constant region by SEQ ID NO:138:

METPAQLLFLLLWLPDITGDIVMTQTPLSLPVTPGEPASISCRSSRSLDSDDGNT
*YLDWYLQKPGQSPQLLIYTL**SYRASGV**PDRFSGSGSDFTL**KISR**VEAEDVGV*
*YYCMQ**RVEFPITFGQ**GRLEIKRTVA**APSVFIFPPSDEQLKSGTASV**VCLNNFY**PREA*
*KVQWKVDNALQSGNSQESVTEQDSK**STYLSSTL**LSKADYEKHKVYACEVTHQGLSSP*
*VTKSFN**R**GEC* (SEQ ID NO:139)

Anti-TIM-1 mAb 2.76

[0293] Nucleotide sequence of heavy chain variable region and a portion of constant region:

5'GAGCAGTCGGGGGGCGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCT
 GTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGTACTGGGTCCGCCAGG
 CTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGCAAT
 AAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCC
 AAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGT
 GTATTACTGTGCGAGGGATTTCTATGATAGTAGTCGTTACCACTACGGTATGGA
 CGTCTGGGGCCAAGGGACACGGTCACCGTCTCCTCAGCTTCCACCAAGGGCCC
 ATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGC

CCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAA
CTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTCT3' (SEQ ID NO:45)

[0294] Amino acid sequence of heavy chain variable region and a portion of constant region encoded by SEQ ID NO:45:

XXXXEQSGGGVVQPGRSLRLSCAASGFTFSSYGMYWVRQAPGKGLEWVAVIW
YDGSNKYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARDFYDSSR
YHYGMDVWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLS (SEQ ID NO:140)

[0295] Nucleotide sequence of light chain variable region and a portion of constant region:

5'ACTCAGTGTCCACTCTCCCTGCCCCGTCACCCCTGGAGAGCCGGCCTCCATCTC
CTGCAGGTCTAGTCAGAGCCTCTTGATAGTGATGATGGAAACACCTATTTGGA
CTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATACGGTTTC
CTATCGGGCCTCTGGAGTCCCAGACAGGTTCAAGTGGCAGTGGGTTCAGGCACTGA
TTTCACACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGAGTTTATTACTG
CATGCAACGTATAGAGTTTCCGATCACCTTCGGCCAAGGGACCCGACTGGAGAT
TAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCA
GTTGAAATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAA3' (SEQ ID NO:47)

[0296] Amino acid sequence of light chain variable region and a portion of constant region encoded by SEQ ID NO:47:

XXXXTQCPLSLPVTPGEPASISCRSSQSLLDSDDGNTYLDWYLQKPGQSPQLLIY
TVSYRASGVPRFSGSGSDFTLTKISRVEAEDVGVYYCMORIEFPITFGQGTRL
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN (SEQ ID NO:141)

Example 20

In Vivo Studies Demonstrating Usefulness of Anti-Tim-1 Antibodies For the Treatment of Ovarian Cancer

[0297] An *in vivo* study was performed to assess the potency and therapeutic efficacy of the antibody-drug conjugate, CR014-vcMMAE, against an established human IGROV-1 ovarian xenograft in athymic mice.

Materials and Methods:

[0298] Test Animals: Five- to 6-week old athymic mice (CD-1 *nu/nu* females), used for human tumor xenografts, were obtained from Charles Rivers Laboratories (Wilmington, DE). Animals were housed in specific pathogen-free conditions, according to the guidelines

of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International). Test animals were provided pelleted food and water *ad libitum* and kept in a room with conditioned ventilation (HVAC), temperature ($22^{\circ} \pm 2^{\circ}\text{C}$), relative humidity ($55\% \pm 15\%$), and photoperiod (12 hr). All studies were carried out with approved institutional animal care and use protocols. Contract Research Organizations. Experiments *in vivo* were conducted at Southern Research Institute (Birmingham, AL).

[0299] Human Ovarian Carcinoma Xenograft Model. The tumor inhibitory activity of the CR014-MMAE immunoconjugate was measured in an anti-tumor xenograft model using athymic mice, according to published methods (Geran RI, Greenberg NH, Macdonald MM, Schumacher AM and Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. *Cancer Chemother Rep* 3:1-104).

[0300] Briefly, test animals were implanted subcutaneously by trocar with small fragments of the IGROV1 carcinoma (30-60 mg) excised from athymic mouse tumor donors. When tumors became established (day 20, 95 mg), the animals were pair-matched into groups ($n=6$ mice/group), and treatment was administered by intravenous injection (tail vein).

[0301] The IGROV1 ovarian carcinoma was derived from a 47 yr. old woman in 1985, and was obtained from the American Type Culture Collection. The effects of treatment were monitored by repetitive tumor measurements across 2 diameters with Vernier calipers; tumor size (in mg) was calculated using a standard formula, $(W^2 \times L)/2$, assuming a specific gravity of 1.0. Tumor size and body weights were assessed twice weekly. Mice were examined daily, however, and moribund animals were humanely euthanized if clinical indications of excessive pain or distress were noted (i.e., prostration, hunched posture, paralysis/paresis, distended abdomen, ulcerations, abscesses, seizures, and/or hemorrhages). Animals with tumors exceeding 2,000 mg were removed from the study and euthanized humanely.

[0302] Xenograft studies in the athymic mouse have been shown to effectively demonstrate anti-tumor effects for a variety of agents which have been found subsequently to have activity against clinical cancer Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M and

Sausville EA (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. *Br J Cancer* 84:1424-1431.

Results:

[0303] Anti-Tumor Effects *In Vivo* vs. IGROV1. Based on the potency and cytotoxicity of CR014-vcMMAE against TIM-1-expressing cells *in vitro*, the anti-tumor effects were examined *in vivo*.

[0304] The effects of vehicle control groups, reference agents and the CR014-vcMMAE immunoconjugate on the growth of subcutaneous human IGROV1 ovarian carcinoma are shown in Figure 20.

[0305] Tumors in animals treated with saline or PBS grew progressively until the tumor mass reached 2,000 mg at which time the animals were removed from the study and euthanized humanely. IGROV1 tumors have a high "take" rate in immunocompromised hosts (93 %) and a very low rate of spontaneous regression (0 %) (Dykes DJ, Abbott BJ, Mayo JG, Harrison Jr. SD, Laster Jr WR, Simpson-Herren L and Griswold Jr. DP (1992) Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs, in *Immunodeficient mice in Oncology*, vol. 42 (Fiebig HH and Berger DPe eds) pp 1-22, Contrib. Oncol. Basel, Karger).

[0306] Two known anti-tumor reference agents, vinblastine sulfate (i.v., 1.7 mg/kg, q4d X4) and paclitaxel (i.v., 24 mg/kg, q2d X4) were used in this study; these agents were administered at the maximum tolerated dose (MTD) determined in prior studies. Vinblastine produced a very slight, but not significant, anti-tumor effect ($P \leq 0.20$); Paclitaxel, however, showed significant tumor growth inhibition and produced complete regression of the ovarian tumors (n= 6/6); re-growth of tumors was not observed during the observation period (i.e., 101 days after the commencement of treatment). Paclitaxel, but not vinblastine, has known efficacy in clinical ovarian carcinoma (Markman, M., *Taxol: an important new drug in the management of epithelial ovarian cancer*. Yale J Biol Med, 1991. 64(6): p. 583-90).

[0307] The anti-tumor effects of CR014-vcMMAE administered i.v. to IGROV1-bearing mice were remarkable. The CR014 immunoconjugate, when dosed at very high levels, however, produced lethal toxicity at 50 mg/kg/treatment (1/6= 17 %) and 100 mg/kg/treatment (6/6= 100 %). Nevertheless, 5/6 animals dosed at 50 mg/kg/treatment showed complete regression of the human ovarian carcinoma. Lower doses, such as 25, 12.5

and 6.25 mg/kg/treatment were therapeutically effective producing tumor growth inhibition which led to complete regressions for the majority of test animals. Tumors that regressed did not re-grow during the observation period.

[0308] The animals in this study (CR014-ONC-1, CGC-17) showed no abnormal treatment effects on gross examination at doses below 100 mg/kg; at 50 mg/kg inhibition of body weight and fatal toxicity occurred in only one of six mice. Below 50 mg/kg/treatment, twice weekly body weight determinations showed no observable or statistically significant effects of treatment with CR014-vcMMAE on body weight or weight gain.

[0309] **Conclusions:** CR014-vcMMAE produces substantial, dose-dependent anti-tumor effects that began as tumor growth inhibition but soon led to complete regression of established human ovarian xenografts; the regressions were long-lived and re-growth of tumors after successful therapy was not been noted during the observation period (101 days after first day of treatment).

Incorporation by Reference

[0310] All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety. In addition, the following references are also incorporated by reference herein in their entirety, including the references cited in such references:

Equivalents

[0311] While the preferred embodiment of the invention has been illustrated and described, it is to be understood that this invention is capable of variation and modification by those skilled in the art to which it pertains, and is therefore not limited to the precise terms set forth, but also such changes and alterations which may be made for adapting the invention to various usages and conditions. Accordingly, such changes and alterations are properly intended to be within the full range of equivalents, and therefore within the purview of the following claims.

[0312] The invention and the manner and a process of making and using it has been described in such full, clear, concise and exact terms so as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.

WHAT IS CLAIMED IS:

1. A method of effectively treating ovarian cancer comprising administering to a patient in need thereof a therapeutically effective dose of an antibody or binding fragment thereof, that specifically binds to T cell, immunoglobulin domain or mucin domain 1 (TIM-1).
2. The method of Claim 1, wherein said antibody comprises the amino acid sequence shown in SEQ ID NO:54.
3. The method of Claim 1, wherein said antibody is a monoclonal antibody.
4. The method of Claim 1, wherein said antibody binds to TIM-1 with a K_d between 10^{-7} and 10^{-14} M.
5. The method of Claim 1, wherein said antibody or binding fragment is conjugated to a therapeutic agent.
6. The method of Claim 5, wherein said therapeutic agent is a toxin.
7. The method of Claim 5, wherein said therapeutic agent is a radioactive isotope.
8. The method of Claim 5, wherein said therapeutic agent is a chemotherapeutic agent.
9. A method of effectively treating renal cancer comprising administering to a patient in need thereof a therapeutically effective dose of an antibody or binding fragment thereof, that specifically binds to T cell, immunoglobulin domain or mucin domain 1 (TIM-1).
10. The method of Claim 9, wherein said antibody comprises the amino acid sequence shown in SEQ ID NO:54.
11. The method of Claim 9, wherein said antibody is a monoclonal antibody.

12. The method of Claim 9, wherein said antibody binds to TIM-1 with a K_d between 10^{-7} and 10^{-14} M.

13. The method of Claim 9, wherein said antibody or binding fragment is conjugated to a therapeutic agent.

14. The method of Claim 13, wherein said therapeutic agent is a toxin.

15. The method of Claim 13, wherein said therapeutic agent is a radioactive isotope.

16. The method of Claim 13, wherein said therapeutic agent is a chemotherapeutic agent.

Figure 1

ELISA assay of anti-TIM-1 mAbs 1.29, 2.56.2, 2.59.2, and 2.45.1 against the TIM-1 antigen




Figure 2

ELISA assay of anti-TIM-1 mAbs 1.29, 2.56.2, 2.59.2, and 2.45.1 against irrelevant protein




Figure 3A

Renal Cell Cancer




Figure 3B

Pancreatic Cancer




Figure 4

Clonogenic assay results of anti-TIM-1 monoclonal antibody mediated toxin killing in the ACHN kidney cancer cell line




Figure 5

Clonogenic assay results of anti-TIM-1 monoclonal antibody mediated toxin killing in the BT549 breast cancer cell line




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18A




Figure 18B




Figure 18C




Figure 18D




Figure 18E




Figure 18F




Figure 18G




Figure 18H




Figure 18I




Figure 18J




Figure 18K







Figure 18L




18M




18N




180




18P




18Q



18R



18S



18T




Figure 19A




Figure 19B




Figure 19C




Figure 19D





Figure 20

Effects of CR014-AE i.v. on Growth of the Human IGROV-1 Ovarian Carcinoma Xenografts in Athymic Mice.



SEQUENCE LISTING

<110> CuraGen Corporation, et al.

<120> METHOD OF TREATING OVARIAN AND RENAL CANCER USING
ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN
AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN

<130> Cura 965A WO

<150> 60/735,574

<151> 2005-11-10

<160> 141

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 509

<212> DNA

<213> Homo Sapiens

<400> 1

```

tgggtcctgt cccaggtgca gctgcaggag tcgggcccag gactggtgaa gccttcggag 60
accctgtccc tcacctgcac tgtctctggt ggctccgtca gcagtgggtg ttactactgg 120
agctggatcc ggcagccccc agggaagggg ctggagtggg ttgggtttat ctattacact 180
gggagcacca actacaaccc ctccctcaag agtcgagtct ccatatcagt agacacgtcc 240
aagaaccagt tctccctgaa gctgagctct gtgaccgctg cggacgcggc cgtgtattac 300
tgtgcgagag attatgactg gagcttccac tttgactact ggggccaggg aaccctggtc 360
accgtctcct cagcctccac caagggccca tcggtcttcc ccctggcgcc ctgctccagg 420
agcacctccg agagcacagc ggccctgggc tgcttggtca aggactactt ccccgaaaccg 480
gtgacgggtg cgtggaactc aggcgctct

```

<210> 2

<211> 121

<212> PRT

<213> Homo Sapiens

<400> 2

```

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1           5           10           15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly
 20           25           30
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
 35           40           45
Trp Ile Gly Phe Ile Tyr Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser
 50           55           60
Leu Lys Ser Arg Val Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
 65           70           75           80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Ala Ala Val Tyr Tyr
 85           90           95
Cys Ala Arg Asp Tyr Asp Trp Ser Phe His Phe Asp Tyr Trp Gly Gln
 100          105          110
Gly Thr Leu Val Thr Val Ser Ser Ala
 115          120

```

<210> 3

<211> 504

<212> DNA

<213> Homo Sapiens

<400> 3

```

cagctcctgg ggctcctgct gctctgggtc ccaggtgcca ggtgtgacat ccagatgacc 60
cagtctccat cctccctgtc tgcatttata ggagacagag tcaccatcac ttgccgggca 120
agtcagggca tttagaatga tttaggctgg tatcagcaga aaccagggaa agcccctaag 180
cgcctgatct atgctgcac cagtttgcaa agtgggggtcc catcaagggt cagcggcagt 240
ggatctggga cagaattcac tctcacaatc agcagcctgc agcctgaaga ttttgcaact 300
tattactgtc tacagcataa tagttaccct ctcactttcg gcggaggggac caaggtggag 360
atcaaacgaa ctgtggctgc accatctgtc ttcattctcc cgccatctga tgagcagttg 420
aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa 480
gtacagtggg aggtggataa cgcc
504

```

<210> 4

<211> 108

<212> PRT

<213> Homo Sapiens

<400> 4

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
85           90           95
Thr Phe Gly Gly Thr Lys Val Glu Ile Lys Arg
100          105

```

<210> 5

<211> 469

<212> DNA

<213> Homo Sapiens

<400> 5

```

cagtgtaggg tgcagctggg ggagctctggg ggaggcttgg tccagcctgg ggggtccctg 60
agactctcct gtgcagcctc tggattcacc tttactaact attggatgag ctgggtccgc 120
caggctccag ggaaggggct ggagtggtg gccaacatac agcaagatgg aagtgaagaa 180
tactatgtgg actctgtgag gggccgattc accatctcca gagacaacgc caagaactca 240
ctgtatctgc aaatgaacag cctgagagcc gaggactcgg ctgtgtatta ctgtgcgaga 300
tgggactact ggggccaggg aaccctggtc accgtctcct cagcctccac caagggccca 360
tcggtcttcc ccctggcgcc ctgctccagg agcacctccg agagcacagc ggccctgggc 420
tgccctggta aggactactt ccccgaaccg gtgagcggtg tcgtggaac
469

```

<210> 6

<211> 113

<212> PRT

<213> Homo Sapiens

<400> 6

```

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asn Tyr
20           25           30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

```

```

      35      40      45
Ala Asn Ile Gln Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
      50      55      60
Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65      70      75      80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Ala Val Tyr Tyr Cys
      85      90      95
Ala Arg Trp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      100      105      110
Ala

```

<210> 7
 <211> 454
 <212> DNA
 <213> Homo Sapiens

```

<400> 7
cttctggggc tgctaagtct ctgggtccct ggatccagtg gggatattgt gatgaccag 60
actccactct cctcaactgt catccttgga cagccggcct ccatctctctg caggtctagt 120
caaagcctcg tacacagtga tggaaacacc tacttgaatt ggcttcagca gaggccaggc 180
cagcctccaa gactcctaatt ttatatgatt tctaaccggg tctctggggg cccagacaga 240
ttcagtggca gtggggcagg gacagatttc aactgaaaa tcagcagggt ggaagctgag 300
gatgtcgggg tttattactg catgcaagct acagaatctc ctcagacgtt cggccaaggg 360
accaaggtgg aaatcaaacg aactgtggct gcaccatctg tcttcatctt cccgccatct 420
gatgagcagt tgaaatctgg aagggcctct gttg 454

```

<210> 8
 <211> 113
 <212> PRT
 <213> Homo Sapiens

```

<400> 8
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Thr Val Ile Leu Gly
1      5      10      15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asp Gly Asn Thr Tyr Leu Asn Trp Leu Gln Gln Arg Pro Gly Gln Pro
      35      40      45
Pro Arg Leu Leu Ile Tyr Met Ile Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
      85      90      95
Thr Glu Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
      100      105      110
Arg

```

<210> 9
 <211> 529
 <212> DNA
 <213> Homo Sapiens

```

<400> 9
gagcagtcgg ggggagggcgt ggtaaagcct ggggggtctc ttagactctc ctgtgcagcc 60
tctggattca ctttcagtaa cgcttgatg acctgggtcc gccaggctcc aggggaagggg 120
ctggagtggg ttggccgtat taaaaggaga actgatggtg ggacaacaga ctacgtgca 180

```

```

ccccgtgaaag gcagattcac catctcaaga gatgattcaa aaaacacgct gtatctgcaa 240
atgaacaacc tgaaaaacga ggacacagcc gtgtattact gtacctcagt cgataatgac 300
gtggactact ggggccaggg aaccctggtc accgtctcct cagcttccac caagggccca 360
tccgtcttcc cctggcgcc ctgctccagg agcacctccg agagcacagc cgccctgggc 420
tgctgggtca aggactactt ccccgaaaccg gtgacgggtg cgtggaactc aggcgccttg 480
accagcggcg tgcacacctt cccggctgtc ctacagtcct caggactct 529

```

<210> 10

<211> 119

<212> PRT

<213> Homo Sapiens

<400> 10

```

Asn Asn Asn Asn Glu Gln Ser Gly Gly Gly Val Val Lys Pro Gly Gly
 1          5          10          15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
      20          25          30
Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35          40          45
Gly Arg Ile Lys Arg Arg Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
      50          55          60
Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Lys Asn Thr
      65          70          75          80
Leu Tyr Leu Gln Met Asn Asn Leu Lys Asn Glu Asp Thr Ala Val Tyr
      85          90          95
Tyr Cys Thr Ser Val Asp Asn Asp Val Asp Tyr Trp Gly Gln Gly Thr
      100          105          110
Leu Val Thr Val Ser Ser Ala
      115

```

<210> 11

<211> 447

<212> DNA

<213> Homo Sapiens

<400> 11

```

ctgactcagt ctccactctc cctgcccgtc acccctggag agccggcctc catctcctgc 60
aggtctagtc agagcctoct gcatagtaat ggatacaact atttggattg gtacctgcag 120
aagccagggc agtctccaca gctcctgata tatttgggtt ctaatcgggc ctccgggggc 180
cctgacaggt tcagtggcag tggatcagga acagatttta cactgaaaat cagcagagtg 240
gaggctgagg atattggtct ttattactgc atgcaagctc tacaaactcc gctcactttc 300
ggcggaggga ccaaggtgga catcaaacga actgtggctg caccatctgt cttcatcttc 360
ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac 420
ttctatccca gagaggccaa agtacag 447

```

<210> 12

<211> 113

<212> PRT

<213> Homo Sapiens

<400> 12

```

Asn Asn Asn Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1          5          10          15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20          25          30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35          40          45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
      50          55          60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

```

```
<400> 15
gaaatccagc  tgactcagtc  tccactctcc  tcacctgtca  cccttggaca  gccggcctcc  60
atctcctgca  ggtctagtc  aagcctcgta  cacagtgatg  gagacaccta  cttgaattgg  120
cttcagcaga  ggccaggcca  gcctccaaga  ctctaatatt  ataagatttc  taccgggttc  180
tctgggggtc  ctgacagatt  cagtggcagt  ggggcaggga  cagatttcac  actgaaaaat  240
agcagggttg  agactcagca  tgtctgggatt  tattactgca  tgcaaaacta  acaaaattct  300
caaatcacct  tcggccaagg  gacacgactg  qagattaaac  gaactgtggc  tgcaccatct  360
```

gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc 420
 ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaagggtgga taacgccctc 480
 caatcgggta 490

<210> 16

<211> 114

<212> PRT

<213> Homo Sapiens

<400> 16

Glu Ile Gln Leu Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 20 25 30
 Asp Gly Asp Thr Tyr Leu Asn Trp Leu Gln Gln Arg Pro Gly Gln Pro
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Thr Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Thr Asp Asp Val Gly Ile Tyr Tyr Cys Met Gln Thr
 85 90 95
 Thr Gln Ile Pro Gln Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
 100 105 110
 Lys Arg

<210> 17

<211> 568

<212> DNA

<213> Homo Sapiens

<400> 17

cagggtgcagc tggagcagtc ggggggaggc gtggtccagc ctgggaggtc cctgagactc 60
 tcctgtgcag cgtctggatt caccttcagt cgctatggca tgcactgggt ccgccaggct 120
 ccaggcaagg ggctgaaatg ggtggcagtt atatggtatg atggaagtaa taaactctat 180
 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagattac 300
 tatgataata gtagacatca ctggggggtt gactactggg gccagggaac cctgggtcacc 360
 gtctctcag cttccaccaa gggcccatcc gtcttcccc tggcgccctg ctccaggagc 420
 acctccgaga gcacagccgc cctgggctgc ctggtcaagg actacttccc cgaaccggtg 480
 acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggtgtccta 540
 cagtcctcag gactctactc cctcagca 568

<210> 18

<211> 124

<212> PRT

<213> Homo Sapiens

<400> 18

Gln Val Gln Leu Glu Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Leu Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly Phe Asp Tyr
 100 105 110
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
 115 120)

<210> 19
 <211> 472
 <212> DNA
 <213> Homo Sapiens

<400> 19
 gacatccagc tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcaagtca gagtatttat agttatttaa attgggtatca gcagaaacca 120
 gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatcc 180
 aggttcagtg gcagtggtatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240
 gaagattttg caacttacta ctgtcaacag agttacagta cccctccgac gttcggccaa 300
 gggaccaagg tggaaatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 360
 tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420
 cccagagagg ccaaagtaca gtggaagggt gataacgccc tccaatcggg ta 472

<210> 20
 <211> 108
 <212> PRT
 <213> Homo Sapiens

<400> 20
 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 21
 <211> 528
 <212> DNA
 <213> Homo Sapiens

<400> 21
 cagtcggggg gaggcttggt aaagcctggg gggtccttta gactctcctg tgcagcctct 60
 ggattcactt tcagtaacgc ctggatgacc tgggtccgcc aggtccagg gaaggggctg 120
 gagggttg gccgtattaa aaggaaaact gatgggtgga caacagacta cgctgcaccc 180
 gtgaaaggca gattcaccat ctcaagagat gattcagaaa acacgctgta tctgcaaatg 240
 aacagcctgg aaaccgagga cacagccgtg tattactgta ccacagtcga taacagtggg 300
 gactactggg gccaggggaa cctggtcacc gtctcctcag cttccaccaa gggcccatcc 360
 gtcttcccc tggcgccctg ctccaggagc acctccgaga gcacagccgc cctgggctgc 420
 ctgggtcaagg actacttccc cgaaccgggt acggtgtcgt ggaactcagg cgccctgacc 480
 agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctct 528

<210> 22
 <211> 119
 <212> PRT
 <213> Homo Sapiens

<400> 22
 Asn Asn Asn Asn Asn Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30
 Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Gly Arg Ile Lys Arg Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
 50 55 60
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Glu Asn Thr
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ser Leu Glu Thr Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Thr Thr Val Asp Asn Ser Gly Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser Ala
 115

<210> 23
 <211> 466
 <212> DNA
 <213> Homo Sapiens

<400> 23
 actcagtcct cactctccct gcccgtcacc cctggagagc cggcctccat ctctgcagg 60
 tctagtcaga gcctcctgca tagtaatgga tacaactatt tggattggta cctgcagaag 120
 ccagggcagt ctccacagct cctgatctat ttgggttcta atcgggcctc cggggtccct 180
 gacaggttca gtggcagtgg atcaggcaca gattttacac tgaaaatcag cagagtggag 240
 gctgaggatg ttggggttta ttactgcatg caagctctac aaactccgct cactttcggc 300
 ggagggacca aggtggagat caaacgaact gtggctgcac catctgtctt catcttcccg 360
 ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 420
 tatccagag aggccaaaagt acagtggaag gtggataacg ccctca 466

<210> 24
 <211> 113
 <212> PRT
 <213> Homo Sapiens

<400> 24
 Asn Asn Asn Asn Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Leu Gln Thr Pro Leu Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110
 Arg

<210> 25
 <211> 537
 <212> DNA
 <213> Homo Sapiens

<400> 25
 caggtgcagc tggagcagtc ggggggaggc gtggtccagc ctgggaggtc cctgagactc 60
 tcctgtgcag cgtctggatt caccttcact aactatggct tgcactgggt ccgccaggct 120
 ccaggcaagg ggctggattg ggtggcagtt atatggtatg atggaagtca taaattctat 180
 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctcttt 240
 ctgcaaataa acagcctgag agccgaggac acggctgtgt attactgtac gcgagatctt 300
 gactactggg gccagggaac cctggtcacc gtctcctcag cttocaccaa gggcccatcc 360
 gtcttccccc tggcgccctg ctccaggagc acctccgaga gcacagccgc cctgggctgc 420
 ctggtcaagg actacttccc cgaaccgggtg acggtgtcgt ggaactcagg cgccctgacc 480
 agcggcgctg acaccttccc ggctgtccta cagtcctcag gactctactc cctcagc 537

<210> 26
 <211> 114
 <212> PRT
 <213> Homo Sapiens

<400> 26
 Gln Val Gln Leu Glu Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asn Tyr
 20 25 30
 Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser His Lys Phe Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Asp Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
 100 105 110
 Ser Ala

<210> 27
 <211> 480
 <212> DNA
 <213> Homo Sapiens

<400> 27
 gaaacgcagc tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagtcacc 60
 ctctcctgca gggccagtca gactgttagc aacaactact tagcctggta ccagcagaaa 120
 cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
 gacaggttca gtggcagtg gtctgggaca gacttcactc tcaccatcag cagactggag 240
 cctgaagatt gtgcagagtg ttactgtcag caatatggta gctcactccc gctcactttc 300
 ggcggaggga ccaaggtgga gatcaaacga actgtggctg caccatctgt cttcatcttc 360
 ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac 420
 ttctatccca gagaggccaa agtacagtgg gaagggtggga taacgcctc caatcgggta 480

<210> 28
 <211> 110
 <212> PRT

<213> Homo Sapiens

<400> 28

```

Glu Thr Gln Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1           5           10           15
Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Asn
          20           25           30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
          35           40           45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
          50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65           70           75           80
Pro Glu Asp Cys Ala Glu Cys Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
          85           90           95
Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
          100          105          110

```

<210> 29

<211> 542

<212> DNA

<213> Homo Sapiens

<400> 29

```

gtccagtgtc aggtgcagct ggtggagtct gggggaggcg tgggtccagcc tgggaggtcc 60
ctgagactct cctgtgcagc gtctggattc accttcagta gctatggcat gcactgggtc 120
cgccaggctc caggcaaggg gctggagtgg gtggcagtta tatggtatga tggaaagtc 180
aaatactatg cagactccgt gaagggccga ttcaccatct ccagagacaa ttccaagaac 240
acgctgtatc tgcaaatgaa cagcctgaga gccgaggaca cggctgtgta ttactctgcg 300
agagattact atgatacgag tcggcatcac tgggggtttg actgctgggg ccagggaacc 360
ctggtcaccg tctcctctgc ttccaccaag ggcccatccg tcttccccct ggcgccctgc 420
tccaggagca cctccgagag cacagccgcc ctgggctgcc tgggtcaagga ctacttccc 480
gaaccggtga cgggtgcgtg gaactcaggc gccctgacca gcggcgtgca caccttccc 540
gc                                                                 542

```

<210> 30

<211> 124

<212> PRT

<213> Homo Sapiens

<400> 30

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
          20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
          35           40           45
Ala Val Ile Trp Tyr Asp Gly Ser His Lys Tyr Tyr Ala Asp Ser Val
          50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Ser
          85           90           95
Ala Arg Asp Tyr Tyr Asp Thr Ser Arg His His Trp Gly Phe Asp Cys
          100          105          110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
          115          120

```

<210> 31

<211> 521
 <212> DNA
 <213> Homo Sapiens

<400> 31
 cagctcctgg ggctgctaata gctctgggtc cctggatcca gtgaggaaat tgtgatgacc 60
 cagactccac tctccctgcc cgtcaccctt ggagagccgg cctccatctc ctgcaggtct 120
 agtcagagcc tcttgatag tgaagatgga aacacctatt tggactggta cctgcagaag 180
 ccagggcagt ctccacagct cctgatctat acgctttccc atcgggcctc tggagtccca 240
 gacaggttca gtggcagtgg gtcaggcact gatttcacac tgaaaatcag caggggtggag 300
 gctgaggatg ttggagttta ttgctgcatg caacgtgtag agtttcctat caccttcggc 360
 caagggacac gactggagat taaacgaact gtggctgcac catctgtctt catcttccc 420
 ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480
 tatcccagag aggccaaagt acagtggaag gtggataacg c 521

<210> 32
 <211> 114
 <212> PRT
 <213> Homo Sapiens

<400> 32
 Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser
 20 25 30
 Glu Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
 35 40 45
 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser His Arg Ala Ser Gly Val
 50 55 60
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
 65 70 75 80
 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Cys Cys Met Gln
 85 90 95
 Arg Val Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
 100 105 110
 Lys Arg

<210> 33
 <211> 547
 <212> DNA
 <213> Homo Sapiens

<400> 33
 cagtcggggc caagactggg gaagccttca cagaccctgt cctcacctg cactgtctct 60
 ggtggctcca tcagtagtga tggttactac tggagctgga tccgccagca cccagggag 120
 ggctggaggt ggattgggta catctattac agtgggagca ccttctacaa cccgtccctc 180
 aagagtcgag ttgccatata agtggacacg tctaagaacc agttctccct gaagctgagc 240
 tctgtgactg ccgcgacac ggccgtgtat tactgtgcga gagaatcccc tcatagcagc 300
 aactggtact cgggctttga ctgctggggc caggaaccc tggtcaccgt ctctcagct 360
 tccaccaagg gccatccgt cttccccctg gcgccctgct ccaggagcac ctccgagagc 420
 acagccggcc tgggctgctt ggtcaaggac tactttcccc gaaccggtga cgggtgcgtg 480
 gaactcaggc gccctgacca gcggcgtgca caccttccc gctgtcctac agtcctcagg 540
 actctct 547

<210> 34
 <211> 125
 <212> PRT
 <213> Homo Sapiens

<400> 34

```

Asn Asn Asn Asn Asn Gln Ser Gly Pro Arg Leu Val Lys Pro Ser Gln
 1           5           10           15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp
      20           25           30
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
      35           40           45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Phe Tyr Asn Pro Ser
      50           55           60
Leu Lys Ser Arg Val Ala Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
      65           70           75           80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
      85           90           95
Cys Ala Arg Glu Ser Pro His Ser Ser Asn Trp Tyr Ser Gly Phe Asp
      100          105          110
Cys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
      115          120          125

```

<210> 35

<211> 450

<212> DNA

<213> Homo Sapiens

<400> 35

```

actcagtcctc cagactttca gtctgtgact ccaaaggaga aagtcacccat cacctgcccgg 60
gccagtcaga gcattggttag taggttacac tggtagccagc agaaaccaga tcagtcctcca 120
aagtcctcca tcaagtatgc ttcccagtc ccctcagggg tcccctcgag gttcagtggc 180
agtggatctg ggacagattt caccctcacc atcaatagcc tggaagctga agatgctgca 240
acgtattact gtcacagag tagtaattta ccattcactt tcggccctgg gaccaaagtg 300
gatatcaaac gaactgtggc tgcaccatct gtcttcactt tcccgccatc tgatgagcag 360
ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctatcc cagagaggcc 420
aaagtacagt ggaagggtga taacgcctc

```

<210> 36

<211> 108

<212> PRT

<213> Homo Sapiens

<400> 36

```

Asn Asn Asn Asn Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
 1           5           10           15
Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Arg
      20           25           30
Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
      35           40           45
Lys Tyr Ala Ser Gln Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
      50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
      65           70           75           80
Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Ser Ser Asn Leu Pro Phe
      85           90           95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg
      100          105

```

<210> 37

<211> 534

<212> DNA

<213> Homo Sapiens

<400> 37

```

caggtgcagc tgggtggaggc tggggggaggc gtggtccagc ctgggagggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcaga agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctgaaatg ggtggcagtt atatggtatg atggaagtaa taaatactat 180
acagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaataa acagcctgag agccgaggac acggctgtgt attactgtgt gagagattac 300
tatgataata gtagacatca ctggggggtt gactactggg gccagggaac cctggtcacc 360
gtctctcag cttccaccaa gggcccatcc gtcttcccc tggcgccctg ctccaggagc 420
acctccgaga gcacagccgc cctgggctgc ctggtcaagg actacttccc cgaaccggtg 480
acgggtgtcgt ggaactcagg cgccctgacc aggcggcgtg cacaccttcc cggc 534

```

<210> 38

<211> 124

<212> PRT

<213> Homo Sapiens

<400> 38

```

Gln Val Gln Leu Val Glu Ala Gly Gly Gly Val Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
      20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp Val
      35           40           45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Thr Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Val Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly Phe Asp Tyr
      100          105          110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
      115          120

```

<210> 39

<211> 470

<212> DNA

<213> Homo Sapiens

<400> 39

```

gacatccaga tgacccagtc tccatcctcc cggtgtgcat ccgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gggcatcaga aatgatttag cttgggtatca gcagaaacca 120
gggaaagccc ctaagcgctt gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagtagatc tgggacagaa ttcaactctca caatcagcag cctgcagcct 240
gaagattttg cagcttatta ctgtctccag cataatagtt accctcccag ttttgccag 300
gggaccaagc tggagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 360
tctgatgagc agttgaaatc tggaactgct agcgttgtgt gcctgctgaa taacttctat 420
cccagagagg ccaaagtaca gtggaagggt gataacgccc tccaatcggg 470

```

<210> 40

<211> 108

<212> PRT

<213> Homo Sapiens

<400> 40

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Arg Cys Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
                        13

```

```

      35      40      45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50      55      60
Ser Arg Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65      70      75      80
Glu Asp Phe Ala Ala Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Pro
      85      90      95
Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
      100      105

```

<210> 41
 <211> 514
 <212> DNA
 <213> Homo Sapiens

```

<400> 41
catgtgcagg tgcagctggt ggagtctggg ggaggcgtgg tccagcctgg gaggtccctg 60
agactctcct gtgcagcgtc tggattcatc ttcagtcgct atggcatgca ctgggtccgc 120
caggctccag gcaaggggct gaaatgggtg gcagttatat ggtatgatgg aagtaataaa 180
ctctatgcag actccgtgaa gggccgattc accatctcca gagacaattc caagaacacg 240
ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ctgtgtatta ctgtgcgaga 300
gattactatg ataatagtag acatcactgg gggtttgact actggggcca gggaaccctg 360
gtcaccgtct cctcagcttc caccaagggc ccatccgtct tccccctggc gccctgctcc 420
aggagcacct ccgagagcac agccgccctg ggctgcctgg tcaaggacta cttccccgaa 480
ccggtgacgg tgtcgtgaa ctcaggcgcc ctga 514

```

<210> 42
 <211> 124
 <212> PRT
 <213> Homo Sapiens

```

<400> 42
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1      5      10      15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Arg Tyr
      20      25      30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp Val
      35      40      45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Leu Tyr Ala Asp Ser Val
      50      55      60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65      70      75      80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85      90      95
Ala Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly Phe Asp Tyr
      100      105      110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
      115      120

```

<210> 43
 <211> 523
 <212> DNA
 <213> Homo Sapiens

```

<400> 43
tcagctcctg gggctgctaa tgctctgggt ccctggatca gtgaggatat tgtgatgacc 60
cagactccac tctccctgcc cgtcaccctt ggagagccgg cctccatctc ctgcaggtct 120
agtcggagcc tcttgatag tgatgatgga aacacctatt tggactggta cctgcagaag 180
ccagggcagt ctccacagct cctgatctac acgctttcct atcgggcctc tggagtccca 240

```

gacaggttca gtggcagtgg gtcaggcact gatttcacac tgaaaatcag cagggtggag 300
 gctgaggatg ttggagtta ttactgcatg caacgtgtag agtttcctat caccttcggc 360
 caagggacac gactggagat taaacgaact gtggctgcac catctgtctt catcttcccg 420
 ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480
 tatcccagag aggccaaagt acagtggaag gtggataacg cct 523

<210> 44
 <211> 114
 <212> PRT
 <213> Homo Sapiens

<400> 44
 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Ser Leu Leu Asp Ser
 20 25 30
 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
 35 40 45
 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val
 50 55 60
 Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
 65 70 75 80
 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
 85 90 95
 Arg Val Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
 100 105 110
 Lys Arg

<210> 45
 <211> 546
 <212> DNA
 <213> Homo Sapiens

<400> 45
 gagcagtcgg ggggcggcgt ggtccagcct gggaggtccc tgagactctc ctgtgcagcg 60
 tctggattca ccttcagtag ctatggcatg tactgggtcc gccaggctcc aggcaagggg 120
 ctggagtggg tggcagttat atggtatgat ggaagcaata aatactatgc agactccgtg 180
 aagggccgat tcaccatctc cagagacaat tccaagaaca cgctgtatct gcaaatgaac 240
 agcctgagag ccgaggacac ggctgtgtat tactgtgcga gggatttcta tgatagtagt 300
 cgttaccact acggtatgga cgtctggggc caagggacca cggtcaccgt ctctcagct 360
 tccaccaagg gcccatccgt cttccccctg gcgcctgct ccaggagcac ctccgagagc 420
 acagccgccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg 480
 aactcaggcg ccctgaccag cggcgtgcac accttccccg ctgtcctaca gtcctcagga 540
 ctctct 546

<210> 46
 <211> 124
 <212> PRT
 <213> Homo Sapiens

<400> 46
 Asn Asn Asn Asn Glu Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Phe Tyr Asp Ser Ser Arg Tyr His Tyr Gly Met Asp Val
 100 105 110
 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala
 115 120

<210> 47
 <211> 419
 <212> DNA
 <213> Homo Sapiens

<400> 47
 actcagtgtc cactctccct gcccgtcacc cctggagagc cggcctccat ctctgcagg 60
 tctagtgcaga gcctcttgga tagtgatgat ggaaacacct atttggactg gtacctgcag 120
 aagccagggc agtctccaca gctcctgac tatacgggtt cctatcgggc ctctggagtc 180
 ccagacaggt tcagtggcag tgggtcaggc actgatttca cactgaaaat cagcaggggtg 240
 gaggtcgagg atgttggagt ttattactgc atgcaacgta tagagtttcc gatcaccttc 300
 ggccaaggga cccgactgga gattaaacga actgtggctg caccatctgt cttcatcttc 360
 ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataa 419

<210> 48
 <211> 114
 <212> PRT
 <213> Homo Sapiens

<400> 48
 Asn Asn Asn Asn Thr Gln Cys Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser
 20 25 30
 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
 35 40 45
 Ser Pro Gln Leu Leu Ile Tyr Thr Val Ser Tyr Arg Ala Ser Gly Val
 50 55 60
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
 65 70 75 80
 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
 85 90 95
 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
 100 105 110
 Lys Arg

<210> 49
 <211> 789
 <212> DNA
 <213> Homo Sapiens

<400> 49
 tctgtaaagg ttggtggaga ggcagggtcca tctgtcacac taccctgccca ctacagtggg 60
 gctgtcacat caatgtgctg gaatagaggc tcatgttctc tattcacatg ccaaaatggc 120
 attgtctgga ccaatggaac ccacgtcacc tatcggaagg acacacgcta taagctattg 180
 ggggaccttt caagaaggga tgtctctttg accatagaaa atacagctgt gtctgacagt 240
 ggcgtatatt gttgcogtgt tgagcaccgt ggggtggttca atgacatgaa aatcaccgta 300
 tcattggaga ttgtgccacc caaggtcacg actactccaa ttgtcacaac tgttccaacc 360
 gtcacgactg ttcgaacgag caccactgtt ccaacgacaa cgactgttcc aacgacaact 420

```

gttccaacaa caatgagcat tccaacgaca acgactgttc cgacgacaat gactgtttca 480
acgacaacga gcgttccaac gacaacgagc attccaacaa caacaagtgt tccagtgaca 540
acaacgggtct ctacctttgt tcctccaatg cctttgcccc ggcagaacca tgaaccagta 600
gccacttcac catcttcacc tcagccagca gaaacccacc ctacgacact gcagggagca 660
ataaggagag aaccaccag ctcaccattg tactcttaca caacagatgg gaatgacacc 720
gtgacagagt cttcagatgg cctttggaat aacaatcaaa ctcaactgtt cctagaacat 780
agtctactg

```

<210> 50

<211> 263

<212> PRT

<213> Homo Sapiens

<400> 50

```

Ser Val Lys Val Gly Gly Glu Ala Gly Pro Ser Val Thr Leu Pro Cys
1          5          10          15
His Tyr Ser Gly Ala Val Thr Ser Met Cys Trp Asn Arg Gly Ser Cys
20        25        30
Ser Leu Phe Thr Cys Gln Asn Gly Ile Val Trp Thr Asn Gly Thr His
35        40        45
Val Thr Tyr Arg Lys Asp Thr Arg Tyr Lys Leu Leu Gly Asp Leu Ser
50        55        60
Arg Arg Asp Val Ser Leu Thr Ile Glu Asn Thr Ala Val Ser Asp Ser
65        70        75        80
Gly Val Tyr Cys Cys Arg Val Glu His Arg Gly Trp Phe Asn Asp Met
85        90        95
Lys Ile Thr Val Ser Leu Glu Ile Val Pro Pro Lys Val Thr Thr Thr
100       105       110
Pro Ile Val Thr Thr Val Pro Thr Val Thr Thr Val Arg Thr Ser Thr
115       120       125
Thr Val Pro Thr Thr Thr Thr Val Pro Thr Thr Thr Val Pro Thr Thr
130       135       140
Met Ser Ile Pro Thr Thr Thr Thr Val Pro Thr Thr Met Thr Val Ser
145       150       155       160
Thr Thr Thr Ser Val Pro Thr Thr Thr Ser Ile Pro Thr Thr Thr Ser
165       170       175
Val Pro Val Thr Thr Thr Val Ser Thr Phe Val Pro Pro Met Pro Leu
180       185       190
Pro Arg Gln Asn His Glu Pro Val Ala Thr Ser Pro Ser Ser Pro Gln
195       200       205
Pro Ala Glu Thr His Pro Thr Thr Leu Gln Gly Ala Ile Arg Arg Glu
210       215       220
Pro Thr Ser Ser Pro Leu Tyr Ser Tyr Thr Thr Asp Gly Asn Asp Thr
225       230       235       240
Val Thr Glu Ser Ser Asp Gly Leu Trp Asn Asn Asn Gln Thr Gln Leu
245       250       255
Phe Leu Glu His Ser Leu Leu
260

```

<210> 51

<211> 114

<212> PRT

<213> Homo Sapiens

<400> 51

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1          5          10          15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20        25        30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

```

```

      35      40      45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50      55      60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65      70      75      80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85      90      95
Ala Arg Asn Asn Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
      100      105      110
Ser Ala

```

<210> 52
 <211> 124
 <212> PRT
 <213> Homo Sapiens

```

<400> 52
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1      5      10      15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20      25      30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35      40      45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50      55      60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65      70      75      80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85      90      95
Ala Asn Asn Asn Tyr Asp Ser Ser Asn Asn Asn Tyr Gly Met Asp Val
      100      105      110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala
      115      120

```

<210> 53
 <211> 125
 <212> PRT
 <213> Homo Sapiens

```

<400> 53
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1      5      10      15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
      20      25      30
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
      35      40      45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
      50      55      60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
      65      70      75      80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
      85      90      95
Cys Ala Arg Asn Asn Asn Asn Ser Ser Ser Trp Tyr Asn Asn Phe Asp
      100      105      110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
      115      120      125

```

<210> 54
 <211> 124
 <212> PRT
 <213> Homo Sapiens

<400> 54
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Tyr Tyr Asp Ser Ser Asn Asn Asn Asn Asn Phe Asp Tyr
 100 105 110
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
 115 120

<210> 55
 <211> 119
 <212> PRT
 <213> Homo Sapiens

<400> 55
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
 50 55 60
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Thr Asn Asn Asp Asn Asn Asn Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser Ala
 115

<210> 56
 <211> 121
 <212> PRT
 <213> Homo Sapiens

<400> 56
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15
 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly
 20 25 30
 Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
 35 40 45
 Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser
 19

50 55 60
 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
 65 70 75 80
 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
 85 90 95
 Cys Ala Arg Asn Asn Asn Trp Asn Asn Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser Ala
 115 120

<210> 57
 <211> 119
 <212> PRT
 <213> Homo Sapiens

<400> 57
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
 50 55 60
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Thr Thr Asn Asn Asn Ser Gly Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser Ala
 115

<210> 58
 <211> 113
 <212> PRT
 <213> Homo Sapiens

<400> 58
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asn Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 100 105 110
 Ala

<210> 59
 <211> 114

<212> PRT

<213> Homo Sapiens

<400> 59

```

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20           25           30
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ser Tyr Ile Ser Ser Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65           70           75           80
Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Asn Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
      100          105          110
Ser Ala

```

<210> 60

<211> 110

<212> PRT

<213> Homo Sapiens

<400> 60

```

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1           5           10           15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
      20           25           30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35           40           45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
      50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65           70           75           80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Asn
      85           90           95
Asn Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
      100          105          110

```

<210> 61

<211> 113

<212> PRT

<213> Homo Sapiens

<400> 61

```

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1           5           10           15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20           25           30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35           40           45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
      50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala

```

85 90 95
 Leu Gln Thr Asn Asn Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110
 Arg

<210> 62
 <211> 108
 <212> PRT
 <213> Homo Sapiens

<400> 62
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
 85 90 95
 Thr Phe Gly Gly Thr Lys Val Glu Ile Lys Arg
 100 105

<210> 63
 <211> 114
 <212> PRT
 <213> Homo Sapiens

<400> 63
 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 20 25 30
 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Thr Gln Phe Pro Asn Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
 100 105 110
 Lys Arg

<210> 64
 <211> 108
 <212> PRT
 <213> Homo Sapiens

<400> 64
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 22

```

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
      20      25      30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
      35      40      45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50      55      60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65      70      75      80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro
      85      90      95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
      100      105

```

<210> 65
 <211> 113
 <212> PRT
 <213> Homo Sapiens

```

<400> 65
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly
 1      5      10      15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
      20      25      30
Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro
      35      40      45
Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
      65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
      85      90      95
Thr Gln Phe Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
      100      105      110
Arg

```

<210> 66
 <211> 114
 <212> PRT
 <213> Homo Sapiens

```

<400> 66
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
 1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser
      20      25      30
Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
      35      40      45
Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val
      50      55      60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
      65      70      75      80
Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
      85      90      95
Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
      100      105      110
Lys Arg

```

<210> 67
 <211> 108
 <212> PRT
 <213> Homo Sapiens

<400> 67
 Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
 1 5 10 15
 Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Ser
 20 25 30
 Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
 35 40 45
 Lys Tyr Ala Ser Gln Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
 65 70 75 80
 Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Ser Ser Ser Leu Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg
 100 105

<210> 68 -
 <211> 108
 <212> PRT
 <213> Homo Sapiens

<400> 68
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Asn
 85 90 95
 Asn Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
 100 105

<210> 69
 <211> 113
 <212> PRT
 <213> Homo Sapiens

<400> 69
 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 20 25 30
 Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Thr Gln Phe Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110
 Arg

<210> 70
 <211> 114
 <212> PRT
 <213> Homo Sapiens

<400> 70
 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser
 20 25 30
 Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
 35 40 45
 Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val
 50 55 60
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
 65 70 75 80
 Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
 85 90 95
 Arg Ile Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
 100 105 110
 Lys Arg

<210> 71
 <211> 108
 <212> PRT
 <213> Homo Sapiens

<400> 71
 Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
 1 5 10 15
 Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Ser
 20 25 30
 Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
 35 40 45
 Lys Tyr Ala Ser Gln Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
 65 70 75 80
 Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Ser Ser Ser Leu Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg
 100 105

<210> 72
 <211> 108
 <212> PRT
 <213> Homo Sapiens

<220>
 <221> misc_feature

<222> (96)..(96)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (97)..(97)

<223> Wherein Xaa may be any amino acid

<400> 72

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Xaa
          85           90           95
Xaa Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
          100          105

```

<210> 73

<211> 16

<212> DNA

<213> Homo Sapiens

<400> 73

ttactatgat aatagt

16

<210> 74

<211> 15

<212> DNA

<213> Homo Sapiens

<400> 74

agacatcact gggggg

15

<210> 75

<211> 17

<212> DNA

<213> Homo Sapiens

<400> 75

atagcagcaa ctggtac

17

<210> 76

<211> 16

<212> DNA

<213> Homo Sapiens

<400> 76

ttactatgat aatagt

16

<210> 77

<211> 15

<212> DNA

<213> Homo Sapiens

<400> 77
agacatcact ggggg 15

<210> 78
<211> 16
<212> DNA
<213> Homo Sapiens

<400> 78
ttactatgat aatagt 16

<210> 79
<211> 15
<212> DNA
<213> Homo Sapiens

<400> 79
agacatcact ggggg 15

<210> 80
<211> 13
<212> DNA
<213> Homo Sapiens

<400> 80
ctatgatagt agt 13

<210> 81
<211> 11
<212> DNA
<213> Homo Sapiens

<400> 81
ttactatgat a 11

<210> 82
<211> 20
<212> DNA
<213> Homo Sapiens

<400> 82
cgagtcggca tcactggggg 20

<210> 83
<211> 22
<212> DNA
<213> Homo Sapiens

<400> 83
caggtgcagc tggagcagtc gg 22

<210> 84
<211> 24
<212> DNA
<213> Homo Sapiens

<400> 84
gctgaggag tagagtcctg agga 24

<210> 85

<211> 19
<212> DNA
<213> Homo Sapiens

<400> 85
cacaccgagg tcacatggc

19

<210> 86
<211> 20
<212> DNA
<213> Homo Sapiens

<400> 86
ctactctagg gcacctgtcc

20

<210> 87
<211> 14
<212> PRT
<213> Homo Sapiens

<400> 87
Pro Met Pro Leu Pro Arg Gln Asn His Glu Pro Val Ala Thr
1 5 10

<210> 88
<211> 12
<212> PRT
<213> Homo Sapiens

<400> 88
Pro Met Pro Leu Pro Arg Gln Asn His Glu Pro Val
1 5 10

<210> 89
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 89
Pro Met Pro Leu Pro Arg Gln Asn His Glu
1 5 10

<210> 90
<211> 8
<212> PRT
<213> Homo Sapiens

<400> 90
Pro Met Pro Leu Pro Arg Gln Asn
1 5

<210> 91
<211> 6
<212> PRT
<213> Homo Sapiens

<400> 91

Pro Met Pro Leu Pro Arg
1 5

<210> 92
<211> 12
<212> PRT
<213> Homo Sapiens

<400> 92
Pro Leu Pro Arg Gln Asn His Glu Pro Val Ala Thr
1 5 10

<210> 93
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 93
Pro Arg Gln Asn His Glu Pro Val Ala Thr
1 5 10

<210> 94
<211> 8
<212> PRT
<213> Homo Sapiens

<400> 94
Gln Asn His Glu Pro Val Ala Thr
1 5

<210> 95
<211> 6
<212> PRT
<213> Homo Sapiens

<400> 95
His Glu Pro Val Ala Thr
1 5

<210> 96
<211> 7
<212> PRT
<213> Homo Sapiens

<400> 96
Pro Leu Pro Arg Asn His Glu
1 5

<210> 97
<211> 6
<212> PRT
<213> Homo Sapiens

<400> 97
Leu Pro Arg Gln Asn His

1 5

<210> 98
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 98
Pro Met Pro Ala Pro Arg Gln Asn His Glu
1 5 10

<210> 99
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 99
Pro Met Pro Leu Ala Arg Gln Asn His Glu
1 5 10

<210> 100
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 100
Pro Met Pro Leu Pro Ala Gln Asn His Glu
1 5 10

<210> 101
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 101
Pro Met Pro Leu Pro Arg Ala Asn His Glu
1 5 10

<210> 102
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 102
Pro Met Pro Leu Pro Arg Gln Ala His Glu
1 5 10

<210> 103
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 103
Pro Met Pro Leu Pro Arg Gln Asn Ala Glu
1 5 10
30

<210> 104
 <211> 8
 <212> PRT
 <213> Homo Sapiens

<400> 104
 Pro Leu Pro Arg Gln Asn His Glu
 1 5

<210> 105
 <211> 7
 <212> PRT
 <213> Homo Sapiens

<400> 105
 Leu Pro Arg Gln Asn His Glu
 1 5

<210> 106
 <211> 8
 <212> PRT
 <213> Homo Sapiens

<400> 106
 Pro Leu Pro Arg Gln Asn His Glu
 1 5

<210> 107
 <211> 7
 <212> PRT
 <213> Homo Sapiens

<400> 107
 Leu Pro Arg Gln Asn His Glu
 1 5

<210> 108
 <211> 882
 <212> DNA
 <213> Homo Sapiens

<400> 108
 atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcc 60
 atggccgata ttgtgatgac ccagactcca ctctccctgc ccgtcaccac tggagagccg 120
 gcctccatct cctgcaggtc tagtcggagc ctcttggata gtgatgatgg aaacacctat 180
 ttggactggg acctgcagaa gccaggggcag tctccacagc tcctgatcta cagcgtttcc 240
 tatcgggcct ctggagtccc agacaggttc agtggcagtg ggtcaggcac tgatttcaca 300
 ctgaaaaatca gcagggtgga ggctgaggat gttggagttt attactgcat gcaacgtgta 360
 gagtttccta tcaccttcgg ccaagggaca cgactggaga ttaaactttc cgcggacgat 420
 gcgaaaaagg atgctgcgaa gaaagatgac gctaagaaag acgatgctaa aaaggacctc 480
 caggtgcagc tgggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 540
 tcctgtgcag cgtctggatt catcttcagt cgctatggca tgcactgggt ccgccaggct 600
 ccaggcaagg ggcgaaatg ggtggcagtt atatggtatg atggaagtaa taaactctat 660
 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 720
 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagattac 780

tatgataata gtagacatca ctggggggttt gactactggg gccaggggaac cctggtcacc 840
gtctcctcag ctagecgatta taaggacgat gatgacaaat ag 882

<210> 109

<211> 271

<212> PRT

<213> Homo Sapiens

<400> 109

Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	Pro	Val	Thr	Pro	Gly
1				5					10					15	
Glu	Pro	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Arg	Ser	Leu	Leu	Asp	Ser
		20						25				30			
Asp	Asp	Gly	Asn	Thr	Tyr	Leu	Asp	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln
	35					40					45				
Ser	Pro	Gln	Leu	Leu	Ile	Tyr	Thr	Leu	Ser	Tyr	Arg	Ala	Ser	Gly	Val
	50				55						60				
Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys
65					70					75					80
Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Met	Gln
			85						90					95	
Arg	Val	Glu	Phe	Pro	Ile	Thr	Phe	Gly	Gln	Gly	Thr	Arg	Leu	Glu	Ile
		100						105					110		
Lys	Leu	Ser	Ala	Asp	Asp	Ala	Lys	Lys	Asp	Ala	Ala	Lys	Lys	Asp	Asp
		115					120					125			
Ala	Lys	Lys	Asp	Asp	Ala	Lys	Lys	Asp	Leu	Gln	Val	Gln	Leu	Val	Glu
	130					135					140				
Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	Ser	Leu	Arg	Leu	Ser	Cys
145					150					155					160
Ala	Ala	Ser	Gly	Phe	Ile	Phe	Ser	Arg	Tyr	Gly	Met	His	Trp	Val	Arg
			165						170					175	
Gln	Ala	Pro	Gly	Lys	Gly	Leu	Lys	Trp	Val	Ala	Val	Ile	Trp	Tyr	Asp
		180						185					190		
Gly	Ser	Asn	Lys	Leu	Tyr	Ala	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile
		195					200					205			
Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu
	210					215					220				
Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Asp	Tyr	Tyr	Asp
225					230					235					240
Asn	Ser	Arg	His	His	Trp	Gly	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu
			245					250						255	
Val	Thr	Val	Ser	Ser	Ala	Ser	Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Lys	
		260						265					270		

<210> 110

<211> 1560

<212> DNA

<213> Homo Sapiens

<400> 110

atggaaaccc	cagcgcagct	tctcttcctc	ctgctactct	ggctcccaga	taccaccgga	60
gatattgtga	tgaccagac	tccactctcc	ctgcccgta	cccctggaga	gccggcctcc	120
atctcctgca	ggctagtcg	gagcctcttg	gatagtgatg	atggaaacac	ctatttggac	180
tggtacctgc	agaagccagg	gcagctctca	cagctcctga	tctacacgct	ttcctatcgg	240
gcctctggag	tcccagacag	gttcagtggc	agtgggtcag	gcactgattt	cacactgaaa	300
atcagcaggg	tggaggctga	ggatgttgga	gtttattact	gcattgcaacg	tgtagagttt	360
cctatcacct	tgggccaagg	gacacgactg	gagattaaag	gtgggtgggtg	ttctggcggc	420
ggcggctccg	gtgggtgggtg	ttcccagggtg	cagctgggtg	agtctggggg	aggcgtggtc	480
cagcctggga	ggccctgag	actctcctgt	gcagcgtctg	gattcatctt	cagtcgctat	540
ggcatgcact	gggtccgcca	ggctccaggc	aaggggctga	aatgggtggc	agttatatgg	600

```

tatgatggaa gtaataaact ctatgcagac tccgtgaagg gccgattcac catctccaga 660
gacaattcca agaacacgct gtatctgcaa atgaacagcc tgagagccga ggacacggct 720
gtgtattact gtgcgagaga ttactatgat aatagtagac atcactgggg gtttgactac 780
tggggccagg gaacctggt caccgtctcc tcaggagggtg gtggatccga tatcaaactg 840
cagcagtcag gggctgaact ggcaagacct ggggcctcag tgaagatgtc ctgcaagact 900
tctggctaca cctttactag gtacacgatg cactgggtaa aacagaggcc tggacagggt 960
ctggaatgga ttggatacat taatcctagc cgtgggtata ctaattacaa tcagaagttc 1020
aaggacaagg ccacattgac tacagacaaa tcctccagca cagcctacat gcaactgagc 1080
agcctgacat ctgaggactc tgcagtctat tactgtgcaa gatattatga tgatcattac 1140
tgccttgact actggggcca aggcaccact ctcacagtct cctcagtcga aggtggaagt 1200
ggaggttctg gtggaagtgg aggttcaggt ggagtcgacg acattcagct gaccagttc 1260
ccagcaatca tgtctgcac tccaggggag aaggtcacca tgacctgcag agccagttca 1320
agtgtgaagt acatgaactg gtaccagcag aagtcaggca cctccccc aaagatggatt 1380
tatgacacat ccaaagtggc ttctggagtc ccttatcgct tcagtggcag tgggtctggg 1440
acctcatact ctctacaat cagcagcatg gaggtgaag atgctgccac ttattactgc 1500
caacagtgga gtagtaaccc gtcacgttc ggtgctggga ccaagctgga gctgaaatag 1560

```

<210> 111

<211> 499

<212> PRT

<213> Homo Sapiens

<400> 111

```

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Ser Leu Leu Asp Ser
20     25     30
Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln
35     40     45
Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val
50     55     60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
65     70     75     80
Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln
85     90     95
Arg Val Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
100    105    110
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115    120    125
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
130    135    140
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Arg Tyr
145    150    155    160
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp Val
165    170    175
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Leu Tyr Ala Asp Ser Val
180    185    190
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
195    200    205
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
210    215    220
Ala Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly Phe Asp Tyr
225    230    235    240
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
245    250    255
Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
260    265    270
Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr
275    280    285
Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile

```

290	295	300
Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe		
305	310	315
Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr		
	325	330
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys		
	340	345
Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly		
	355	360
Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly		
	370	375
Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr Gln Ser		
385	390	395
Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys		
	405	410
Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser		
	420	425
Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser		
	435	440
Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser		
	450	455
Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys		
465	470	475
Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu		
	485	490
Glu Leu Lys		495

<210> 112

<211> 1635

<212> DNA

<213> Homo Sapiens

<400> 112

```

atggaaaccc cagcgagct tctcttctc ctgctactct ggctcccaga taccaccgga 60
gatattgtga tgaccagac tccactctcc ctgcccgtca cccctggaga gccggcctcc 120
atctcctgca ggtctagtcg gagcctcttg gatagtgat atggaaacac ctatttggac 180
tggtacctgc agaagccagg gcagctctca cagctcctga tctacacgct ttcctatcgg 240
gcctctggag tcccagacag gttcagtggc agtgggtcag gcaactgattt cacactgaaa 300
atcagcaggg tggaggctga ggatgttggg gtttattact gcatgcaacg tgtagagttt 360
cctatcacct tcggccaagg gacacgactg gagattaaac ttccgcgga cgtgcgaaa 420
aaggatgctg cgaagaaaga tgacgctaag aaagacgatg ctaaaaagga cctgcagggtg 480
cagctgggtg agtctggggg aggcgtgggc cagcctggga ggctccctgag actctcctgt 540
gcagcgtctg gattcatctt cagtcgctat ggcattgcact gggctccgca ggctccaggc 600
aaggggctga aatgggtggc agttatatgg tatgatggaa gtaataaact ctatgcagac 660
tccgtgaagg gccgattcac catctccaga gacaattcca agaacacgct gtatctgcaa 720
atgaacagcc tgagagccga ggacacggct gtgtattact gtgagagaga ttactatgat 780
aatagtagac atcactgggg gtttgactac tggggccagg gaaccctggg caccgtctcc 840
tcaggagggt gtggatccga tatcaaactg cagcagtcag gggctgaact ggcaagacct 900
ggggcctcag tgaagatgtc ctgcaagact tctggctaca cctttactag gtacacgatg 960
cactgggtaa aacagaggcc tggacagggt ctggaatgga ttggatacat taatcctagc 1020
cgtgggtata ctaattacaa tcagaagtgc aaggacaagg ccacattgac tacagacaaa 1080
tcctccagca cagcctacat gcaactgagc agcctgacat ctgaggactc tgcagtctat 1140
tactgtgcaa gatattatga tgatcattac tgccttgact actggggcca aggcaccact 1200
ctcacagtct cctcactttc cgcggacgat gcgaaaaagg atgctgcaaa gaaagatgac 1260
gctaagaaag acgatgctaa aaaggacctg gacattcagc tgaccagtc tccagcaatc 1320
atgtctgcat ctccagggga gaaggtcacc atgacctgca gagccagttc aagtgttaagt 1380
taccatgaact ggtaccagca gaagtcaggc acctccccca aaagatggat ttatgacaca 1440
tccaaagtgg cttctggagt cccttatcgc ttcagtggca gtgggtctgg gacctcatac 1500
tctctcacia tcagcagcat ggaggctgaa gatgctgcca cttattactg ccaacagtgg 1560

```

agtagtaacc cgctcacgtt cgggtgctggg accaagctgg agctgaaaga ttataaggac 1620
 gatgatgaca aatag 1635

<210> 113

<211> 524

<212> PRT

<213> Homo Sapiens

<400> 113

Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	Pro	Val	Thr	Pro	Gly
1				5					10					15	
Glu	Pro	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Arg	Ser	Leu	Leu	Asp	Ser
		20						25					30		
Asp	Asp	Gly	Asn	Thr	Tyr	Leu	Asp	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln
		35					40					45			
Ser	Pro	Gln	Leu	Leu	Ile	Tyr	Thr	Leu	Ser	Tyr	Arg	Ala	Ser	Gly	Val
		50				55					60				
Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys
65					70					75					80
Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Met	Gln
				85					90					95	
Arg	Val	Glu	Phe	Pro	Ile	Thr	Phe	Gly	Gln	Gly	Thr	Arg	Leu	Glu	Ile
			100					105						110	
Lys	Leu	Ser	Ala	Asp	Asp	Ala	Lys	Lys	Asp	Ala	Ala	Lys	Lys	Asp	Asp
			115				120					125			
Ala	Lys	Lys	Asp	Asp	Ala	Lys	Lys	Asp	Leu	Gln	Val	Gln	Leu	Val	Glu
			130				135				140				
Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	Ser	Leu	Arg	Leu	Ser	Cys
145					150					155					160
Ala	Ala	Ser	Gly	Phe	Ile	Phe	Ser	Arg	Tyr	Gly	Met	His	Trp	Val	Arg
				165					170					175	
Gln	Ala	Pro	Gly	Lys	Gly	Leu	Lys	Trp	Val	Ala	Val	Ile	Trp	Tyr	Asp
			180					185					190		
Gly	Ser	Asn	Lys	Leu	Tyr	Ala	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile
		195					200					205			
Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu
		210				215					220				
Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	Asp	Tyr	Tyr	Asp
225					230					235					240
Asn	Ser	Arg	His	His	Trp	Gly	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu
				245					250					255	
Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Ile	Lys	Leu	Gln	Gln
			260					265					270		
Ser	Gly	Ala	Glu	Leu	Ala	Arg	Pro	Gly	Ala	Ser	Val	Lys	Met	Ser	Cys
		275					280					285			
Lys	Thr	Ser	Gly	Tyr	Thr	Phe	Thr	Arg	Tyr	Thr	Met	His	Trp	Val	Lys
		290				295					300				
Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile	Gly	Tyr	Ile	Asn	Pro	Ser
305					310					315					320
Arg	Gly	Tyr	Thr	Asn	Tyr	Asn	Gln	Lys	Phe	Lys	Asp	Lys	Ala	Thr	Leu
				325					330					335	
Thr	Thr	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu
			340					345					350		
Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Cys	Ala	Arg	Tyr	Tyr	Asp	Asp	
		355					360					365			
His	Tyr	Cys	Leu	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Thr	Leu	Thr	Val	Ser
		370				375					380				
Ser	Leu	Ser	Ala	Asp	Asp	Ala	Lys	Lys	Asp	Ala	Ala	Lys	Lys	Asp	Asp
385					390					395					400
Ala	Lys	Lys	Asp	Asp	Ala	Lys	Lys	Asp	Leu	Asp	Ile	Gln	Leu	Thr	Gln
				405					410					415	

Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr
 420 425 430
 Cys Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys
 435 440 445
 Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala
 450 455 460
 Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr
 465 470 475 480
 Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr
 485 490 495
 Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys
 500 505 510
 Leu Glu Leu Lys Asp Tyr Lys Asp Asp Asp Asp Lys
 515 520

<210> 114
 <211> 169
 <212> PRT
 <213> Homo Sapiens

<400> 114
 Trp Val Leu Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val
 1 5 10 15
 Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser
 20 25 30
 Val Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly
 35 40 45
 Lys Gly Leu Glu Trp Ile Gly Phe Ile Tyr Tyr Thr Gly Ser Thr Asn
 50 55 60
 Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Ser Val Asp Thr Ser
 65 70 75 80
 Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Ala
 85 90 95
 Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Asp Trp Ser Phe His Phe Asp
 100 105 110
 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 115 120 125
 Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
 130 135 140
 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 145 150 155 160
 Val Thr Val Ser Trp Asn Ser Gly Ala
 165

<210> 115
 <211> 168
 <212> PRT
 <213> Homo Sapiens

<400> 115
 Gln Leu Leu Gly Leu Leu Leu Trp Phe Pro Gly Ala Arg Cys Asp
 1 5 10 15
 Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly Asp
 20 25 30
 Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu
 35 40 45
 Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr
 50 55 60
 Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser

```

65          70          75          80
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
      85          90          95
Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu Thr
      100          105          110
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro
      115          120          125
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
      130          135          140
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
145          150          155          160
Val Gln Trp Lys Val Asp Asn Ala
      165

```

<210> 116
 <211> 156
 <212> PRT
 <213> Homo Sapiens

```

<400> 116
Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
 1          5          10          15
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr
      20          25          30
Asn Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
      35          40          45
Trp Val Ala Asn Ile Gln Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp
      50          55          60
Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
65          70          75          80
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Ala Val Tyr
      85          90          95
Tyr Cys Ala Arg Trp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
      100          105          110
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys
      115          120          125
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
      130          135          140
Asp Tyr Phe Pro Glu Pro Val Ser Gly Val Val Glu
145          150          155

```

<210> 117
 <211> 151
 <212> PRT
 <213> Homo Sapiens

```

<400> 117
Leu Leu Gly Leu Leu Met Leu Trp Val Pro Gly Ser Ser Gly Asp Ile
 1          5          10          15
Val Met Thr Gln Thr Pro Leu Ser Ser Thr Val Ile Leu Gly Gln Pro
      20          25          30
Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly
      35          40          45
Asn Thr Tyr Leu Asn Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg
      50          55          60
Leu Leu Ile Tyr Met Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg
65          70          75          80
Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg
      85          90          95

```

Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Thr Glu
 100 105 110
 Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 115 120 125
 Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
 130 135 140
 Lys Ser Gly Arg Ala Ser Val
 145 150

<210> 118

<211> 180

<212> PRT

<213> Homo Sapiens

<220>

<221> misc_feature

<222> (1)..(1)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (2)..(2)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (3)..(3)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Wherein Xaa may be any amino acid

<400> 118

Xaa Xaa Xaa Xaa Glu Gln Ser Gly Gly Gly Val Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30
 Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Gly Arg Ile Lys Arg Arg Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
 50 55 60
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Asn Leu Lys Asn Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Thr Ser Val Asp Asn Asp Val Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
 115 120 125
 Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
 130 135 140
 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
 145 150 155 160
 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
 165 170 175
 Ser Ser Gly Leu
 180

<400> 120																
Gln	Val	Gln	Leu	Glu	Gln	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1				5				10						15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Thr	Tyr	
			20					25					30			
Ser	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
		35					40					45				
Ser	Tyr	Ile	Arg	Ser	Ser	Thr	Ser	Thr	Ile	Tyr	Tyr	Ala	Glu	Ser	Leu	
	50					55				60						
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Ser	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
65					70				75						80	
Leu	Gln	Met	Asn	Ser	Leu	Arg	Asp	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	

<400> 122																
Gln	Val	Gln	Leu	Glu	Gln	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	
1				5					10					15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Arg	Tyr	
			20					25					30			
Gly	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Lys	Trp	Val	
		35				40						45				
Ala	Val	Ile	Trp	Tyr	Asp	Gly	Ser	Asn	Lys	Leu	Tyr	Ala	Asp	Ser	Val	
	50				55					60						
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
65					70					75					80	

```

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85                      90                      95
Ala Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly Phe Asp Tyr
      100                    105                    110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
      115                    120                    125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
      130                    135                    140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
      145                    150                    155                    160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
      165                    170                    175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
      180                    185

```

```

<210> 123
<211> 159
<212> PRT
<213> Homo Sapiens

```

```

<400> 123
Asp Ile Gln Leu Met Thr Leu Gln Ser Pro Ser Ser Leu Ser Ala Ser
  1           5                      10                      15
Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr
      20                    25                    30
Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
      35                    40                    45
Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe
      50                    55                    60
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
      65                    70                    75                    80
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr
      85                    90                    95
Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val
      100                   105                   110
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
      115                   120                   125
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
      130                   135                   140
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
      145                   150                   155

```

```

<210> 124
<211> 181
<212> PRT
<213> Homo Sapiens

```

```

<220>
<221> misc_feature
<222> (1)..(1)
<223> Wherein Xaa may be any amino acid

```

```

<220>
<221> misc_feature
<222> (2)..(2)
<223> Wherein Xaa may be any amino acid

```

```

<220>
<221> misc_feature

```

<222> (3)..(3)
 <223> Wherein Xaa may be any amino acid

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Wherein Xaa may be any amino acid

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Wherein Xaa may be any amino acid

<400> 124
 Xaa Xaa Xaa Xaa Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30
 Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Gly Arg Ile Lys Arg Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
 50 55 60
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Glu Asn Thr
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ser Leu Glu Thr Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Thr Thr Val Asp Asn Ser Gly Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
 115 120 125
 Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
 130 135 140
 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
 145 150 155 160
 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
 165 170 175
 Ser Ser Gly Leu Ser
 180

<210> 125
 <211> 159
 <212> PRT
 <213> Homo Sapiens

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Wherein Xaa may be any amino acid

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Wherein Xaa may be any amino acid

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Wherein Xaa may be any amino acid

<400> 125

```

Xaa Xaa Xaa Xaa Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1           5           10           15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20           25           30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35           40           45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
      50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
      85           90           95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
      100          105          110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
      115          120          125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
      130          135          140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
145          150          155

```

<210> 126

<211> 179

<212> PRT

<213> Homo Sapiens

<400> 126

```

Gln Val Gln Leu Glu Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asn Tyr
      20           25           30
Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
      35           40           45
Ala Val Ile Trp Tyr Asp Gly Ser His Lys Phe Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Thr Arg Asp Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
      100          105          110
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser
      115          120          125
Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
      130          135          140
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
145          150          155          160
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
      165          170          175
Ser Leu Ser

```

<210> 127

<211> 160

<212> PRT

<213> Homo Sapiens

<400> 127

```

Glu Thr Gln Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1          5          10          15
Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Asn
          20          25          30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
          35          40          45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
          50          55          60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
          65          70          75          80
Pro Glu Asp Cys Ala Glu Cys Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
          85          90          95
Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val
          100          105          110
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
          115          120          125
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
          130          135          140
Glu Ala Lys Val Gln Trp Glu Gly Gly Ile Thr Pro Ser Asn Arg Val
          145          150          155          160

```

<210> 128

<211> 182

<212> PRT

<213> Homo Sapiens

<400> 128

```

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
 1          5          10          15
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
          20          25          30
Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
          35          40          45
Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser His Lys Tyr Leu Tyr
          50          55          60
Ala Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
          65          70          75          80
Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
          85          90          95
Ala Val Tyr Tyr Ser Ala Arg Asp Tyr Tyr Asp Thr Ser Arg His His
          100          105          110
Trp Gly Phe Asp Cys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
          115          120          125
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
          130          135          140
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
          145          150          155          160
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
          165          170          175
Gly Val His Thr Phe Pro
          180

```

<210> 129

<211> 173

<212> PRT

<213> Homo Sapiens

<400> 129

```

Gln Leu Leu Gly Leu Leu Met Leu Trp Val Pro Gly Ser Ser Glu Glu
 1           5           10           15
Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu
          20           25           30
Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Glu
          35           40           45
Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          50           55           60
Pro Gln Leu Leu Ile Tyr Thr Leu Ser His Arg Ala Ser Gly Val Pro
          65           70           75           80
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          85           90           95
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Cys Cys Met Gln Arg
          100          105          110
Val Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
          115          120          125
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
          130          135          140
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
          145          150          155          160
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
          165          170

```

<210> 130

<211> 187

<212> PRT

<213> Homo Sapiens

<220>

<221> misc_feature

<222> (1)..(1)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (2)..(2)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (3)..(3)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (5)..(5)

<223> Wherein Xaa may be any amino acid

<400> 130

```

Xaa Xaa Xaa Xaa Xaa Gln Ser Gly Pro Arg Leu Val Lys Pro Ser Gln
 1           5           10           15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp
          45

```

```

      20      25      30
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu
      35      40      45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Phe Tyr Asn Pro Ser
      50      55      60
Leu Lys Ser Arg Val Ala Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65      70      75      80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
      85      90      95
Cys Ala Arg Glu Ser Pro His Ser Ser Asn Trp Tyr Ser Gly Phe Asp
      100      105      110
Cys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
      115      120      125
Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
      130      135      140
Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Arg Thr
145      150      155      160
Gly Asp Gly Val Val Glu Leu Arg Arg Pro Asp Gln Arg Arg Ala His
      165      170      175
Leu Pro Gly Cys Pro Thr Val Leu Arg Thr Leu
      180      185

```

<210> 131

<211> 154

<212> PRT

<213> Homo Sapiens

<220>

<221> misc_feature

<222> (1)..(1)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (2)..(2)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (3)..(3)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Wherein Xaa may be any amino acid

<400> 131

```

Xaa Xaa Xaa Xaa Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
 1      5      10      15
Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Gly Ser Arg
      20      25      30
Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile
      35      40      45
Lys Tyr Ala Ser Gln Ser Phe Ser Gly Val Pro Ser Arg Phe Ser Gly
      50      55      60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala
65      70      75      80
Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Ser Ser Asn Leu Pro Phe
      85      90      95

```

Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu
 145 150

<210> 132
 <211> 180
 <212> PRT
 <213> Homo Sapiens

<400> 132
 Gln Val Gln Leu Val Glu Gln Ala Gly Gly Gly Val Val Gln Pro Gly
 1 5 10 15
 Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser
 20 25 30
 Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys Trp
 35 40 45
 Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Leu Tyr Thr Asp
 50 55 60
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
 65 70 75 80
 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Val Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly Phe
 100 105 110
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
 115 120 125
 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
 130 135 140
 Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
 145 150 155 160
 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Arg Arg Arg Ala
 165 170 175
 His Leu Pro Gly
 180

<210> 133
 <211> 156
 <212> PRT
 <213> Homo Sapiens

<400> 133
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Arg Cys Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Arg Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Ala Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Pro
 85 90 95
 Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
 47

```

          100          105          110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
          115          120          125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
          130          135          140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145          150          155

```

<210> 134
 <211> 171
 <212> PRT
 <213> Homo Sapiens

```

<400> 134
His Val Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro
1      5      10      15
Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser
          20      25      30
Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Lys
          35      40      45
Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Leu Tyr Ala Asp
          50      55      60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
          65      70      75      80
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
          85      90      95
Tyr Cys Ala Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly Phe
          100     105     110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
          115     120     125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser
          130     135     140
Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
145     150     155     160
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
          165     170

```

<210> 135
 <211> 174
 <212> PRT
 <213> Homo Sapiens

```

<400> 135
Ser Ala Pro Gly Ala Ala Asn Ala Leu Gly Pro Trp Ile Ser Glu Asp
1      5      10      15
Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu
          20      25      30
Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Ser Leu Leu Asp Ser Asp
          35      40      45
Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          50      55      60
Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro
          65      70      75      80
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
          85      90      95
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg
          100     105     110
Val Glu Phe Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
          115     120     125

```

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 130 135 140
 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
 145 150 155 160
 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala
 165 170

<210> 136
 <211> 1428
 <212> DNA
 <213> Homo Sapiens

<400> 136
 cgccgccta tttaccacaga gacagggaga ggctcttctg tgtgtagtgg ttgtgcagag 60
 cctcatgcat cacggagcat gagaagacat tcccctcctg ccacctgctc ttgtccacgg 120
 ttagcctgct gtagaggaag aaggagccgt cggagtccag cacgggaggc gtgggtctgt 180
 agttgttctc cggctgcca ttgctctccc actccacggc gatgtcgtg gggtagaagc 240
 ctttgaccag gcaggtcagg ctgacctggt tcttggtcat ctccctcctg gatgggggca 300
 ggggtgtacac ctgtgggtct cggggctgcc ctttggtctt ggagatgggt ttctcgatgg 360
 aggaacgggag gcctttgttg gagacctgc acttgactc cttgccgttc agccagtcct 420
 ggtgcaggac ggtgaggacg ctgaccacac ggtacgtgct gttgaactgc tcctcccgcg 480
 gctttgtctt ggcattatgc acctccacgc catccacgta ccagttgaac tggacctcgg 540
 ggtcttctctg gctcacgtcc accaccacgc acgtgacctc aggggtccgg gagatcatga 600
 gagtgtcctt gggttttggg gggaacagga agactgatgg tccccccagg aactcaggtg 660
 ctgggcatga tgggcatggg ggaccatatt tggactcaac tctcttgtcc accttgggtg 720
 tgcctgggctt gtgatctacg ttgcaggtgt aggtcttcgt gcccaagctg ctggagggca 780
 cggtcaccac gctgctgagg gtagtagtgc ctgaggactg taggacagcc gggaagggtg 840
 gcacgccgct ggtcagggcg cctgagttcc acgacaccgt caccggttcg gggaagtagt 900
 ccttgaccag gcagcccagg gcggtgtgct tctcggagggt gctcctggag cagggcgcca 960
 gggggaagac ggatggggcc ttgggtggaag ctgaggagac ggtgaccagg gttccctggc 1020
 cccagtagtc aaacccccag tgatgtctac tattatcata gtaatctctc gcacagtaat 1080
 acacagccgt gtcctcggct ctccaggctgt tcatttgcag atacagcgtg ttcttgggaat 1140
 tgtctctgga gatggtgaat cggcccttca cggagtctgc atagagttta ttacttccat 1200
 cataccatat aactgccacc catttcagcc ccttgccctg agcctggcgg acccagtgca 1260
 tgccatagcg actgaagatg aatccagacg ctgcacagga gagtctcagg gacctcccag 1320
 gctggaccac gcctcccca gactccacca gctgcacctg acactggaca ccttttaaaa 1380
 tagccacaag aaaaagccag ctccagcccaa actccatggt ggtcgact 1428

<210> 137
 <211> 469
 <212> PRT
 <213> Homo Sapiens

<400> 137
 Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly
 1 5 10 15
 Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln
 20 25 30
 Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe
 35 40 45
 Ser Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60
 Lys Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Leu Tyr Ala
 65 70 75 80
 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
 85 90 95
 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
 100 105 110
 Tyr Tyr Cys Ala Arg Asp Tyr Tyr Asp Asn Ser Arg His His Trp Gly
 115 120 125

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser
 130 135 140
 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr
 145 150 155 160
 Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro
 165 170 175
 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
 180 185 190
 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
 195 200 205
 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr
 210 215 220
 Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val
 225 230 235 240
 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe
 245 250 255
 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 260 265 270
 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 275 280 285
 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
 290 295 300
 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
 305 310 315 320
 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 325 330 335
 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
 340 345 350
 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 355 360 365
 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
 370 375 380
 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 385 390 395 400
 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 405 410 415
 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
 420 425 430
 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
 435 440 445
 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 450 455 460
 Leu Ser Leu Gly Lys
 465

<210> 138

<211> 741

<212> DNA

<213> Homo Sapiens

<400> 138

agtcgaccac catggaaacc ccagcgcagc ttctcttccct cctgctactc tggctcccag 60
 ataccaccgg agatattgtg atgaccaga ctccactctc cctgcccgtc acccctggag 120
 agccggcctc catctcctgc aggtctagtc ggagcctctt ggatagtgat gatggaaaca 180
 cctatttggga ctggtacctg cagaagccag ggcagtctcc acagctcctg atctacacgc 240
 tttcctatcg ggcctctgga gtcccagaca ggttcagtgg cagtgggtca ggcactgatt 300
 tcacactgaa aatcagcagg gtggaggctg aggatgttgg agttttattac tgcattgcaac 360
 gtgtagagtt tcctatcacc ttcggccaag ggacacgact ggagattaaa cgaactgtgg 420
 ctgcaccatc tgtcttcac ttcccgcct ctgatgagca gttgaaatct ggaactgcct 480
 ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag tggaagggtg 540

ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac agcaaggaca 600
 gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag aaacacaaag 660
 tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag agcttcaaca 720
 ggggagagtg ttaggcggcc g 741

<210> 139

<211> 240

<212> PRT

<213> Homo Sapiens

<400> 139

Met	Glu	Thr	Pro	Ala	Gln	Leu	Leu	Phe	Leu	Leu	Leu	Leu	Trp	Leu	Pro
1				5				10					15		
Asp	Thr	Thr	Gly	Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	Pro
			20					25					30		
Val	Thr	Pro	Gly	Glu	Pro	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Arg	Ser
			35				40					45			
Leu	Leu	Asp	Ser	Asp	Asp	Gly	Asn	Thr	Tyr	Leu	Asp	Trp	Tyr	Leu	Gln
			50			55					60				
Lys	Pro	Gly	Gln	Ser	Pro	Gln	Leu	Leu	Ile	Tyr	Thr	Leu	Ser	Tyr	Arg
65					70					75					80
Ala	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp
				85					90					95	
Phe	Thr	Leu	Lys	Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr
			100					105					110		
Tyr	Cys	Met	Gln	Arg	Val	Glu	Phe	Pro	Ile	Thr	Phe	Gly	Gln	Gly	Thr
			115				120					125			
Arg	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe
			130			135					140				
Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys
145					150					155					160
Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val
			165						170					175	
Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln
			180				185						190		
Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser
		195					200					205			
Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His
	210					215					220				
Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys
225					230					235					240

<210> 140

<211> 186

<212> PRT

<213> Homo Sapiens

<220>

<221> misc_feature

<222> (1)..(1)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (2)..(2)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (3)..(3)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Wherein Xaa may be any amino acid

<400> 140

Xaa	Xaa	Xaa	Xaa	Glu	Gln	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20					25					30		
Gly	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35				40						45			
Ala	Val	Ile	Trp	Tyr	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val
50					55					60					
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
65					70					75					80
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85					90					95		
Ala	Arg	Asp	Phe	Tyr	Asp	Ser	Ser	Arg	Tyr	His	Tyr	Gly	Met	Asp	Val
		100						105				110			
Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly
		115				120						125			
Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Cys	Ser	Arg	Ser	Thr	Ser	Glu	Ser
130						135					140				
Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val
145					150					155					160
Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe
			165					170					175		
Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Ser						
		180						185							

<210> 141

<211> 143

<212> PRT

<213> Homo Sapiens

<220>

<221> misc_feature

<222> (1)..(1)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (2)..(2)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (3)..(3)

<223> Wherein Xaa may be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Wherein Xaa may be any amino acid

<400> 141

Xaa Xaa Xaa Xaa Thr Gln Cys Pro Leu Ser Leu Pro Val Thr Pro Gly

1				5					10					15
Glu	Pro	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Gln	Ser	Leu	Leu	Asp
			20					25					30	
Asp	Asp	Gly	Asn	Thr	Tyr	Leu	Asp	Trp	Tyr	Leu	Gln	Lys	Pro	Gly
		35					40					45		
Ser	Pro	Gln	Leu	Leu	Ile	Tyr	Thr	Val	Ser	Tyr	Arg	Ala	Ser	Gly
	50					55				60				
Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu
65					70					75				80
Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Met
			85						90				95	
Arg	Ile	Glu	Phe	Pro	Ile	Thr	Phe	Gly	Gln	Gly	Thr	Arg	Leu	Glu
			100					105					110	
Lys	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser
		115					120					125		
Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn
	130					135					140			

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/44090

A. CLASSIFICATION OF SUBJECT MATTER

IPC: A61K 051/00;G01N 033/53;A61K 039/395;C12N 005/06;C07K 016/46

USPC: 424/178.1;435/328,7.1;530/391.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/178.1; 435/328, 7.1; 530/391.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004084823 (LANDES et al) 7 October 2004 (07.10.2004), Abstract, paragraphs 11, 25 and 28-33, in particular.	1, 3-9 and 11-16

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 March 2007 (30.03.2007)

Date of mailing of the international search report

25 APR 2007

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Parithosh K. Tungathurthi
Telephone No. (571) 272-0600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/44090

A. CLASSIFICATION OF SUBJECT MATTER		
IPC: A61K 051/00;G01N 033/53;A61K 039/395;C12N 005/06;C07K 016/46		
USPC: 424/178.1;435/328,7.1;530/391.1		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/178.1; 435/328, 7.1; 530/391.1		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004084823 (LANDES et al) 7 October 2004 (07.10.2004), Abstract, paragraphs 11, 25 and 28-33, in particular.	1, 3-9 and 11-16
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 30 March 2007 (30.03.2007)		Date of mailing of the international search report 25 APR 2007
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201		Authorized officer Parithosh K. Tungathurthi Telephone No. (571) 272-0600